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disease	 (COPD)	 represents	 a	 major	 cause	 of	 morbidity	 and	 mortality,	 and	 is	 currently	 the	 third	
leading	cause	of	death	worldwide.	COPD	 is	a	devastating	progressive	 lung	disease	characterized	by	
airflow	 limitation,	 chronic	 bronchitis	 and	 bronchiolitis,	 emphysema,	 and	 small	 airway	 remodeling.	
There	are	no	curative	options	for	COPD	to	date,	thus	there	is	a	desperate	need	for	novel	approaches	
and	 treatments.	To	 this	end,	 the	goal	of	 this	 thesis	work	was	 to	develop	and	evaluate	a	novel	 cell	
product	 composed	 of	mesenchymal	 stem/stromal	 cells	 (MSCs)	 genetically	modified	 to	 express	 the	





driving	 AAT	 expression,	 and	 in	 the	 relative	 position	 of	 the	 expression	 cassettes	 within	 the	 vector	
backbone.	 The	 vectors	 were	 then	 compared	 with	 regards	 to	 viral	 titers,	 transduction	 efficacy	 of	
primary	 human	MSCs,	 AAT	 expression	 in	 the	 supernatant	 of	 transduced	 cells,	 and	 cell	 yield	 after	
antibiotic	selection.	The	best	results	for	all	parameters	were	obtained	when	AAT	was	expressed	from	
the	human	eukaryotic	translation	elongation	factor	1	alpha	1	short	(EFS)	promoter,	and	the	pac	gene	





construct,	 however,	 followed	 a	 clear	 dose-response,	 reaching	 transduction	 efficacies	 >80%	 at	 the	
highest	MOI	 tested.	 In	 vitro	 functionality	 of	 the	 protease	 inhibitor	 AAT	 expressed	 from	MSCs	was	
confirmed	 using	 a	 neutrophil	 elastase	 inhibition	 assay.	 A	 process	 for	 large	 scale	 transduction	 and	
expansion	 of	 gene-modified	 MSCs	 was	 subsequently	 developed.	 To	 evaluate	 the	 potential	
therapeutic	benefit	of	AAT-MSCs	in	vivo,	a	mouse	model	of	elastase-induced	emphysema	was	used.	
Treatment	 of	 the	mice	with	 AAT-MSCs	 resulted	 in	 significant	 improvement	 of	 pulmonary	 function	
parameters,	 while	 only	 a	 slight	 functional	 amelioration	 was	 observed	 after	 treatment	 with	 non-
modified	 MSCs.	 Histopathologic	 examination	 of	 AAT-MSC-treated	 mice	 revealed	 a	 significant	
decrease	of	airspace	enlargement,	indicating	regeneration	of	pulmonary	tissue.	Again,	the	effect	was	











Chronisch	 entzündliche	 Erkrankungen	 sind	 heutzutage	 ein	 globales,	 im	 Steigen	 begriffenes	
Gesundheitsproblem.	Ein	wichtiges	Beispiel	 ist	die	chronisch	obstruktive	Lungenerkrankung	(COPD),	
eine	 verheerende,	 fortschreitende	 Erkrankung	 der	 Lunge	 mit	 hoher	 Morbidität	 und	 Mortalität,	
gegenwärtig	 die	 dritthäufigste	 Todesursache	 weltweit.	 Symptome	 der	 COPD	 sind	 Atemnot,	 eine	
chronische	Entzündung	der	Bronchien	und	Bronchiolen,	die	Entwicklung	eines	Emphysems	und	ein	
Umbau	 der	 engen	 Atemwege.	 Da	 bislang	 eine	 Heilung	 der	 COPD	 nicht	 möglich	 ist,	 besteht	 ein	
dringender	 Bedarf	 an	 innovativen	 Therapieansätzen.	Wir	 entwickelten	 ein	 neuartiges	 Zellprodukt,	
basierend	 auf	 mesenchymalen	 Stamm-/Stromazellen	 (MSCs),	 die	 genetisch	 modifiziert	 wurden,	
sodass	 sie	 den	 Protease-Inhibitor	 Alpha-1	 Antitrypsin	 (AAT)	 exprimieren.	 Diese	 Kombination	
ermöglicht	 es,	 die	 immunmodulatorischen	 und	 zytoprotektiven	 Eigenschaften	 der	MSCs	mit	 jenen	
von	AAT	 in	 einem	Produkt	 zu	 vereinen.	 Dabei	wurde	 in	 der	 vorliegenden	Arbeit	 ein	 Fokus	 auf	 die	
Entwicklung	 eines	 optimierten	 Expressionskonstruktes	 gelegt.	 Es	 wurden	 acht	 gamma-retrovirale	
Vektoren	 für	 die	 Expression	 von	 AAT	 und	 Puromycin-N-Acetyltransferase	 (pac),	 das	 eine	
Antibiotikaselektion	 genmodifizierter	 Zellen	 erlaubt,	 konzipiert	 und	 kloniert.	 Diese	 Konstrukte	
unterscheiden	sich	sowohl	im	Promoter,	der	für	die	AAT-Expression	verwendet	wird,	als	auch	in	der	
relativen	Anordnung	der	Expressionskassetten	im	Plasmid.	Die	Auswahl	des	besten	Konstrukts	wurde	
anhand	 eines	 Vergleichs	 der	 Vektoren	 hinsichtlich	 der	 erzielten	 viralen	 Titer,	 der	
Transduktionseffizienz	 von	 primären	 humanen	MSCs,	 des	 AAT-Gehalts	 im	 Zellkulturüberstand	 von	
transduzierten	 MSCs	 sowie	 der	 Zellausbeute	 nach	 Antibiotikaselektion	 durchgeführt.	 Die	 jeweils	
besten	 Ergebnisse	 wurden	 erzielt,	 wenn	 AAT	 von	 der	 kurzen	 Form	 des	 Promoters	 des	 humanen	
eukaryotischen	 Translationselongationsfaktors	 1	 alpha	 1	 (EFS)	 exprimiert	wurde,	 und	 das	 pac	 Gen	
durch	 eine	 interne	 ribosomale	 Eintrittsstelle-	 (IRES)-Sequenz	 verknüpft	 war.	 Diese	 favorisierte	
Expressionskassette	 wurde	 in	 ein	 lentivirales	 Plasmid	 transferiert,	 um	 zu	 untersuchen,	 ob	
Transduktion	 und	 AAT-Expression	 in	 einem	 solchen	 System	 weiter	 verbessert	 werden	 können.	 Es	
zeigte	sich,	dass	mittels	des	gamma-retroviralen	Vektors	größere	Transduktionseffizienzen	und	AAT-





Expansionsprozesse	 zur	 Herstellung	 von	 AAT-MSCs	 im	 Großformat	 etabliert	 wurden.	 Um	 die	








MSCs	 signifikant	 vermindert	 werden	 konnte,	 was	 auf	 eine	 Regeneration	 des	 Lungengewebes	
hindeutet.	 Auch	 in	 dieser	 Auswertung	 fiel	 der	 durch	 die	 Behandlung	mit	 nicht-modifizierten	MSCs	
erzielte	 Effekt	 geringer	 aus,	 was	 eine	 additive	 Wirkung	 von	 AAT	 und	 MSCs	 nahelegt.	
Zusammenfassend	kann	festgestellt	werden,	dass	die	vorliegende	Arbeit	einen	ersten	Nachweis	des	









1.1. Chronic obstructive pulmonary disease 
1.1.1. Epidemiology and economics 
Chronic	 inflammatory	 diseases	 are	 a	 growing	 health	 problem	 worldwide,	 imposing	 an	 increasing	
burden	on	 individuals,	 populations,	 and	economies	 1.	Among	 them,	 chronic	obstructive	pulmonary	
disease	(COPD)	must	be	given	a	central	role.	 It	 is	a	heterogeneous,	common,	and	complex	disorder	
that	is	at	present	the	third	leading	cause	of	mortality	globally,	being	responsible	for	more	than	three	
million	 deaths	 worldwide	 (equal	 to	 6%	 of	 all	 deaths)	 in	 2012	 2.	 Since	 mild	 disease	 often	 goes	
unrecognized	 and	 thus	 undiagnosed,	 it	 is	 difficult	 to	 obtain	 prevalence	 data	 for	 COPD	 3.	 It	 is,	
however,	 estimated	 that	 in	 2013	 COPD	 affected	 329	 million	 people	 or	 nearly	 5%	 of	 the	 global	
population	 4,5.	 COPD	 is	 also	 associated	 with	 a	 substantial	 economic	 burden.	 As	 of	 2010,	 COPD	 is	
believed	to	result	in	global	economic	costs	of	$2.1	trillion,	where	$1.9	trillion	are	direct	costs	such	as	
medical	care,	and	$0.2	trillion	are	indirect	costs	such	as	missed	work	6.	In	the	European	Union,	COPD	








Furthermore,	 the	 clinical	 picture	 can	 often	 be	 accompanied	 by	 cardiovascular	 disease,	 fatigue,	
depression,	 musculoskeletal	 dysfunction,	 weight	 loss,	 and	 osteoporosis	 3,11.	 The	 severity	 of	 the	
disease	 is	 currently	 categorized	 based	 on	 GOLD	 (Global	 initiative	 for	 chronic	 Obstructive	 Lung	
Disease)	criteria	on	a	0–4	scale,	depending	on	symptoms	and	the	decline	in	lung	function	8.	Patients	
suffering	from	advanced	disease	(GOLD	score	2	and	higher)	progressively	experience	more	frequent	
and	severe	acute	exacerbations	as	 their	 condition	continues	 to	deteriorate	 12.	These	exacerbations	
are	most	often	the	result	of	viral	or	bacterial	chest	infections	or	environmental	pollutants	8.		
Classically,	 COPD	 is	 diagnosed	 by	 spirometry,	with	 the	 clinical	 criteria	 defining	 COPD	 comprising	 a	
forced	expiratory	volume	after	one	second	(FEV1)	value	of	<80%	predicted,	and	a	post-bronchodilator	
FEV1:FVC	(forced	vital	capacity)	ratio	<0.70	13.		
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1.1.3. Risk factors for COPD development 
The	 most	 important	 risk	 factor	 for	 the	 development	 of	 COPD	 is	 tobacco	 smoking,	 probably	
accounting	for	80–95%	of	all	COPD	cases	in	industrialized	countries	10,14,15;	however,	only	15–25%	of	
smokers	 develop	 COPD	 16–18.	 Other	 environmental	 factors	 such	 as	 increasing	 air	 pollution,	 whose	




It	 is	 commonly	 accepted	 that	 the	 chronic	 inflammation	 seen	 in	 the	 respiratory	 tract	 of	 patients	
suffering	from	COPD	results	from	an	excessive	immune	response	to	chronic	irritants	such	as	tobacco	
smoke.	 The	 reasons	 for	 this	 inflammation	 are	 not	 yet	 fully	 understood,	 but	 could	 be	 in	 part	
genetically	determined,	 since	 there	clearly	are	COPD	patients	who	are	non-smokers,	and	 there	are	
also	 many	 smokers	 who	 never	 develop	 COPD,	 despite	 having	 chronic	 lung	 inflammation	 that	
continues	 for	many	years	even	after	smoking	cessation	7,15.	Moreover,	COPD	 is	known	to	cluster	 in	









tissue	homeostasis	within	 the	 lung,	 (2)	oxidative	 stress,	and	 (3)	protease-antiprotease	 imbalance	 3.	
However,	 the	 interplay	of	 these	pathways	and	the	molecular	mechanisms	 leading	to	COPD	are	still	
incompletely	understood	11.		




lung	 parenchyma,	 bronchoalveolar	 lavage	 fluid	 (BALF)	 and	 sputum	 34,35,	 and	macrophage	 numbers	
strongly	correlate	with	disease	severity	36.	Macrophages	are	potent	immune	effector	cells,	and	upon	
contact	with	cigarette	smoke	or	other	noxious	substances	they	can	secrete	inflammatory	mediators	
such	 as	 tumor	 necrosis	 factor-alpha	 (TNF-alpha),	 monocyte	 chemoattractant	 protein-1	 (MCP-1),	












1.1.4.2. Oxidative stress 
A	second	important	aspect	in	the	pathogenesis	of	COPD	is	oxidative	stress,	a	very	important	factor	to	
consider	with	 regards	 to	 the	massive	 oxidant	 burden	 seen	 in	 smokers.	 Cigarette	 smoke	 comprises	
over	4700	chemical	compounds	and	more	than	1015	free	radicals	and	oxidants,	which	can	give	rise	to	
damaging	levels	of	ROS	produced	by	inflammatory	and	epithelial	cells	42.	Generation	of	ROS	further	










extracellular	 matrix	 (specifically	 elastin)	 in	 the	 lung	 parenchyma	 is	 destroyed	 by	 action	 of	 the	
proteinases	resulting	in	airspace	enlargement	and	emphysema	47.	The	major	proteinases	involved	in	
COPD	are	neutrophil	elastase,	proteinase-3	and	various	matrix	metalloproteinases	48,49.	With	regards	
to	 the	 present	 work,	 it	 is	 important	 to	 point	 out	 that	 AAT	 acts	 as	 a	 major	 endogenous	 serine	
proteinase	 inhibitor	 and	 thus	 plays	 an	 important	 role	 in	 counterbalancing	 the	 excessive	 release	of	
proteinases.	 As	 described	 above,	 patients	 suffering	 from	 AAT	 deficiency	 are	 at	 increased	 risk	 of	
developing	emphysema	and	COPD	28,31,50.	AAT	may	also	have	additional	modes	of	action	relevant	for	
emphysema	and	COPD	apart	 from	 its	 function	as	protease	 inhibitor,	since	mutations	 in	AAT	clearly	
are	associated	with	these	diseases,	while	mutations	in	neutrophil	elastase	are	not	3.		








improving	 air	 quality	 51,	 as	 well	 as	 influenza	 and	 pneumococcus	 vaccinations	 for	 patients	 already	
suffering	from	COPD	and	experiencing	exacerbations	54,55.		
Once	patients	are	diagnosed	with	COPD,	the	focus	of	therapy	is	on	managing	the	disease	and	treating	
the	 symptoms,	 preventing	 and	 treating	 acute	 exacerbations,	 as	 well	 as	 controlling	 associated	
illnesses	56.	The	only	therapeutic	approaches	that	have	been	described	to	reduce	COPD	mortality	are	
supplemental	oxygen	and	smoking	cessation,	of	which	 the	 latter	can	decrease	 the	 risk	of	death	by	
18%	57,58.	Other	current	standard	pharmacologic	medications	are	primarily	used	to	reduce	symptoms	
and	 improve	 lung	 function;	 however,	 to	 date	 there	 are	 no	 drugs	 found	 that	 can	 significantly	 limit	
disease	 progression	 9.	 Drugs	 that	 can	 provide	 a	measure	 of	 help	 include	 inhaled	 short-acting	 and	




Additional	 treatment	 options	 include	 antibiotics,	which	 are	mainly	 used	 in	 patients	 suffering	 from	
two	or	more	acute	exacerbations	per	 year	 62,63.	 The	 last	 treatment	option	 for	patients	with	 severe	
COPD	 is	surgery.	This	can	be	either	 lung	volume	reduction	surgery	to	remove	the	parts	of	 the	 lung	
that	 are	 destroyed	 by	 emphysema	 and	 thus	 allow	 the	 remaining	 parts	 of	 the	 lung	 to	 work	more	
effectively,	or	–	 in	very	 severe	cases,	and	primarily	 in	younger	 subjects	–	 lung	 transplantation	 64,65.	
However,	 despite	 improved	 survival	 rates	 after	 lung	 transplantation,	 this	 is	 unfortunately	 not	 an	
option	for	most	patients	due	to	the	increasing	demand	and	the	scarcity	of	donor	organs	65,66.		
During	 the	 last	 decade,	 new	 therapeutic	 strategies	 such	 as	 TNF-alpha	 antagonism	 67–69	 or	 IL-8	





inflammatory	 lung	 diseases	 such	 as	 COPD	 that	 aim	 at	 persistently	 controlling	 the	 underlying	
inflammatory	processes,	while	at	the	same	time	leading	to	regeneration	of	the	damaged	lung	tissue.	
This	thesis	presents	an	innovative	cell	therapy-based	approach	to	accomplish	this	task.	
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1.2. Cell therapy and mesenchymal stem/stromal cells  
Since	the	first	successful	hematopoietic	stem	cell	(HSC)	transplantation	reported	in	1959	71,	there	has	
been	 a	 continuing	 expansion	 in	 the	 number	 of	 clinical	 trials	 investigating	 the	 application	 of	 stem	
cells	72.	In	addition	to	HSCs,	embryonic	stem	cells	(ESCs)	73,74,	induced	pluripotent	stem	cells	(iPSCs)	75,	
limbal	stem	cells	76,	neural	stem	cells	77,78,	and	endothelial	stem	and	progenitor	cells	79,80	are	currently	
being	 tested	 in	 clinical	 trials	 for	 the	 treatment	 of	 a	 variety	 of	 diseases	 including	 macular	




under	 investigation,	 with	 as	 many	 as	 520	 registered	 clinical	 trials	 (studies	 with	 unknown	 status	
excluded)	listed	in	the	NIH	clinical	trial	database	on	June	15,	2016	83.	Due	to	their	broad	repertoire	of	
beneficial	 features	 including	 immunomodulation,	 growth	 factor	 production,	 anti-fibrosis	 and	 anti-
apoptosis,	 angiogenesis,	 and	 neuroprotection,	 MSCs	 are	 under	 clinical	 trial	 for	 the	 treatment	 of	
diverse	diseases,	and	the	results	to	date	have	been	highly	encouraging	in	the	potential	treatment	of	
Graft	 versus	 Host	 Disease	 (GvHD)	 84,85,	 type	 1	 diabetes	 86,	 transplant	 rejection	 87,88,	 myocardial	
ischemia	and	infarction	89,90,	and	Crohn’s	disease	91,92.	MSCs	are	also	being	investigated	for	therapy	of	
lung	 diseases	 such	 as	 acute	 respiratory	 distress	 syndrome	 (ARDS)	 93,	 and	 COPD	 94,	 thus	 far	
demonstrating	an	excellent	safety	profile.	These	studies	are	only	 in	 the	early	phases	of	 testing	and	
thus	 not	 yet	 empowered	 to	 assess	 efficacy	 94.	 However,	 positive	 outcomes	 indicative	 of	 potential	
efficacy	have	been	seen,	as	for	instance	a	significant	reduction	of	C-reactive	protein	(CRP)	levels	in	a	
subgroup	of	patients	who	had	elevated	levels	at	baseline	in	a	clinical	trial	of	MSCs	in	COPD	94.	
The	 following	 section	 sets	 out	 to	 describe	 the	 biology	 of	 MSCs	 in	 greater	 detail	 and	 to	 highlight	
features	specifically	important	to	the	treatment	of	inflammatory	lung	diseases	such	as	COPD.		
1.2.1. General MSC biology 
MSCs	 are	 multipotent	 progenitor	 cells	 of	 non-hematopoietic	 origin	 that	 were	 first	 described	 by	
Friedenstein	 and	 colleagues	 in	 the	 late	 1960s	 as	 the	 “colony-forming	 unit	 fibroblast”	 95.	 They	
described	 adult,	 plastic-adherent,	 spindle-shaped,	 fibroblast-like	 cells	 which	were	 defined	 by	 their	
capacity	to	form	new	bone	when	transplanted	to	an	ectopic	site	96,97.	These	cells	were	later	renamed	
“mesenchymal	stem	cells”	and	their	differentiation	potential	expanded	to	“tri-lineage”	mesenchymal	
tissues;	 bone,	 cartilage,	 and	 fat	 98.	 However,	 their	 level	 of	 “stemness”	 is	 still	 a	 matter	 of	 debate	
among	scientists	as	in	vivo	confirmation	of	their	stem	cell	characteristics	has	not	been	established	99.	
The	International	Society	for	Cellular	Therapy	(ISCT)	published	a	statement	paper	in	2005	addressing	
this	 inconsistency	 between	 nomenclature	 and	 biologic	 characteristics,	 suggesting	 that	 the	 term	
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One	major	 advantage	MSCs	have	 regarding	 their	 clinical	 utilization	with	 respect	 to	other	 stem	cell	
types	is	their	ease	of	accessibility	for	 isolation:	MSCs	have	successfully	been	isolated	and	expanded	
from	 various	 tissues	 including	 bone	 marrow,	 umbilical	 cord,	 adipose	 tissue,	 dental	 pulp,	 and	
placenta	101,102.	It	is	thought	that	most	organs	have	endogenous	populations	of	MSCs,	and	that	MSCs	
may	have	a	perivascular	origin	103,104.	 In	the	bone	marrow,	MSCs	can	be	found	 in	the	so-called	HSC	
niche,	 where	 they	 support	 the	 survival,	 self-renewal,	 migration,	 and	 differentiation	 of	 HSCs	 and	
precursor	cells	105.	In	lung	tissue,	MSCs	are	predominantly	localized	to	the	perivascular	region	106,107.	
Since	 there	 is	 no	 distinct	 surface	 marker	 defining	 MSCs,	 and	 MSCs	 are	 represented	 by	 a	 fairly	


















		 		 		 HLA-DR	
3	 In	vitro	differentiation	into	osteoblasts,	adipocytes,	and	chondroblasts	
	
1.2.2. Mode of action of MSCs 
In	early	MSC	research	it	was	thought	that	the	beneficial	effect	of	MSCs	is	mainly	derived	from	their	
supportive	 action	 on	 HSCs	 109,	 their	 co-localization	 and	 engraftment	 at	 the	 site	 of	 injury,	 and	
replacement	of	damaged	tissue	110.	However,	the	field	has	since	undergone	a	paradigm	shift.	Today	
more	emphasis	has	been	placed	on	 the	 trophic	and	 immunomodulatory	capabilities	of	MSCs,	 their	
secretion	of	a	plethora	of	 cytokines,	growth	 factors,	and	of	extracellular	vesicles	 99,111–114.	 It	 is	now	
thought	 that	 the	 cells	 may	 only	 briefly	 interact	 with	 injured	 tissues,	 but	 in	 this	 time	 they	 act	 on	
inflammatory	 and	 damaged	 cells	 to	 dampen	 inflammation,	 limit	 tissue	 destruction,	 and	 enhance	
repair	109,	a	mechanism	that	has	been	referred	to	as	“hit-and-run”	by	some	researchers.	Interestingly,	
recent	data	show	that	even	though	MSCs	do	not	persist	in	vivo,	the	beneficial	effects	they	exert	can	







innate	 immune	 pro-inflammatory	 responses,	 and	 vascular	 integrity,	 leading	 to	 significant	 MSC-
induced	amelioration	of	sepsis	117.		
1.2.3. MSCs and tissue repair by paracrine signaling 
Due	 to	 their	 wide	 tissue	 distribution,	 and	 their	 multipotent	 differentiation	 capabilities,	 MSCs	 are	
thought	to	play	important	roles	in	the	repair	of	damaged	tissues	118.	During	tissue	injury,	such	as	the	
emphysema	present	 in	COPD,	 immune	cells	are	recruited	to	the	site	of	damage	by	factors	secreted	
from	 apoptotic	 and	 necrotic	 cells,	 injured	 microvasculature,	 and	 stroma,	 so-called	 damage-
associated	 molecular	 patterns	 (DAMPs)	 119–121.	 These	 inflammatory	 cells	 in	 turn	 produce	 pro-
inflammatory	 cytokines	 such	 as	 interleukin	 1-beta	 (IL-1beta),	 interferon	 gamma	 (IFN-gamma),	 and	
TNF-alpha,	 chemokines,	 and	 free	 radicals,	which	 conversely	 induce	 the	 secretion	of	growth	 factors	
from	MSCs,	 including	 interleukin	 6	 (IL-6),	 epidermal	 growth	 factor	 (EGF),	 fibroblast	 growth	 factor	
(FGF),	platelet-derived	growth	factor	(PDGF),	vascular	endothelial	growth	factor	(VEGF),	hepatocyte	
growth	 factor	 (HGF),	 keratinocyte	 growth	 factor	 (KGF),	 insulin-like	 growth	 factor-1	 (IGF-1),	
antiopoietin-1	(ANGPT1),	stromal	cell	derived	factor-1	(SDF-1),	and	transforming	growth	factor-beta	
(TGF-beta)	 122–125.	These	molecules	orchestrate	a	molecular	program	that	 leads	 to	a	 support	of	 the	
development	of	myofibroblasts,	endothelial	cells	as	well	as	tissue	progenitor	cells,	resulting	in	tissue	




MSC-induced	 tissue	 regeneration	 is	 IL-6,	 which	 has	 been	 recently	 described	 to	 support	 the	
regeneration	of	airway	ciliated	cells	from	basal	stem	cells	in	vivo	136.		
Apart	from	classical	growth	factors	and	cytokines,	MSCs	also	secrete	other	types	of	molecules	such	
as	 the	 anti-microbial	 peptide	 LL37	 137	 and	 Lipoxin	 A4,	 a	 lipid	 mediator	 which	 has	 recently	 been	
described	 to	 lead	 to	 significant	 amelioration	 of	 acute	 lung	 injury	 138.	 These	 molecules	 could	 be	
especially	important	in	light	of	the	treatment	of	COPD	patients	suffering	from	acute	exacerbations	of	
disease	due	to	bacterial	and	viral	infections.	
1.2.4. Immunomodulatory properties of MSCs 
MSCs	possess	highly	effective	immunoregulatory	properties,	affecting	both	the	innate	and	adaptive	
immune	system	111.	 It	 is	 important	 to	note	 that	 there	 is	a	plasticity	of	MSCs	 in	 immunomodulation	
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that	 is	 dependent	 on	 the	 microenvironment	 139,140.	 In	 the	 context	 of	 inflammation,	 MSCs	 are	
predominantly	 instructing	 anti-inflammatory	 functions,	while	 in	 an	 anti-inflammatory	 environment	
they	 support	 pro-inflammatory	 actions	 of	 immune	 cells,	 providing	 a	 mechanism	 to	 maintain	 a	
balanced	immune	response	141.		
In	 co-culture	 experiments	 MSCs	 have	 been	 shown	 to	 have	 the	 ability	 to	 modulate	 a	 variety	 of	
immune	 cells,	 including	 T	 cells,	 B	 cells,	 neutrophils,	 macrophages,	 natural	 killer	 (NK)	 cells,	 and	
dendritic	 cells	 (DCs)	 142,143.	 These	 effects	 are	 thought	 to	 be	 primarily	 mediated	 via	 a	 number	 of	
soluble	 factors	 secreted	 by	 MSCs	 including:	 indoleamine	 2,3-dioxygenase	 (IDO),	 prostaglandin	 E2	
(PGE2),	 interleukin	 10	 (IL-10),	 IL-1	 receptor	 antagonist	 (IL-1ra),	 TGF-beta,	 HLA-G5,	 and	 TNF-alpha-
stimulated	 gene	 6	 (TSG-6)	 141.	 These	 paracrine	 factors	 can	 influence	 immune	 processes	 as	
demonstrated	by	the	example	of	IL-1ra	secreted	by	MSCs,	shown	to	mediate	both	anti-inflammatory	




can	 help	 induce	 a	 shift	 towards	 a	 regulatory	 T	 cell	 phenotype,	 even	 in	 the	 case	 of	 Th17	 effector	
cells	147–150.	Interestingly,	these	effects	of	MSCs	on	T	cell	biology	have	also	been	described	in	models	
of	allergic	airway	 inflammation	and	acute	 lung	 injury	 151,152.	Direct	 cell-cell	 contact	 via	 the	FAS/FAS	
ligand	death	pathway	 is	 thought	 to	play	 a	 role	 in	 the	 induction	of	 apoptosis	of	 T	 cells	 by	MSCs	as	
described	 in	 mouse	 models	 of	 systemic	 sclerosis	 and	 experimental	 colitis	 153.	 Furthermore,	 MSCs	
have	been	shown	to	suppress	B	cell	proliferation	and	differentiation	towards	plasma	cells	154,155,	and	
to	induce	the	development	of	IL-10-secreting	regulatory	B	cells	156.		
In	 addition,	 MSCs	 have	 the	 ability	 to	 regulate	 T	 and	 B	 cells	 through	 their	 effects	 on	 antigen-
presenting	 cells,	 such	 as	 DCs	 or	 monocytes,	 both	 of	 which	 adopt	 a	 suppressive,	 IL-10-producing	
phenotype	in	the	presence	of	MSCs	157–159.		
As	detailed	above,	macrophages	and	neutrophils,	cells	of	the	innate	immune	system,	are	thought	to	
represent	major	 effector	 immune	 cell	 types	 involved	 in	 the	 pathogenesis	 of	 COPD.	MSCs	 can	 also	
regulate	macrophage	and	neutrophil	biology	142,143.	Upon	exposure	to	MSCs,	macrophages	undergo	a	
phenotypic	 switch	 from	 classically	 activated	 pro-inflammatory	 macrophages	 (M1),	 to	 alternatively	
activated	 anti-inflammatory	macrophages	 (M2),	 in	 response	 to	 PGE2	 and	 TSG-6	 secreted	 by	MSCs	
under	 inflammatory	 conditions	 160,161.	 Accordingly,	 MSCs	 have	 been	 described	 to	 alleviate	
emphysema	 and	 airway	 inflammation	 in	 a	 rat	 model	 through	 their	 interaction	 with	 alveolar	
macrophages	 162.	 It	 has	 furthermore	 been	 shown	 that	 MSCs	 effectively	 decrease	 neutrophil	
infiltration	 in	 mouse	 models	 of	 experimental	 emphysema	 and	 obliterative	 bronchiolitis	 163,164	 and	
inhibit	neutrophil-mediated	tissue	damage	in	a	murine	model	of	vasculitis	165.		
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A	 newly	 discovered	mechanism	 of	 cell	 communication	 is	 based	 on	 their	 secretion	 of	 extracellular	






1.2.5. Advantages of MSCs for clinical use 
Apart	 from	 their	 outstanding	 immunomodulatory	 and	 tissue-protective	 functions,	 MSCs	 have	
additional	characteristics	that	make	them	very	attractive	candidate	cells	for	clinical	use.	As	described	
above,	one	is	their	ease	of	access.	They	can	be	isolated	from	a	variety	of	different	tissues,	some	of	
which	 otherwise	would	 even	 be	 subject	 to	 discard,	 such	 as	 adipose	 tissue	 or	 placenta.	Moreover,	
they	can	readily	be	expanded	using	basic	standard	cell	culture	methods,	which	to	date	is	not	possible	
to	that	extent	 for	many	other	cell	 types	such	as	e.g.	HSCs	168.	Furthermore,	 in	comparison	to	ESCs,	
there	are	no	ethical	issues	associated	with	the	clinical	use	of	MSCs,	and	as	opposed	to	iPSCs,	MSCs	do	
not	entail	the	risk	of	teratoma	formation	due	to	the	fact	that	they	are	not	pluripotent	169.	Owing	to	
their	 limited	 lifespan	and	other	 intrinsic	 factors,	also	 the	overall	 risk	of	 tumorigenicity	seems	to	be	
negligible	 170.	 Another	 advantage	MSCs	have	 in	 contrast	 to	 other	 cell	 types	 is	 the	 fact	 that	 due	 to	
their	 immunomodulatory	 properties,	 they	 are	 immune-evasive	 and	 can	 be	 administered	 in	 an	
allogeneic	 setting	 99.	 In	 fact,	 most	 patients	 in	 clinical	 trials	 receive	 allogeneic	 MSCs	 171,	 and	 their	
application	 seems	 to	 be	 feasible	 and	 safe	 so	 far	 115,172.	 One	 major	 advantage	 MSCs	 have	 in	
comparison	to	other	therapies,	such	as	small	molecules	or	biologics,	 is	 that	based	on	their	 intrinsic	
ability	 to	home	to	sites	of	 injury	and	 inflammation,	 they	exert	 their	effects	 locally,	 thus	minimizing	
the	toxicity	oftentimes	seen	with	the	first-mentioned	substances	173.	Moreover,	while	many	non-cell-
based	medications	have	to	be	applied	many	times	to	yield	a	 therapeutic	benefit	due	to	their	short	
half-life,	 it	 is	 thought	that	even	a	single	application	of	MSCs	 is	beneficial	due	to	their	“hit-and-run”	
mode	 of	 action	 115,116,174,175.	 All	 these	 features	 taken	 together	make	MSCs	 an	 extremely	 attractive	
candidate	cell	for	clinical	applications.		
MSCs	 seem	 ideally	 suited	 as	 therapy	 vehicles	 for	 the	 treatment	 of	 COPD	 due	 to	 their	 potent	
immunomodulatory	 and	 regenerative	 properties	 combined	with	 their	 ease	 of	 clinical	 applicability.	
Recently,	 gene	modification	 has	 emerged	 as	 a	 potent	 tool	 to	modulate	 cell	 therapy	 products.	 The	
goal	of	this	thesis	is	focused	at	exploring	the	potential	of	genetically	modified	MSCs	as	an	optimized	
cell	product	for	the	treatment	of	COPD.	
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1.3. Cell-based gene therapy 
Cell-based	gene	therapy	is	described	as	the	introduction	of	genetic	material	into	cells,	and	the	use	of	
these	 gene-modified	 cells	 with	 their	 new	 or	 enhanced	 therapeutic	 properties	 for	 the	 prevention,	
alleviation,	 or	 cure	 of	 a	 disease.	 The	 most	 common	 strategy	 employed	 for	 the	 introduction	 of	
transgenes	 into	 cells	 makes	 use	 of	 integrating	 viral	 vectors	 such	 as	 gamma-retroviral	 or	 lentiviral	
vectors	 176,177.	 Since	 its	 infancy	 in	 the	 1970s,	 when	 the	 first	 clinical	 trials	 using	 gene	 therapy	
approaches	were	performed	 178–181,	 gene	 therapy	has	undergone	great	ups	and	downs,	but	 in	May	
2016	 the	 first	 ex	 vivo	 stem	 cell	 gene	 therapy	 product	 received	 marketing	 authorization	 by	 the	
European	 Commission	 182.	 However,	 as	 straight	 forward	 as	 this	 approach	 sounds,	 the	 obstacles	 of	
putting	it	into	practice	are	extremely	challenging.	New	genetic	information	must	be	introduced	into	
the	 target	 cells	 past	 complicated	 cellular	 barriers;	 the	 transgene	 has	 to	 be	 expressed	 at	 sufficient	
levels	 to	 yield	 a	 therapeutic	 benefit	 without	 disrupting	 important	 regulatory	 mechanisms;	 the	
genetically	modified	 cells	must	 then	 be	 produced	 in	 sufficient	 amounts;	 and	when	 applied	 to	 the	
patient,	 the	 cells	 must	 evade	 the	 patient’s	 immunological	 surveillance	 long	 enough	 to	 be	 able	 to	
exert	their	therapeutic	effects	177.	Thus	it	is	not	surprising	that	only	a	limited	number	of	clinical	gene	
therapy	trials	performed	during	the	last	two	decades	were	able	to	demonstrate	clear	benefits	for	the	





life-threatening	 diseases	 like	 primary	 immunodeficiencies	 184,188,189,	 Wiskott-Aldrich	 syndrome	 190,	
thalassemia	 191,	 and	neurodegenerative	 storage	diseases	 192,193.	 These	have	been	made	possible	by	




example	armed	with	a	suicide	gene,	are	currently	 in	a	 first-in-human	phase	 I/II	 study	 for	advanced	
gastrointestinal	 tumors	 196	 and	 have	 demonstrated	 an	 excellent	 safety	 profile	 so	 far	 (C.	 Günther,	
personal	 communication).	 Of	 course,	 suicide	 genes	 represent	 only	 one	 approach	 for	 genetically	
modifying	 MSCs	 with	 to	 give	 them	 additional	 features.	 The	 potential	 importance	 of	 AAT	 for	
inflammatory	lung	diseases,	especially	emphysematous	COPD,	has	been	laid	out	above.	Thus,	out	of	
the	 plethora	 of	 potentially	 beneficial	 genes	 that	 could	 be	 used	 to	 equip	 MSCs	 for	 the	 enhanced	
treatment	of	inflammatory	diseases,	we	chose	AAT	based	on	its	variety	of	functions	described	in	the	
following	section.	
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1.4. Alpha-1 antitrypsin 
1.4.1. The discovery of AAT 
The	ability	of	human	plasma	to	inhibit	proteases	was	first	described	in	1894	197.	It	was	not	until	1955	
that	Schultze	and	colleagues	discovered	the	protein	responsible	for	this	anti-protease	activity.	They	




this	 protein	 for	 human	 health	 and	 disease.	 At	 the	 same	 time	 it	 was	 described	 that	 intratracheal	






AAT	 action	 203–206.	 At	 the	 same	 time,	 a	 close	 link	 between	 smoking	 and	 the	 development	 of	
emphysema	 was	 identified	 207,208.	 In	 further	 studies,	 a	 protease-antiprotease	 imbalance	 was	
hypothesized	 as	 the	 cause	of	 emphysema	not	 only	 for	 patients	 suffering	 from	AAT	deficiency,	 but	
also	by	extension,	for	COPD	patients	45,209,210.	Supported	by	the	work	of	Gadek	and	colleagues	211,	the	




1.4.2. AAT deficiency 
AAT	deficiency	is	a	genetic	disorder	marked	by	production	of	defective	AAT	protein,	decreased	serum	
AAT	 concentrations,	 and	 accumulation	 of	 misfolded	 protein	 in	 the	 endoplasmic	 reticulum	 (ER)	 of	
hepatocytes	219.	The	most	severe	variant,	the	so-called	Z-phenotype,	affects	approximately	1	in	2000	
North	 European	 Caucasians	 220.	 Clinically,	 this	 archetypal	 conformational	 serpinopathy	 is	
characterized	 by	 early-onset	 panlobular	 basal	 lung	 emphysema	 due	 to	 uninhibited	 breakdown	 of	
lung	 tissue	 by	 proteases	 200,221.	 As	 such,	 AAT	 deficiency	 is	 the	 only	 known	 genetic	 cause	 of	
emphysema	 3	 and	 the	 only	 recognized	 genetic	 factor	 that	 increases	 the	 predisposition	 to	 develop	
COPD	222,223.	 In	addition	to	 lung	disease,	patients	carrying	the	severe	Z	deficiency	allele	often	suffer	
from	neonatal	hepatitis,	cirrhosis,	and	hepatocellular	carcinoma	224,225.	Furthermore,	AAT	deficiency	
has	 been	 linked	 to	 several	 inflammatory	 diseases	 such	 as	 panniculitis,	 vasculitis	 (in	 particular	
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Wegener’s	 granulomatosis),	 bronchiectasis,	 and	 ulcerative	 colitis,	 suggesting	 that	 neutrophil	
proteases	 are	 also	 involved	 in	 the	 pathogenesis	 of	 these	 diseases	 226,	 and	 demonstrating	 the	
importance	of	AAT	in	maintaining	tissue	homeostasis	and	controlling	inflammation.		
1.4.3. Biochemical characteristics of AAT 
AAT,	also	termed	alpha-1	proteinase	inhibitor	(A1PI),	 is	a	52kDa,	water-soluble	and	tissue-diffusible	
394-amino	acid	circulating	glycoprotein	encoded	by	the	SERPINA1	gene	227–229.	AAT	is	the	prototypic	
member	 of	 the	 serine	 protease	 inhibitor	 (SERPIN)	 superfamily	 230.	 Serpins	 are	 protease	 inhibitors	
found	in	all	kingdoms	of	life	that	play	important	roles	in	a	variety	of	biological	processes	including	the	
control	of	 inflammation	or	coagulation	 231,232.	Despite	 its	name,	 the	major	 target	of	 this	 inhibitor	 is	
the	serine	protease	elastase	released	from	neutrophils	during	inflammation,	and	AAT	binds	to	it	with	
one	of	the	highest	association	rate	constants	observed	in	biology	233.	In	addition,	AAT	can	also	block	
proteinase	 3,	myeloperoxidase,	 and	 cathepsin	 G	 secreted	 by	 neutrophils,	 the	 coagulation	 cascade	






context	 during	 inflammatory	 reactions	 216,238–242.	 Bone	 marrow-derived	 MSCs	 do	 not	 appear	 to	







1.4.4. Mechanism of proteinase inhibition 
The	irreversible	suicide	substrate-like	inhibitory	mechanism	that	AAT	is	well-known	for	is	linked	to	its	
tertiary	structure,	which	is	highly	similar	among	all	serpins.	It	consists	of	three	beta	sheets	(named	A,	




(Figure	 1B)	 and	 initiates	 a	 dramatic	 conformational	 change	 for	 both	 AAT	 as	 well	 as	 the	 protease	
Introduction   
	
13
(Figure	 1C).	 During	 this	 so-called	 stressed	 to	 relaxed	 transition,	 the	 covalently	 bound	 protease	 is	
transferred	 from	 one	 pole	 of	 the	 AAT	 protein	 to	 the	 other	 by	 the	 RCL.	 This	 mousetrap-like	
mechanism	is	a	suicide	interaction	for	both	parties	involved	and	results	in	an	energetically	favorable	
conformation	 of	 the	 serpin	 and	 complete	 distortion	 of	 the	 structure	 of	 the	 protease,	 thereby	
inactivating	 it	 and	at	 the	 same	 time	 inducing	 clearing	pathways	 to	degrade	 the	 inactivated	 serpin-
protease-complex	216,255,256.		
	
Figure	 1:	 Proteases	 are	 inhibited	 by	 AAT	 by	 a	 suicide	 substrate-like	 mechanism.	 A:	 Tertiary	
structure	of	AAT.	Indicated	are	the	RCL	(red)	with	the	reactive	site	centered	at	Met358	–	Ser359	(green	
and	yellow	balls,	respectively).	B:	AAT-protease	docking	complex.	The	protease	binds	to	Ser359	in	an	
attempt	 to	 cleave	 the	 reactive	 site	bond	between	Met358	 –	 Ser359.	C:	 Final	AAT-protease	 complex.	
After	 cleaving	 the	 reactive	 site	 bond,	 the	 protease	 remains	 stably	 bound	 to	 Ser359,	 while	 AAT	
undergoes	a	conformational	change,	leading	to	structural	distortion	and	inactivation	of	the	protease.	
Figure	 modified	 from	 PeproTechFocus.	 Serpins,	 Serpinopathies,	 and	 Conformational	 Diseases	
(n.d.)252.		
1.4.5. Anti-inflammatory and immunomodulatory properties of AAT 
Solely	 considering	 the	 name	 of	 the	 protein,	 one	 is	 tempted	 to	 assume	 that	 the	 anti-inflammatory	
activity	of	AAT	is	purely	biochemical	and	related	to	the	inhibition	of	proteases	during	inflammatory	
processes.	 However,	 during	 the	 last	 decade	 it	 has	 been	 recognized	 that	 AAT	 not	 only	 is	 a	 potent	
protease	inhibitor	protecting	tissues	from	the	damaging	effect	of	enzymes	excessively	released	from	
inflammatory	cells,	but	also	has	powerful	immunomodulatory	and	tissue-protective	properties,	some	
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1.4.5.1. AAT as acute phase protein – anti-inflammatory effects 
AAT	 is	 a	 hepatic	 acute	 phase	 protein	 with	 an	 inflammation-,	 cortisol-	 and	 hypoxia-inducible	 gene	
promoter	258.	Upon	induction,	 its	concentration	can	increase	more	than	4-fold	in	plasma,	and	up	to	
11-fold	 in	 tissues	 such	 as	 the	 lung,	 pancreas	 or	 intestine	 due	 to	 it	 being	 locally	 synthesized	 by	
inflammatory	cells	as	a	protective	response	to	infection	and	inflammation	251,259–263.	AAT	levels	in	the	
circulation	 also	 rise	 during	 pregnancy,	 a	 state	 in	 which	 the	 induction	 of	 tolerance	 is	 especially	
important	264.		
Many	of	the	anti-inflammatory	functions	of	AAT	are	related	to	its	ability	to	 inhibit	proteases.	 It	has	
e.g.	 been	 described	 that	 serine	 proteases	 activate	 IL-1	 precursor	 proteins	 exposed	 from	 necrotic	
cells,	 which	 is	 diminished	 in	 the	 presence	 of	 increased	 levels	 of	 AAT	 265.	 This	 mechanism	 is	 of	
particular	 importance	 for	 the	 present	work,	 since	 it	 is	 commonly	 accepted	 that	 IL-1	 is	 one	 of	 the	
major	 pro-inflammatory	 cytokines	 involved	 in	 the	 pathogenesis	 of	 smoke-induced	 COPD	 266.	 It	 has	
also	been	suggested	that	the	anti-inflammatory	potential	of	AAT	 is	mediated	by	the	 inactivation	of	
serine	proteases	which	signal	via	a	group	of	membrane	protein	receptors	named	protease-activated	





with	 thrombospondin	 motifs	 4	 (ADAMTS-4),	 a	 protein	 involved	 in	 rheumatoid	 arthritis,	 or	 matrix	
metallopeptidase-9	(MMP-9),	which	is	related	to	COPD	272–274.		
Furthermore,	AAT	has	been	described	to	have	anti-inflammatory	functions	that	are	 independent	of	





shock	 proteins	 like	 heat	 shock	 protein	 90kDa	 beta	 member	 1	 (HSP90B1)	 and	 heat	 shock	 protein	
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1.4.5.2. Effects on innate immunity 
It	 is	 thought	 that	AAT	has	 the	ability	 to	shift	 local,	as	well	as	systemic	cytokine	environments	 from	
pro-	to	anti-inflammatory	257.	This	is	thought	to	be	mediated	by	effects	on	cells	of	the	innate	immune	
system	such	as	monocytes/macrophages	and	neutrophils	–	cell	types	significantly	associated	with	the	
pathogenesis	of	COPD	266.	 It	has	been	shown	 in	numerous	studies	 that	AAT	has	a	potent	 inhibitory	
effect	 on	 the	 production	 of	 pro-inflammatory	 cytokines	 such	 as	 IL-1beta,	 TNF-alpha,	 and	 IL-8	 by	




to	a	major	chemoattractant	 for	neutrophils,	 the	cytokine	 IL-8	 275.	The	same	group	recently	showed	
that	 AAT	 regulates	 TNF-alpha-induced	 degranulation	 of	 neutrophils,	 and	 thus	 the	 release	 of	
elastase	278.		
AAT	also	exerts	tolerance-inducing	effects	on	DCs	and	macrophages.	Recently,	it	was	reported	that	in	
the	 presence	 of	 AAT,	 the	 expression	 of	 CD40,	 CD84	 and	major	 histocompatibility	 complex	 (MHC)	
class	 II	 in	 stimulated	 DCs	 is	 reduced.	 At	 the	 same	 time,	 IL-10	 production	 is	 increased	 and	 the	











and	anti-tumor	effects	 297–300.	The	hypothesized	underlying	mechanism	 is	 that	 the	effect	of	AAT	on	
NK	 cells	 is	 immune	 permissive	 in	 the	 case	 of	 infected	 or	 transformed	 cells,	 but	 suppressive	 if	 the	
target	cells	are	healthy	and	the	immune	signal	predominantly	antigen	presenting	cell-mediated	258.		
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cell	 receptor	 repertoire	 and	 expansion	 of	 Tregs	 in	 models	 of	 autoimmunity	 or	
allotransplantation	285,286,290,303–306.	 It	 is	 suspected	 that	 all	 these	 effects	 on	 the	 adaptive	 immune	
system	result	from	a	shift	of	the	cytokine	environment	from	pro-	to	anti-inflammatory	and	from	the	
induction	of	 tolerogenic,	 IL-10-secreting	DCs	 257,290.	Another	effect	AAT	appears	 to	exert	on	cells	of	
the	adaptive	immune	system	is	a	suppression	of	the	activation	and	proliferation	of	B	lymphocytes,	as	
recently	 shown	 in	 a	 model	 of	 allogeneic	 skin	 transplantation	 307.	 Surprisingly,	 antigen-specific	





1.4.6. Anti-apoptotic and regenerative effects 
Of	special	importance	for	the	present	work	is	the	observation	that	AAT	has	significant	anti-apoptotic	
and	 cytoprotective	 effects	 in	 addition	 to	 its	 anti-inflammatory	 potential.	 Petrache	 and	 colleagues	
showed	 that	 AAT	 is	 able	 to	 inhibit	 pulmonary	 alveolar	 cell	 apoptosis	 by	 suppression	 of	 caspase-3	
activation	 and	 oxidative	 stress,	 and	 attenuate	 emphysema	 development	 in	 animal	 models	 of	
apoptosis-dependent	 emphysema	 lacking	 neutrophilic	 inflammation	 237,309.	 Furthermore,	 two	




while	 also	 inducing	 the	 production	 and	 preventing	 the	 elastase-dependent	 degradation	 of	 VEGF,	
thereby	contributing	to	tissue	neovascularization	and	regeneration	314,315.	
1.4.7. Anti-microbial functions 
In	addition	to	its	 immunomodulatory	and	regenerative	properties,	AAT	has	been	described	to	exert	
anti-bacterial	 and	 anti-viral	 functions.	 Shapiro	 and	 colleagues	 initially	 found	 that	 while	 in	 vitro	
infection	of	human	whole	blood	with	the	human	immunodeficiency	virus	(HIV)	does	not	occur,	whole	
blood	 from	AAT-deficient	patients	 is	 readily	 infected	 316.	 Later,	 the	 same	group	described	 that	HIV	
infection	 is	 linked	 to	 reduced	 serum	AAT	 levels	 317	 and	 that	patients	 suffering	 from	AAT	deficiency	
might	be	at	higher	risk	for	acquiring	HIV	infection	299.	Furthermore,	aerosolized	AAT	has	been	shown	
to	 be	 able	 to	 suppress	 Pseudomonas	 aeruginosa	 proliferation	 in	 a	 rat	 model	 of	 chronic	 lung	
infection318	 and	 in	 patients	 suffering	 from	 cystic	 fibrosis	 319.	 Another	 anti-bacterial	 property	
associated	with	AAT	is	its	binding	to	the	secreted	enteropathogenic	Escherichia	coli	proteins	B	and	D	
(EspB,	 EspD),	 thereby	 potently	 inhibiting	 hemolysis	 of	 red	 blood	 cells	 320.	 These	 anti-microbial	







Taken	 together,	 AAT	 is	 not	 a	 prototypic	 anti-inflammatory	 molecule	 that	 blocks	 the	 activity	 of	
immune	cells,	but	rather	an	immune	modulator	that	permits	an	effective	immune	reaction,	while	at	
the	 same	 time	 limits	 an	excessive	 inflammatory	 response,	 induces	 immunological	 tolerance	 that	 is	





type	1,	 cystic	 fibrosis,	 sarcoidosis,	 solid	 organ	 and	 islet	 cell	 transplantation,	HIV	disease	 and	GvHD	
with	very	promising	results	so	far	319,321–324,	it	represents	an	excellent	candidate	molecule	to	combine	
with	MSC-based	approaches	for	the	potential	treatment	of	chronic	airway	disorders.	





• MSCs	 have	 been	 shown	 to	 exert	 extremely	 potent	 immunomodulatory	 and	 regenerative	
functions	on	a	variety	of	cells	in	response	to	inflammatory	stimuli.	Moreover,	they	have	been	
proven	to	be	anti-microbial	and	hypoimmunogenic	when	used	in	an	allogeneic	setting.	They	
are	 currently	 being	 investigated	 in	 more	 than	 500	 clinical	 trials,	 most	 of	 them	 related	 to	
inflammatory	diseases	 including	COPD,	with	 very	promising	 results	 and	 an	excellent	 safety	
profile	so	far.	Compared	to	other	stem	cell	types	or	small	molecules	and	biologics,	MSCs	have	
several	advantages	regarding	their	clinical	usability.		
• AAT	 is	 an	 acute	 phase	 protein	 and	 the	 prototypic	 serine	 protease	 inhibitor	 in	 the	 human	
body,	 protecting	 tissues	 from	 the	 damaging	 effect	 of	 enzymes	 secreted	 by	 immune	 cells	
during	 inflammation.	Moreover,	AAT	has	 lately	also	been	recognized	as	a	protein	with	very	
potent	regenerative,	anti-inflammatory	and	immunoregulatory	functions	affecting	all	parts	of	
the	 immune	 system.	 It	 has	 also	 been	 shown	 to	 efficiently	 prevent	 viral	 and	 bacterial	
infections.	AAT	has	been	used	for	the	chronic	treatment	of	AAT	deficiency	for	almost	three	





• Cell-based	 gene	 therapy	 has	 yielded	 striking	 results	 in	 the	 treatment	 of	 various	 previously	
incurable	 diseases	 during	 the	 last	 years.	 This	 innovative	 therapeutic	 approach	 offers	 the	
possibility	of	combining	the	function	of	one	or	more	transgenes	with	the	cells’	endogenous	
properties,	 resulting	 in	a	more	potent	cell	product	 for	 the	treatment	of	various	diseases.	 It	
was	only	very	recently	 that	the	first	ex	vivo	 stem	cell-based	gene	therapy	product	received	
market	authorization	by	the	European	Commission	for	the	treatment	of	the	so	far	hopeless	
disease	 adenosine	 deaminase-deficient	 severe	 combined	 immunodeficiency	 (ADA-
SCID)182,325.	
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regards	 to	 viral	 titers,	 transduction	 efficacy,	 and	 AAT	 expression.	 Three	 different	 human	
physiological	 gene	 promoters	would	 be	 tested	 in	 parallel	 for	 driving	 SERPINA1	 expression.	
The	pac	gene	enabling	selection	of	gene-modified	cells	using	the	antibiotic	puromycin	should	
be	 driven	 either	 by	 a	 second	 promoter,	 or	 expressed	 via	 an	 internal	 ribosome	 entry	 site	
(IRES)	 sequence	 3’	 of	 the	SERPINA1	 gene.	 In	 case	of	 constructs	 containing	 two	promoters,	
different	 configurations	 of	 the	 expression	 cassettes	 should	 be	 assessed,	 i.e.	 the	 SERPINA1	
cassette	would	be	placed	5’	of	the	pac	cassette	in	some	constructs,	and	3’	in	others.		
• Generation	 of	 functional	 viral	 supernatants	 and	 titration	 on	 HT1080	 fibrosarcoma	 cells.	
Viral	 supernatants	of	 the	eight	 transfer	plasmids	 in	combination	with	the	respective	helper	






• Comparison	 of	 best	 expression	 cassette	 in	 gamma-retroviral	 vs.	 lentiviral	 backbone.	 To	










• Confirmation	of	 efficacy	 of	AAT-MSCs	 in	 an	 in	 vivo	model	 of	 lung	 emphysema.	 Finally,	 it	
should	 be	 assessed	 if	 therapy	 with	 AAT-MSCs	 was	 able	 to	 improve	 lung	 function	 and	
histological	parameters	in	a	mouse	model	of	elastase-induced	pulmonary	emphysema.		
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Primers	were	designed	 following	general	primer	design	 rules	 326,	 checked	 for	hairpin	 structure	and	
































































































































































































Incubator	Heraeus	BBD6220	 Thermo Fisher Scientific 
Incubator	Heraeus	Function	Line	 Thermo Fisher Scientific 
Incubator	MCO-20AIC	 Sanyo 
Incubator	shaker	KS-15	A	Control	 Edmund	Bühler	GmbH	


































2.2.1. Design and molecular cloning strategy of viral expression plasmids 
2.2.1.1. Gamma-retroviral plasmids 
The	 in	vitro	synthesized	5’	UTR	and	CDS	of	the	human	SERPINA1	cDNA	transcript	1	were	purchased	
from	GeneArt,	with	 the	 following	 sequence	modifications:	A	BamHI	 restriction	enzyme	 recognition	
site	present	in	the	5’UTR	was	destroyed	by	replacing	a	cytosine	by	an	adenine	at	position	181	of	the	
5’	UTR	(GGATCA	instead	of	GGATCC).	A	modified	Kozak	consensus	sequence	(GCCACC)	was	inserted	
at	 the	 3’	 end	 of	 the	 5’UTR	 sequence,	 immediately	 5’	 of	 the	 SERPINA1	 start	 codon	 for	 efficient	
initiation	 of	 translation	 327.	 The	SERPINA1	 CDS	was	 codon	optimized	 for	Homo	 sapiens	 to	 increase	
protein	production.	Two	additional	stop	codons	were	added	3’	of	the	SERPINA1	stop	codon	to	ensure	
efficient	 release	 of	 the	 amino	 acid	 chain	 from	 the	 ribosome	 during	 translation.	 An	 AgeI	 site	 was	
added	to	the	5’	end	of	the	cassette,	and	a	PacI	site	to	the	3’	to	enable	easy	transfer	of	this	expression	






Plasmid	numbers	 represent	 apceth’s	 internal	plasmid	denomination	and	will	 be	used	hereafter	 for	
simplicity.	The	gamma-retroviral	backbone	used	to	generate	all	transfer	plasmids	is	pSERS11	328.	The	
5’-LTR	 comprises	 a	 simian	 vacuolating	 virus	 40	 (SV40)	 enhancer	 fused	 to	 the	 Rous	 sarcoma	 virus	
(RSV)	promoter,	and	the	spleen	focus	forming	virus	 (SFFVp)	R	and	U5	regions.	The	3’	 long	terminal	
repeat	 (LTR)	 contains	 an	 SFFVp	 U3	 region	 that	 has	 a	 deletion	 and	 thus	 renders	 the	 vector	 self-
inactivating,	 SFFV	 R	 and	 U5	 regions	 as	 well	 as	 a	 PolyA	 signal.	 To	 clone	 plasmid	 #114	
pSERS11_pPGK_SERPINA1_IRES_pac,	 in	a	first	step	a	unique	PacI	restriction	site	was	generated	in	a	
plasmid	 previously	 cloned	 at	 apceth	 (#110	 pSERS11_pPGK_IFN-beta_fw_IRES_pac,	 Supplemental	
figure	 1)	 by	 site-directed	 mutagenesis	 using	 the	 GeneArt	 Site-Directed	Mutagenesis	 PLUS	 Kit	 and	
primers	 Mutagenesis_PacI_F,	 Mutagenesis_PacI_R,	 Mutagenesis_Vector_F,	 Mutagenesis_Vector_R	
(cf.	 2.1.3	 for	 sequences).	Utilizing	 this	 newly	 created	 restriction	 site	3’	 of	 the	 interferon-beta	 (IFN-
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beta)	 cassette	 present	 in	 plasmid	 #110,	 the	 IFN-beta	 cassette	 was	 replaced	 by	 the	 SERPINA1	
expression	 cassette	 ordered	 from	 GeneArt	 using	 restriction	 enzymes	 PacI	 and	 AgeI.	 After	 the	
integrity	 of	 this	 first	 construct	was	 confirmed	 by	 analytical	 restriction	 enzyme	 digestion,	 in	 a	 next	
step	 the	 phosphoglycerate	 kinase	 (PGK)	 promoter	 was	 replaced	 by	 the	 eukaryotic	 translation	
elongation	factor	1	alpha	1	(EF1a)	promoter	present	in	another	plasmid	previously	cloned	at	apceth,	
#112	pSERS11_pEF1a_IFN-beta_fw_IRES_pac	 Supplemental	 figure	2),	 using	 the	 restriction	 sites	 SalI	
and	AgeI,	 yielding	 construct	#115	pSERS11_pEF1a_SERPINA1_IRES_pac.	 In	order	 to	 clone	 construct	
#116	 in	which	 the	 SERPINA1	 cDNA	 is	 driven	 by	 the	 CAG	 promoter,	 in	which	 the	 CMV	 enhancer	 is	
followed	by	the	chicken	beta	actin	promoter	and	the	rabbit	beta	globin	splice	acceptor,	a	cassette	of	
the	 configuration	 SalI-pCAG-AgeI	 was	 ordered	 from	 GeneArt	 and	 transferred	 to	 plasmid	 #114	 by	
digesting	both	plasmids	with	SalI	and	AgeI,	 thereby	replacing	the	PGK	promoter	present	 in	plasmid	
#114	with	the	CAG	promoter.	The	same	strategy	was	used	to	generate	the	fourth	construct,	#129,	in	
which	the	short	 intron-less	 form	of	EF1a	(EFS	329)	 is	driving	the	SERPINA1	 cDNA.	The	SalI-pEFS-AgeI	
cassette	 was	 ordered	 from	 GeneArt	 with	 one	 modification	 (A79T)	 compared	 to	 the	 published	
sequence	to	remove	an	AgeI	site	present	 in	pEFS,	and	SalI	and	AgeI	were	used	to	remove	the	PGK	
promoter	 present	 in	 plasmid	 #114	 and	 to	 insert	 the	 EFS	 promoter.	 Before	 maxipreps	 and	 viral	
supernatants	were	generated,	all	four	plasmids	were	sequenced	to	confirm	their	integrity.		
Cloning	of	“2nd	generation”	AAT	constructs	






the	 resulting	 insert	 (promoter_SERPINA1)	 was	 transferred	 to	 the	 optimized	 retroviral	 backbone	
(plasmid	 #139	 pSERS11_Leader_MCS_oPRE,	 Supplemental	 figure	 3)	 that	 had	 been	 linearized	 using	
the	 same	 restriction	 enzymes.	 The	 resulting	 intermediate	 constructs	 were	 #154	
pSERS11_pPGK_SERPINA1,	#155	pSERS11_pEF1a_SERPINA1,	and	#156	pSERS11_pEFS_SERPINA1.	To	
remove	pEFS	and	pPGK	from	GeneArt	cassette	#153,	the	plasmid	was	digested	with	ClaI	and	SnaBI,	
respectively,	 and	 the	 remaining	 plasmid	 was	 re-ligated.	 The	 promoter_pac	 cassettes	 were	 then	
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pSERS11_pEFS_SERPINA1_IRES_pac,	 and	 with	 SalI	 and	 PacI	 to	 generate	 plasmid	 #193	
pSERS11_pPGK_SERPINA1_pac.		
2.2.1.2. Lentiviral plasmid 
The	 pEFS_SERPINA1_IRES_pac_oPRE	 cassette	 was	 transferred	 from	 plasmid	 #194	 to	 the	 lentiviral	




#172	pCCL-c-EFS-hADA_WPRE	 (Supplemental	 figure	 5)	was	 kindly	 provided	by	Donald	Kohn,	UCLA,	
and	 linearized	using	 the	 restriction	enzymes	KpnI	 and	ClaI.	 The	primer	design,	 PCR,	 recombination	
reaction	(using	100ng	of	purified	PCR	fragment	and	100ng	of	linearized	vector),	and	transformation	
of	 bacteria	 were	 all	 carried	 out	 following	manufacturer’s	 specifications	 (Protocol	 I),	 with	 the	 only	
modification	 that	 50ng	 of	 plasmid	 #194	 template	 were	 used	 in	 the	 PCR	 reaction	 to	 generate	
homology	arms	on	the	insert	instead	of	1ng	as	recommended	(Table	2).	For	primer	sequences	please	
cf.	 2.1.3.	 A	 plasmid	 map	 of	 the	 resulting	 lentiviral	 AAT	 transfer	 plasmid	 #215	
pCCL_pEFS_SERPINA1_IRES_pac	is	depicted	in	Supplemental	figure	18.	
Table	2:	PCR	master	mix	composition	and	cycling	conditions	for	the	In-Fusion	cloning	PCR.		
PCR	In-Fusion	cloning	#215	 	 	 	 Cycling	conditions	 	
Component	 Amount	[µL]	
Final	
concentration	 	 Temperature	 Time	 	
CloneAmp	HiFi	PCR	Premix	(2X)	 12,5	 1X	 	 98°C	 10	sec	 30	
cycles	Primer	1	[10µM]	 0,5	 [200nM]	 	 55°C	 10	sec	
Primer	2	[10µM]	 0,5	 [200nM]	 	 72°C	 20	sec	
Template	(Plasmid	DNA)	 1,0	 50ng	 	 	 	 	
H2O	 10,5	 	 	 	 	 	
Total	volume	 25,0	 	 	 	 	 	
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2.2.2. Molecular cloning 
2.2.2.1. Production of LB medium/circlegrow medium for E.coli 
25g	 of	 high	 salt	 Luria-Bertani	 (LB)	 medium	 powder	 or	 40g	 of	 circlegrow	 medium	 powder,	
respectively,	were	weighed	into	a	1	liter	(L)	bottle,	1L	deionized	water	was	added,	and	the	medium	
was	 autoclaved.	 When	 required,	 medium	 was	 allowed	 to	 cool	 down	 to	 <60°C,	 and	 antibiotics	 –	
Ampicillin	to	a	final	concentration	of	[100µg/mL],	Kanamycin	to	a	final	concentration	of	[50µg/mL]	–	
were	added.		
2.2.2.2. Production of agar plates 
40g	 of	 LB	Agar	 Powder	were	 added	 to	 a	 1L	 shaking	 flask,	 1L	 deionized	water	was	 added,	 and	 the	




2.2.2.3. Cultivation of E.coli 
Generally,	DH5α	and	Stbl3	cells	were	cultured	in	LB	medium	at	37°C	and	225	revolutions	per	minute	
(rpm)	 shaking.	 When	 problems	 cultivating	 E.coli	 in	 LB	 medium	 occurred,	 the	 richer	 circlegrow	
medium	was	used	instead.		
2.2.2.4. Preparation and inoculation of glycerol stocks 
For	the	long-term	storage	of	bacteria,	glycerol	stocks	were	prepared	by	mixing	250µL	of	autoclaved	
glycerol	with	750µL	of	an	overnight	bacterial	culture.	The	mix	was	stored	at	-80°C	until	re-initiation	of	
the	 culture.	 To	 inoculate	 a	 new	 culture	 from	 the	 glycerol	 stock,	 the	 vial	 was	 removed	 from	 the	
freezer	 without	 letting	 it	 thaw.	 Using	 an	 inoculation	 loop,	 a	 small	 amount	 of	 frozen	 bacteria	 was	
streaked	out	onto	an	agar	plate	containing	the	respective	antibiotic.	After	an	overnight	incubation	at	
37°C,	a	single	bacterial	colony	was	picked	to	inoculate	a	small-scale	liquid	culture.		
2.2.2.5. Restriction enzyme digestion 
All	 restriction	 enzymes	 and	 reaction	 buffers	 used	 in	 this	work	were	 purchased	 from	New	 England	
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2.2.2.6. Gel electrophoresis 
DNA	samples	were	mixed	with	the	respective	volume	of	6X	loading	dye	before	gel	electrophoresis.	A	
100	 base	 pair	 (bp)	 or	 1	 kilobase	 (kb)	 ladder	 was	 also	 run	 on	 the	 gel	 for	 sizing	 and	 approximate	
quantification	of	the	DNA	bands.	Agarose	gels	were	prepared	by	mixing	agarose	with	1X	TAE	Buffer	in	
a	 shaking	 flask	 and	 bringing	 the	 solution	 to	 a	 boil.	 Percentages	 of	 agarose	 gels	 were	 chosen	
depending	on	the	expected	DNA	fragment	sizes;	generally,	concentrations	ranging	from	0.8%	to	2%	
were	used.	After	a	short	cool-down	of	the	liquid	gel,	ethidium	bromide	or	peqGREEN	were	added	at	
concentrations	 recommended	 by	 the	manufacturers	 for	 visualization	 of	DNA	 in	 the	 gel.	 Gels	were	
cast	and	run	using	the	BIO-RAD	Horizontal	Electrophoresis	Systems	at	voltages	ranging	from	100V	to	
120V	depending	on	the	size	of	the	gel.	Gels	were	imaged	on	a	Biometra	UviproChemi	system.		
2.2.2.7. Gel extraction 
Gel	pieces	of	interest	were	cut	out	of	the	agarose	gel	using	a	scalpel,	and	subsequent	gel	extraction	
was	performed	according	to	manufacturer’s	instructions.		
2.2.2.8. Determination of DNA concentration 











Minipreps,	 midipreps,	 and	 maxipreps	 were	 performed	 according	 to	 manufacturer’s	 instructions.	
Bacterial	 culture	 sizes	used	were	generally	3mL	 for	minipreps,	 40mL	 for	midipreps,	 and	200mL	 for	
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maxipreps.	 For	 the	 inoculation	 of	 midi-	 and	 maxipreps,	 a	 small-scale	 bacterial	 overnight	 culture	
(started	from	a	single	colony	on	the	agar	plate)	was	used	at	a	ratio	of	1:500–1:1000.		
2.2.2.12. Sequencing of plasmids 
























































2.2.3. Production of gamma-retroviral and lentiviral supernatants 
Gamma-retroviral	 supernatants	 were	 generated	 by	 transient	 triple	 transfection	 of	 293T	 human	
embryonic	kidney	cells.	Cells	were	seeded	on	the	day	prior	to	transfection	at	5x106	cells/10cm	Æ	dish	
in	10mL	293T	medium.	On	 the	day	of	 transfection,	medium	was	exchanged	 for	5mL	293T	medium	
containing	25µM	chloroquine,	and	cells	were	cultured	 in	the	presence	of	chloroquine	for	at	 least	1	
hour	before	transfection.	Transfection	was	performed	using	Sigma’s	Calcium	Phosphate	Transfection	





collected	 supernatants	 were	 stored	 at	 4°C	 until	 the	 second	 harvest,	 one	 day	 later.	 Supernatants	
collected	on	both	days	were	pooled,	 filtered	using	a	0.45µM	syringe	 filter	and	cryopreserved	 in	1–
2mL	aliquots	at	-80°C.		
Lentiviral	supernatants	were	produced	as	described	above;	lentiviral	packaging	plasmids	#170	pCMV-









enzymatically	 detached	 using	 TrypLE	 Select,	 1mL	 PBS	 was	 added	 to	 each	 well,	 and	 cells	 were	




Supernatants	were	 removed	 carefully,	 and	 cell	 pellets	 were	 resuspended	 in	 50µL	 PBS	 each.	 Exact	
volumes	were	determined	by	using	a	micropipette.	10µL	of	each	cell	suspension	were	counted	using	
a	Neubauer	hemocytometer,	and	cell	numbers	were	recorded.	The	average	of	the	three	counts	was	
used	 to	 calculate	 viral	 titers	 later	 on.	 For	 transduction,	 viral	 supernatants	 were	 diluted	 in	 293T	
medium	over	a	 range	 from	1:2–1:200,	and	at	 least	 three	different	dilutions	were	 test	 in	duplicate;	
medium	on	HT1080	cells	was	discarded	and	replaced	with	800µL	diluted	viral	supernatant.	Two	wells	
were	kept	as	non-transduced	negative	controls,	and	800µL	293T	medium	was	added	to	each	of	those	
wells.	 Cells	were	 incubated	 at	 37°C,	 5%	 CO2	 in	 a	 humidified	 atmosphere	 overnight.	 On	 day	 three,	
diluted	viral	supernatants	and	293T	medium,	respectively,	were	replaced	with	fresh	HT1080	medium.	








%	AAT	positive	cells ∗ number	of	cells	seeded ∗ dilution
100 ∗ 0.8	 volume	of	viral	supernatant
	
	
2.2.5. Isolation of primary human MSCs from human bone marrow 
Bone	 marrow	 was	 harvested	 from	 healthy	 donors	 after	 informed	 consent	 had	 been	 obtained.	






adherent,	 spindle-shaped	 cells	were	 visible,	 cells	were	enzymatically	 detached	using	 TrypLE	 select,	
and	cryopreserved	in	either	90%	FBS	+	10%	dimethyl	sulfoxide	(DMSO)	or	apceth’s	cryopreservation	
solution	 consisting	 of	 45%	 of	 hydroxyethyl	 starch	 (HAES)	 injection	 solution	 (10%	 in	 isotonic	 saline	
solution),	45%	human	albumin	 (HA)	 injection	solution	 ([50g/L]	 in	 isotonic	 saline	solution),	and	10%	
DMSO	in	aliquots	of	1x106-5x106	cells	(P0).		
2.2.6. Culture of primary human MSCs 
MSCs	were	generally	cultured	in	Bio-M	or	Bio-1	culture	medium	(cf.	Table	5)	at	37°C	and	5%	CO2	in	a	
humidified	 atmosphere.	 Care	was	 taken	 to	 never	 let	MSCs	 grow	 to	 complete	 confluency	 to	 avoid	
contact	 inhibition	of	growth	and	differentiation	of	the	cells.	 In	order	to	propagate	MSCs,	cells	were	
washed	once	with	PBS	before	enzymatic	detachment	using	TrypLE	select	for	10	minutes	at	37°C.	The	




volume	 of	 fresh	 medium	 was	 at	 least	 5	 times	 the	 initial	 volume)	 or	 centrifuged	 at	 300xg	 for	 5	






	 	DMEM	low	glucose	 Biochrom	 87.5%	
FBS	 Biochrom	 10%	
HEPES	[1M]	 Gibco	 25mM	
	 	 	Bio-1	 apceth's	proprietary	cell	culture	medium	
	 	 	293T	medium	
	 	DMEM	high	glucose	 Biochrom	 90%	
FBS	 Biochrom	 10%	
	 	 	HT1080	medium	
	 	EMEM	 Lonza	 90%	
FBS	 Biochrom	 10%	
	 	 	Cryopreservation	solution	




2.2.7. Culture of tumor cell lines 
Tumor	cell	lines	were	cultured	under	equal	conditions	as	MSCs	in	their	respective	medium	(Table	5)	
and	cryopreserved	in	90%	FBS	+	10%	DMSO.		
2.2.8. Cell counting 
Determination	 of	 cell	 numbers	 was	 performed	 by	 manual	 counting	 using	 a	 Neubauer	
hemocytometer	 in	 all	 experiments	 performed.	 In	 some	 experiments,	 cells	 were	 diluted	 in	 Trypan	
Blue	before	counting	to	analyze	cell	viability.		










2.2.10. Thawing of cells 
Vials	were	 quickly	 removed	 from	 the	 liquid	 nitrogen	 tank	 and	 immediately	 transferred	 to	 a	water	
bath	pre-heated	to	37°C.	When	still	some	small	 ice	clumps	were	visible	in	the	vial,	 it	was	moved	to	
the	 laminar	 air	 flow	 cabinet,	 and	 the	 cell	 solution	was	 pipetted	 into	 the	 respective	 culture	 vessel	
already	containing	culture	medium.		
2.2.11. Transduction of MSCs by centrifugation of viral supernatants onto PLL-coated 
plates 
Wells	 of	 6-	 or	 12-well	 plates	 were	 coated	 with	 Poly-L-Lysin	 (PLL)	 diluted	 1:10	 in	 PBS	 to	 a	 final	
concentration	 of	 [10µg/mL]	 for	 at	 least	 one	 hour.	 PLL	 was	 discarded,	 and	 wells	 were	 carefully	
washed	with	PBS	before	viral	 supernatant	was	added.	The	amount	of	viral	 supernatant	needed	 for	
transduction	was	calculated	based	on	 the	cell	number	 to	be	 transduced,	 the	desired	MOI,	and	 the	
titer	 of	 the	 viral	 supernatant.	 Viral	 supernatant	 was	 added	 to	 the	 PLL-coated	 plates;	 in	 some	
experiments,	the	supernatant	was	diluted	with	293T	medium.	293T	medium	only	was	added	to	two	







2.2.12. Transduction of MSCs by direct seeding 
Cells	were	enzymatically	detached	using	TrypLE	select,	resuspended	in	PBS,	counted,	spun	down	at	
300xg	 for	 5	 minutes,	 and	 resuspended	 in	 PBS.	 The	 amount	 of	 viral	 supernatant	 needed	 for	
transduction	was	 calculated	 based	 on	 the	 cell	 number,	 the	 desired	MOI,	 and	 the	 titer	 of	 the	 viral	
supernatant.	 In	a	 first	 step,	PLL	 [100µg/mL]	was	added	 to	 the	viral	 supernatant	at	a	 ratio	of	1:100	
yielding	a	final	concentration	of	PLL	of	[1µg/mL].	 In	the	next	step,	the	cells	were	added	to	the	PLL-
viral	supernatant	mixture,	and	the	transduction	mix	was	seeded	into	appropriate	culture	vessels.	One	
small	 extra	 flask	 of	 transduced	 cells	 was	 usually	 plated	 for	 the	 flow	 cytometric	 assessment	 of	
transduction	 efficacy	 before	 antibiotic	 selection,	 so	 that	 the	 transduced	 batch	 did	 not	 have	 to	 be	
disturbed	for	this	analysis.	After	three	hours	of	incubation,	the	same	amount	of	culture	medium	was	






2.2.13. Detection of transgenic AAT by intracellular flow cytometry 
Cells	 were	 analyzed	 for	 the	 expression	 of	 transgenic	 intracellular	 (ic)	 AAT	 48–72	 hours	 after	
transduction.	To	enhance	the	detection	of	the	protein,	HT1080	cells	were	treated	with	1µL	and	MSCs	
with	 10µL,	 respectively,	 of	 GolgiPlug	 Protein	 Transport	 Inhibitor	 per	mL	medium	 for	 16–24	 hours	
before	the	staining,	so	that	proteins	were	accumulated	in	the	Golgi	complex	and	not	secreted.	Cells	
were	detached	by	 trypsinization,	 counted,	washed	once	with	1mL	PBS,	 and	up	 to	1x106	 cells	were	
permeabilized	 using	 250µL	 BD	 Cytofix/Cytoperm	 Fixation	 and	 Permeabilization	 Solution	 for	 20	
minutes	 at	 4°C.	 After	 2	washes	with	 1mL	 1X	 Perm/Wash	 Buffer	 and	 centrifugation	 at	 500xg	 for	 5	
minutes	 each,	 the	 cell	 pellet	 was	 resuspended	 in	 100µL	 Perm/Wash	 Buffer	 and	 stained	 with	 a	
polyclonal	 FITC-conjugated	 Anti-alpha	 1	 Antitrypsin	 antibody	 (1µL	 antibody/100µL	 cell	 suspension)	
for	 20–30	 minutes	 at	 4°C	 in	 the	 dark.	 After	 the	 incubation,	 cells	 were	 washed	 with	 1mL	 1X	
Perm/Wash	 Buffer,	 resuspended	 in	 400µL	 PBS,	 and	 analyzed	 on	 a	 Beckman	 Coulter	 FC500	 flow	
cytometer.	Non-transduced	cells	were	treated	as	described	above	and	used	as	negative	controls	for	
gating.	 In	 titration	 experiments,	 only	 values	 <25%	 intracellular	 AAT-positive	 cells	were	 included	 in	
titer	calculations.		
2.2.14. Antibiotic selection 
Antibiotic	selection	of	 transduced	cells	was	started	48–72	hours	after	 transduction.	Puromycin	was	
diluted	 in	 fresh	Bio-M	medium	 to	a	 final	 concentration	of	 [3µg/mL],	 and	medium	on	 the	 cells	was	
replaced	 with	 medium	 containing	 puromycin.	 Medium	 was	 exchanged	 for	 fresh	 puromycin-
containing	 medium	 after	 2–3	 days,	 and	 cells	 were	 selected	 for	 a	 total	 of	 5	 days.	 After	 visual	
inspection	 of	 the	 control	 well	 and	 confirmation	 that	 all	 plated	 non-transduced	 MSCs	 were	 dead,	
medium	was	replaced	with	regular	Bio-M	for	subsequent	expansion	of	the	cells.		
2.2.15. Determination of VCN 
DNA	of	transduced,	puromycin-selected	MSCs	and	non-transduced	control	cells	was	extracted	using	
Qiagen’s	DNeasy	Blood	&	Tissue	Kit	 following	manufacturer’s	 recommendations.	 To	determine	 the	
average	 vector	 copy	 number	 (VCN)	 in	 the	 bulk	 cell	 population,	 two	 singleplex	 quantitative	
polymerase	chain	reactions	(qPCRs)	were	carried	out	for	each	DNA	sample:	One	primer	and	probe	set	
was	detecting	 the	optimized	posttranscriptional	 regulatory	element	 (oPRE)	 sequence,	a	part	of	 the	
viral	 vector	 that	 is	 integrated	 into	 the	 genome	 of	 the	 cell	 after	 transduction,	 a	 second	 set	 was	
recognizing	 factor	 VII	 (FVII),	 a	 human	 single	 copy	 gene,	 that	 was	 utilized	 as	 a	 reference	 gene	 to	
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correct	 for	 variability	 in	DNA	amounts	used	 in	 the	qPCR.	Plasmid	 standard	 curves	 ranging	 from	1–
1x105	copies	were	included	in	the	experiments	to	determine	qPCR	efficiencies	of	the	two	primer	and	
probe	 sets.	 Sequences	 of	 the	 primers	 are	 listed	 in	 2.1.3,	 composition	 of	 master	 mixes	 as	 well	 as	
cycling	conditions	are	mentioned	in	Table	6	and	Table	7.	All	samples	were	measured	in	triplicate	on	a	
LightCycler	480	Instrument	II.	A	calibrator	DNA	extracted	from	an	HT1080	cell	clone	with	one	single	
viral	 integration	 as	 confirmed	 by	 linear	 amplification	 mediated	 (LAM)	 PCR	 was	 included	 in	 each	
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-80°C	 until	 further	 use.	 On	 the	 day	 of	 the	 experiment,	 supernatants	 were	 thawed	 on	 ice	 and	
centrifuged	at	3000xg	for	10	minutes	to	remove	cell	debris.	The	AAT	ELISA	was	performed	according	
to	manufacturer’s	instructions;	sample	pre-dilutions	were	usually	1:200	in	Diluent	N.	
2.2.17. Neutrophil elastase inhibitor screening assay 





picked	 up	 by	 the	 assay.	 Cells	 were	 cultured	 in	 Dulbecco's	 Modified	 Eagle's	 Medium	 (DMEM)	
supplemented	with	1X	GlutaMAX	and	1mM	Sodium	Pyruvate	for	16–24	hours	at	37°C	and	5%	CO2	in	
a	 humidified	 atmosphere.	 After	 incubation,	 supernatants	 were	 cryopreserved	 in	 aliquots	 at	 -80°C	
until	 further	 use.	 In	 some	 experiments,	 supernatants	 were	 concentrated	 using	 Amicon	 Ultra	 4mL	
Centrifugal	Filters	before	cryopreservation.		
2.2.17.2. Neutrophil elastase inhibitor screening assay 
The	 neutrophil	 elastase	 inhibitor	 screening	 assay	 was	 performed	 according	 to	 manufacturer’s	
instructions	with	minor	modifications,	 i.e.	 instead	of	 the	positive	control	 included	 in	the	kit	 (SPCK),	
active	natural	AAT	 full	 length	protein	purified	 from	human	plasma	 in	 four	different	 concentrations	
ranging	from	[250–2000ng/µL]	was	used	as	a	more	commensurable	positive	control.		
In	brief,	neutrophil	elastase	(NE)	assay	buffer	and	substrate	included	in	the	kit	were	thawed;	aliquots	
were	 prepared	 and	 stored	 at	 -20°C.	 Neutrophil	 elastase	 was	 reconstituted	 in	 220µL	 of	 NE	 assay	
buffer;	aliquots	were	prepared	and	stored	at	-80°C.	Active	AAT	full	length	protein	was	reconstituted	
in	 ddH2O	 to	 yield	 a	 concentration	 of	 [1µg/µL];	 aliquots	 were	 prepared	 and	 stored	 at	 -80°C	 until	
further	use.	On	the	day	of	the	assay,	MSC	supernatants	were	thawed,	and	dilutions	were	prepared	in	
DMEM	 supplemented	 with	 1X	 GlutaMAX	 and	 1mM	 Sodium	 Pyruvate.	 Active	 full	 length	 AAT	 was	
thawed	and	diluted	in	DMEM	supplemented	with	1X	GlutaMAX	and	1mM	Sodium	Pyruvate	to	yield	
concentrations	of	[2000ng/mL],	[1000ng/mL],	[500ng/mL],	and	[250ng/mL].	Undiluted,	concentrated	
supernatant	 from	 non-transduced	 MSCs	 was	 included	 as	 a	 negative	 control.	 The	 substrate	 was	
diluted	 1:12.5	 in	 NE	 assay	 buffer	 and	 kept	 at	 room	 temperature	 in	 the	 dark	 until	 further	 use.	
Immediately	before	starting	the	assay,	neutrophil	elastase	was	diluted	1:25	 in	NE	assay	buffer,	and	
50µL	 diluted	 elastase	 working	 solution	 were	 added	 per	 well	 of	 a	 96-well	 flat	 clear	 bottom	 black	
polystyrene	 plate.	 25µL	 of	 positive	 and	 negative	 control	 samples	 and	MSC	 supernatant	 dilutions,	
respectively,	were	added	and	mixed	by	pipetting	up	and	down	carefully.	All	samples	were	measured	
in	duplicate.	After	an	incubation	of	5	minutes	at	37°C,	25µL	diluted	substrate	working	solution	were	




plate	 reader	 immediately.	 The	 plate	 was	 then	 incubated	 for	 20	 minutes	 at	 37°C,	 and	 after	 that	









2.2.18. Generation of large MSC batches for in vitro and in vivo experiments 
2.2.18.1. Process description 
P0-MSCs	 were	 generally	 thawed	 on	 a	 Friday,	 and	 the	 cells	 were	 cultured	 in	 750mL	 Bio-1	 in	 a	
CellSTACK	cell	culture	system	with	5	chambers.	Cells	were	transduced	as	described	in	“Transduction	
of	 primary	 human	 MSCs	 by	 direct	 seeding”	 on	 the	 following	 Tuesday.	 Transduction	 efficacy	 was	
analyzed	by	 intracellular	flow	cytometry	for	AAT	protein	72	hours	after	transduction	using	the	cells	





the	 selection	 control	 well	 (non-transduced	 MSCs)	 were	 completely	 dead	 (usually	 after	 5	 days	 of	









2.2.18.2. Quality control assays for batches 
To	assess	if	MSCs	fulfilled	apceth’s	quality	standards,	one	vial	of	cryopreserved	MSCs	of	each	batch	
was	 thawed,	 and	 a	 panel	 of	 standard	 quality	 control	 assays	 was	 performed.	 Standard	 assays	 and	
required	specifications	are	listed	in	Table	8.	In	addition	to	these	tests	which	were	carried	out	for	all	
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batches	 produced,	 genetically	modified	 batches	were	 additionally	 analyzed	 for	 percentage	 of	 AAT	
positive	MSCs	pre-	and	post-selection,	VCN,	amount	of	AAT	protein	expressed	per	1x105	cells	 in	48	
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3x104	 MSCs	 were	 seeded	 per	 well	 in	 5	 wells	 each	 of	 two	 24-well	 plates	 (one	 for	 adipogenic	
differentiation,	one	for	osteogenic	differentiation)	in	1mL	Bio-M	or	Bio-1	and	cultured	until	complete	
confluency	 (1–3	 days).	 Bio-M/Bio-1	 was	 then	 replaced	 by	 1mL	 of	 StemMACS	 AdipoDiff	Media	 for	
adipogenic	 differentiation	 and	 1mL	 of	 StemMACS	 OsteoDiff	 Media	 for	 osteogenic	 differentiation,	
respectively,	on	three	wells	per	respective	plate.	Two	wells	served	as	control	wells	and	received	fresh	
Bio-M/Bio-1.	Fresh	differentiation	media	and	Bio-M/Bio-1,	respectively,	were	added	every	3–5	days	
for	a	minimum	of	 two	weeks.	Cells	were	 then	stained	with	Oil	Red	O	 to	assess	differentiation	 into	
adipocytes,	and	with	Alizarin	Red	to	confirm	osteogenic	mineralization.	
Oil	Red	O	Staining	(adipogenic	differentiation)	
All	 fixation	 and	 staining	 steps	 were	 performed	 at	 room	 temperature.	 Oil	 Red	 O	 staining	 working	
solution	 was	 prepared	 by	 mixing	 6mL	 filtered	 Oil	 Red	 O	 staining	 stock	 solution	 [3mg/mL	 in	 2-
Propanol]	with	4mL	de-ionized	water.	 The	 solution	was	 incubated	 for	10	minutes	after	mixing	and	
then	 filtered.	Cells	on	 the	24-well	plate	 for	adipogenic	differentiation	were	washed	 twice	with	PBS	
and	 fixed	with	 2mL	 10%	 Formalin	 for	 30–45	minutes.	 In	 a	 second	 step,	 the	 Formalin	 solution	was	
removed;	cells	were	washed	twice	with	2mL	tap	water,	and	fixed	again	with	1mL	60%	2-Propanol	for	
3–5	minutes.	After	discarding	the	60%	2-Propanol,	1mL	Oil	Red	staining	working	solution	was	added	













Detection	 of	 possible	 Mollicutes	 (Mycoplasma,	 Acholeplasma,	 Spiroplasma)	 contamination	 in	 cell	
cultures	was	performed	using	the	Microsart	RESEARCH	Mycoplasma	Detection	Kit	for	qPCR	following	
manufacturer’s	 recommendations	using	DNA	extracted	 from	MSCs	 (isolated	using	Qiagen’s	DNeasy	
Blood	&	Tissue	Kit	according	to	manufacturer’s	instructions)	as	template.	








Table	11.	All	 samples	were	measured	 in	 triplicate	on	a	LightCycler	480	 Instrument	 II.	Commercially	
available	 human	 genomic	 DNA	 and	DNA	 extracted	 from	HT1080	 cells	 served	 as	 negative	 controls,	
pCDNA3-MLV-gagpol	 and	 pCMV-dR8.91	 plasmid	 DNA	 [5	 copies/µL],	 respectively,	 was	 used	 as	 a	
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2.2.19. In vivo experiments 
The	mouse	experiments	were	performed	in	collaboration	with	Dr.	Yildirim	from	the	Comprehensive	
Pneumology	Center	at	the	Helmholtz	Zentrum	München.		
2.2.19.1. Preparation of cells 
For	each	of	the	two	cell	applications,	three	vials	[5x106	cells/vial]	each	of	a	quality-controlled	native	
MSC	 batch	 and	 a	 quality-controlled	 batch	 of	MSCs	 transduced	with	 gamma-retroviral	 supernatant	
#194,	 respectively,	were	 thawed	and	cultured	 in	one	CellSTACK	culture	system	with	5	chambers	 in	
750mL	 Bio-M	 each	 for	 48	 hours.	 Cells	 were	 enzymatically	 detached	 using	 TrypLE,	 counted,	
resuspended	 in	 PBS	 to	 yield	 a	 concentration	 of	 5x106	 cells/mL,	 and	 transferred	 to	 the	 Helmholtz	
Zentrum	on	ice	for	immediate	intratracheal	injection.	
2.2.19.2. Elastase-induced emphysema mouse model 
Female	 C57BL/6N	 mice	 aged	 8–10	 weeks	 were	 housed	 under	 specific	 pathogen	 free	 conditions,	
exposed	to	a	12-hour	light	cycle	with	access	to	food	and	water	ad	libitum,	in	rooms	maintained	at	a	
constant	temperature	and	humidity.	Mice	were	divided	into	4	groups	consisting	of	6	mice	per	group	
(Table	 12).	 Mice	 in	 groups	 2–4	 were	 oropharyngeally	 exposed	 to	 a	 single	 application	 of	 40	
units/kilogram	(kg)	body	weight	porcine	pancreatic	elastase	 in	80μL	volume	on	day	0.	Control	mice	
were	 treated	 with	 80μL	 of	 PBS.	 On	 day	 7,	 mice	 in	 groups	 3	 and	 4	 were	 treated	 with	 one	
oropharyngeal	application	of	5x105	native	MSCs	or	5x105	MSCs	transduced	with	a	gamma-retroviral	
vector	 to	express	AAT.	Mice	 in	 control	 groups	1	and	2	 received	 saline	 instead	of	 the	 cells.	Mice	 in	
groups	3	 and	4	were	 additionally	 treated	with	 a	 second	oropharyngeal	 application	of	 5x105	native	
MSCs	or	5x105	AAT-MSCs	on	day	14	after	elastase	treatment.	All	mice	were	analyzed	on	day	21.		
Table	12:	Mouse	groups	and	respective	treatments.		







1	 PBS	 Saline	 N.a.	 100	 Oropharyngeal	 6	
2	 Elastase	 Saline	 N.a.	 100	 Oropharyngeal	 6	
3	 Elastase	 MSCs	 5x105	(2x)	 100	 Oropharyngeal	 6	
4	 Elastase	 AAT-MSCs	 5x105	(2x)	 100	 Oropharyngeal	 6	
	
2.2.19.3. Pulmonary function measurements 




laboratory	 set-up	 semi-automatically	 provides	 three	 different	 maneuvers:	 Boyle’s	 Law	 functional	




A	 breathing	 frequency	 of	 150	 breaths/minute	was	 imposed	 by	 pressure	 control	 ventilation	 until	 a	
regular	 breathing	 pattern	 and	 complete	 expiration	 at	 each	 breathing	 cycle	 were	 obtained.	 To	
measure	functional	residual	capacity	(FRC),	ventilation	was	stopped	at	the	end	of	expiration	with	an	
immediate	 closure	 of	 a	 valve	 located	proximally	 to	 the	 endotracheal	 tube.	 Spontaneous	 breathing	
maneuvers	 against	 a	 closed	 valve	 with	 consequent	 pressure	 changes	 were	 then	 recorded.	 To	
measure	inspiratory	capacity	(IC)	and	vital	capacity	(VC),	the	quasistatic	pressure	volume	maneuver	
was	 performed,	 which	 inflates	 the	 lungs	 to	 a	 standard	 pressure	 of	 +30cm	 H2O	 and	 then	 slowly	
exhales	 until	 a	 negative	 pressure	 of	 -30cm	 H2O	 is	 reached.	With	 the	 fast	 flow	 volume	maneuver,	
lungs	were	 first	 inflated	 to	+30cm	H2O	and	 immediately	afterwards	connected	to	a	highly	negative	
pressure	 in	 order	 to	 enforce	 expiration.	 Forced	 vital	 capacity	 (FVC),	 forced	 expiratory	 volume	 at	
100ms	 (FEV100ms),	 and	 peak	 expiratory	 flow	 (PEF)	 were	 recorded	 during	 this	 maneuver.	 In	 every	
animal,	each	maneuver	was	repeated	until	three	acceptable	measurements	were	recorded,	of	which	
the	average	was	then	calculated.	
2.2.19.4. BALF and serum 
Bronchoalveolar	 lavage	 fluid	 (BALF)	 was	 obtained	 for	 total	 and	 differential	 cell	 counts	 to	 assess	
inflammatory	 cell	 recruitment	 of	macrophages,	 neutrophils	 and	 lymphocytes	 to	 the	 lungs.	 Lavage	
was	performed	using	3×500μL	of	PBS.	Cells	were	pelleted	at	400xg,	the	supernatant	stored	at	–80°C,	
and	the	cells	were	resuspended	 in	RPMI-1640	medium	for	total	cell	count	using	a	hemocytometer.	
Cytospins	of	 the	 cell	 suspension	were	prepared	and	 stained	using	May–Grünwald–Giemsa	 staining	
mixes	 for	 differential	 cell	 counting	 (200	 cells/sample)	 using	 morphological	 criteria.	 Serum	 was	
collected	 for	chemokine	and	cytokine	analysis.	Mice	were	bled	 from	the	 femoral	artery;	blood	was	
left	 to	 clot	 for	 several	 hours	 and	 then	 centrifuged	 at	 1300xg	 for	 15	minutes.	 Serum	was	 stored	 in	
aliquots	at	-80°C.		







To	 quantify	 emphysema	 development,	 an	 emphysema	 state	 was	 ascribed	 to	 each	 H&E-stained	
sample	 in	 a	 blinded	 fashion	 by	 a	 pathologist.	 The	 score	 of	 elastase	 induced-emphysema	 was	
determined	 as	 follows:	 0	 –	 normal;	 1	 –	 up	 to	 10%	 loss	 of	 septal	 tissue;	 2	 –	 11-20%	 loss	 of	 septal	
tissue;	3	–	21-40%	loss	of	septal	tissue;	4	–	41-60%	loss	of	septal	tissue;	5	–	>60%	loss	of	septal	tissue.	








deep;	 3	 –	 a	 ring	 of	 inflammatory	 cells	 three	 or	 more	 than	 three	 cell	 layer-deep.	 The	 slides	 were	
randomly	examined	in	more	than	10	fields	of	view	in	a	blinded	fashion.	
2.2.20. Statistical analyses 
Data	 is	 depicted	 as	 mean	 ±	 standard	 deviation	 (SD).	 Statistical	 analyses	 were	 performed	 using	








3.1. Design and cloning of gamma-retroviral AAT expression constructs 





coding	 sequence	 (CDS)	 comprises	 bases	 262	 to	 1518	 of	 the	 full	 reference	 sequence	 published	 at	
http://www.ncbi.nlm.nih.gov/nuccore/NM_000295.4.	 Bases	 1	 to	 261	 were	 included	 in	 the	
expression	cassette	 to	preserve	 the	physiological	SERPINA1	 transcript	variant	1	5’	UTR.	The	3’	UTR	
was	 not	 included	 due	 to	 size	 restrictions	 of	 the	 viral	 backbone.	 To	 increase	 protein	 expression,	 a	
Kozak	consensus	sequence	327	was	inserted	5’	of	the	SERPINA1	start	codon,	and	the	cDNA	was	codon-
optimized	for	Homo	sapiens.	For	a	graphical	representation,	please	cf.	Figure	3.	
3.1.2. Cloning of four “1st generation” gamma-retroviral expression plasmids 
Plasmid	 numbers	mentioned	 throughout	 this	work	 represent	 apceth’s	 internal	 plasmid	 numbering	
and	will	be	used	below	for	the	sake	of	simplicity.		
As	the	influence	of	different	promoters	on	the	expression	of	transgenic	AAT	from	primary	MSCs	was	




a	 different	 project	 was	 replaced	 with	 the	 SERPINA1	 expression	 cassette,	 yielding	 plasmid	 #114	
pPGK_SERPINA1_IRES_pac;	as	a	next	step,	the	PGK	promoter	present	in	plasmid	#114	was	exchanged	
for	 promoters	 EF1a,	 CAG,	 or	 EFS,	 resulting	 in	 plasmids	 #115,	 #116,	 and	 #129.	 Figure	 5	 shows	 a	
schematic	representation	of	the	4	gamma-retroviral	plasmids.		




was	 not	 expressed	 in	 sufficient	 amounts.	 After	 a	 thorough	 investigation	 and	 the	 performance	 of	
multiple	 experiments,	 it	 was	 discovered	 that	 this	 phenomenon	 was	 due	 to	 a	 non-functional	 IRES	
sequence	used	to	design	and	clone	the	original	retroviral	plasmid	containing	the	IFN-beta	expression	
cassette.	 Consequently,	 the	 retroviral	 backbone	 was	 corrected	 using	 a	 published	 IRES	 sequence	
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derived	 from	 the	 encephalomyocarditis	 virus	 (EMCV)	 332,333,	 and	 the	 integrity	 of	 the	 complete	
backbone	checked	by	sequencing.	Additional	modifications	to	improve	the	backbone	were	included,	
such	as	exchanging	 the	wPRE	 sequence	 for	an	optimized	version,	 the	oPRE	 sequence	described	by	








3.1.3. Cloning of eight “2nd generation” gamma-retroviral expression plasmids 
Titration	 and	 preliminary	 transduction	 experiments	 were	 performed	 in	 order	 to	 compare	 the	
different	 constructs	 using	 the	 four	 “1st	 generation”	 gamma-retroviral	 supernatants.	 The	 results	
indicated	that	although	the	CAG	promoter	led	to	high	levels	of	AAT	expression	as	was	expected	335,	
the	 titer	 of	 supernatant	 #116	 as	 well	 as	 transduction	 efficacies	 achieved	 on	 MSCs	 using	 that	
supernatant	were	unacceptably	 low	(data	not	shown).	Thus,	 it	was	decided	to	not	 include	the	CAG	
promoter	 in	subsequent	cloning	strategies.	 Instead	the	 influence	of	the	remaining	three	promoters	
on	AAT	expression	were	analyzed,	while	at	the	same	time	different	configurations	of	the	SERPINA1	
and	pac	 expression	 cassettes	were	 assessed.	 In	 the	 first	 three	 “2nd	 generation”	 constructs	 cloned,	
pPGK,	 pEFS,	 and	 pEF1a	were	 used	 to	 drive	SERPINA1	 gene	 expression,	 followed	 by	 either	 pEFS	 or	
pPGK	expressing	pac	(constructs	#159,	#160,	and	#161).	To	avoid	unwanted	recombination	events	in	
the	 viral	 vector,	 the	 same	 promoter	was	 never	 used	 twice	 in	 one	 plasmid.	 To	 determine	 possible	
position	effects	of	the	expression	cassettes	within	the	viral	vector	on	AAT	expression,	a	second	set	of	
three	 plasmids	 was	 cloned	 in	 which	 the	 pac	 cassette	 was	 positioned	 5’	 of	 the	 SERPINA1	 cassette	
(constructs	 #162,	 #163,	 and	 #164).	 To	 circumvent	 the	 possible	 problem	 of	 transcriptional	
interference	336,337,	two	more	constructs	were	cloned	in	which	an	EMCV	IRES	sequence	was	used	to	
initiate	 cap-independent	 translation	 of	 the	 pac	mRNA,	 thereby	 eliminating	 the	 need	 for	 a	 second	
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promoter.	 The	 detailed	 cloning	 strategy	 is	 described	 in	 2.2.1.	 Figure	 6	 shows	 a	 schematic	




Figure	 6:	 Schematic	 representation	 of	 the	 eight	 “2nd	 generation”	 plasmids.	 Three	 different	
promoters	 (pPGK,	 pEFS,	 and	 pEF1a)	 were	 used	 to	 drive	 the	 expression	 of	 SERPINA1;	 pac	 was	
expressed	from	either	pPGK	or	pEFS,	depending	on	which	promoter	was	used	for	the	expression	of	
SEPRINA1.	 In	constructs	#159,	#160,	and	#161,	the	SERPINA1	expression	cassette	was	positioned	5’	






3.2. Comparison of constructs and selection of lead candidate 
3.2.1. Viral vectors are functional on HT1080 cells 
In	the	next	set	of	experiments,	the	general	goal	was	to	determine	which	of	the	constructs	described	
above	was	most	suitable	for	the	transduction	of	human	cells	and	the	expression	of	transgenic	AAT.	
Thus,	 as	 a	 first	 step,	 gamma-retroviral	 supernatants	 of	 all	 2nd	 generation	 transfer	 plasmids	 cloned	
were	produced	by	transient	triple	transfection	of	293T	cells	as	described	in	detail	in	2.2.3.	To	be	able	








the	 highest	 average	 titer	 of	 [3x105	 TU/mL]	 was	 achieved	 for	 viral	 supernatant	 #159	
(pPGK_SERPINA1_pEFS_pac),	 followed	 by	 #160	 (pEFS_SERPINA1_pPGK_pac),	 #163	
(pPGK_pac_pEFS_SERPINA1),	 #194	 (pEFS_SERPINA1_IRES_pac),	 and	 #193	





correlation	 (Figure	 7C,	 R²	 =	 0.78,	 P	 =	 0.035).	 This	 result	 suggests	 that	 higher	 genetic	 payload	 and	
resulting	 larger	 transfer	plasmids	can	 lead	to	decreased	titers	and	 is	 in	 line	with	 findings	published	
for	retroviral	vectors	338,339.		
3.2.2. Viral vectors are functional on primary human MSCs 
3.2.2.1. Constructs containing the EFS promoter to drive SERPINA1 expression yield the 







post-transduction.	 The	 results	 are	 provided	 in	 Figure	 8A.	 Normalized	 transduction	 efficacies	 were	
comparable	 for	 constructs	 #160,	 #163,	 #194	 (the	 three	 vectors	 containing	 pEFS	 for	 SERPINA1	
expression),	 and	 #193	 (pPGK_SERPINA1_IRES_pac).	 Results	 seen	 with	 #159	 and	 #162	 (constructs	
containing	pPGK	to	drive	SERPINA1	expression)	showed	a	decreased	efficiency	of	approximately	30%,	
and	 transduction	 efficacies	 using	 supernatants	 #161	 and	 #164	 (constructs	 in	 which	 SERPINA1	 is	
driven	by	pEF1a)	were	only	30%	(P	<	0.01)	and	10%	(P	<	0.001),	respectively,	of	those	achieved	with	
the	best	supernatants.	This	was	unexpected	as	the	same	amount	of	viral	particles	had	been	used	for	
each	 transduction;	 however,	 the	 volumes	 of	 the	 supernatants	 that	 had	 to	 be	 used	 to	 achieve	
comparable	MOIs	were	different	by	up	to	factor	~30	due	to	the	enormous	differences	in	viral	titers.	
By	comparing	viral	titers	with	the	transduction	efficacies	achieved,	a	positive	correlation	was	found	








Figure	 7:	Viral	 vectors	 are	 functional.	A:	 Titers	 of	 viral	 supernatants	 #159-#194.	Constructs	 #159,	
#160,	 163,	 #193,	 and	 #194	 yielded	 comparable	 titers	 on	 HT1080	 fibrosarcoma	 cells,	 while	 titers	
achieved	with	constructs	#161	and	164	were	almost	two	log	units	 lower;	titers	of	viral	supernatant	
#162	 were	 intermediate.	 Viral	 titers	 were	 determined	 by	 transduction	 of	 HT1080	 cells	 and	 flow	
cytometry	 for	 intracellular	AAT	protein.	 Symbols	 represent	 average	 values	 from	4–13	 independent	
transductions	 per	 viral	 vector	 ±	 standard	 deviation	 (SD).	 Small	 numbers	 below	 the	 graph	 indicate	
number	 of	 transductions	 performed	 for	 each	 supernatant.	 B:	 Payload	 sizes	 of	 2nd	 generation	
gamma-retroviral	transfer	constructs.	pEF1a	plasmids	are	~1kb	larger	than	pPGK	and	pEFS	vectors.	
Colors	of	bars	represent	the	promoter	driving	SERPINA1	(pPGK:	dark	gray;	pEFS:	medium	gray;	pEF1a:	
light	 gray).	C:	 Titers	 of	 viral	 supernatants	 and	 expression	 cassette	 sizes	 are	 inversely	 correlated.	
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highest	 in	MSCs	 transduced	with	 viral	 supernatants	 #160,	 #163,	 #194,	 and	#193.	 Transduction	of	
primary	human	MSCs	was	highest	when	supernatants	#160,	#163,	#194	(constructs	in	which	pEFS	is	
driving	 SERPINA1	 expression),	 and	 #193	 (pPGK_SERPINA1_IRES_pac)	 were	 used.	 Primary	 human	
MSCs	 derived	 from	 two	 healthy	 donors	 were	 transduced	 with	 viral	 supernatants	 #159–#194,	 and	
transduction	efficacies	were	assessed	by	intracellular	flow	cytometry	for	AAT	protein.	Bars	represent	
average	 values	 of	 4–8	 independent	 transduction	 experiments	 ±	 SD.	 Due	 to	 high	 variance	 in	
transduction	 results	 depending	 on	 the	 donor,	 values	were	 normalized	 to	 the	 highest	 transduction	
achieved	 in	 each	 experiment	 (=	 100%).	 Small	 numbers	 below	 the	 graph	 indicate	 the	 number	 of	
separate	 experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	




viral	 titers	 are	 positively	 correlated.	 Correlation	 analysis	 of	 expression	 cassette	 sizes	 and	 average	
viral	 titers	 revealed	 a	 strong	 correlation	 between	 these	 two	 variables	 (R²	 =	 0.73,		
P	=	0.0066).	Statistical	correlation	was	determined	by	calculating	the	Pearson	correlation	coefficient.	
Gaussian	distribution	was	confirmed	using	the	Kolmogorov-Smirnov	test.		
3.2.2.2. EF1a and EFS promoters yield higher AAT expression than pPGK 
To	 analyze	 the	 strength	 of	 AAT	 expression	 yielded	 after	 transduction	 of	 human	 MSCs	 with	 the	
different	 constructs,	 expression	 of	 AAT	 in	 bulk	MSC	 populations	 was	 assessed	 by	 flow	 cytometric	
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viral	 supernatants	 generated	 from	constructs	 in	which	SEPRINA1	 is	driven	by	either	pEF1a	or	pEFS	
resulted	in	higher	AAT	expression	as	compared	to	values	achieved	with	pPGK.	Primary	human	MSCs	
derived	 from	 two	 healthy	 donors	 were	 transduced	 with	 viral	 supernatants	 #159–#194,	 and	 MFIs	
were	assessed	by	intracellular	flow	cytometry	for	AAT	protein.	Bars	represent	average	values	of	4–8	
independent	transduction	experiments	±	SD.	Small	numbers	below	the	graph	indicate	the	number	of	
separate	 experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	




3.2.3. Viral vectors allow for long-term modification of MSCs and sustained AAT 
expression after antibiotic selection and expansion 
3.2.3.1. Constructs in which SEPRINA1 and pac are linked via an IRES sequence yield 
highest VCNs after antibiotic selection and long-term culture of MSCs 
After	 transduction	 efficacies	 and	 AAT	 expression	 were	 characterized	 in	 non-selected	 cells	 shortly	
after	 transduction,	 in	 a	 next	 set	 of	 experiments	 we	 wanted	 to	 analyze	 if	 transduction	 of	 primary	
human	MSCs	with	the	viral	constructs	led	to	stable	genetic	modification	of	the	cells	as	well	as	long-
lasting	 AAT	 expression	 after	 antibiotic	 selection	 and	 expansion	 of	 the	 cells.	 These	 processes	 are	
needed	for	the	generation	of	a	cell	therapy	product	for	clinical	use.	Thus,	bulk	populations	of	MSCs	
transduced	with	the	eight	different	supernatants	were	subjected	to	antibiotic	selection	to	yield	pure	
populations	of	 gene-modified	 cells.	 Figure	10	 shows	a	 representative	 example	of	 intracellular	 flow	
cytometry	stains	of	transduced	cells	before	and	after	antibiotic	selection.		
After	 completion	 of	 the	 selection	 process,	 cells	 were	 expanded	 in	 Bio-M	 or	 Bio-1	 for	 usually	 two	
weeks,	 when	 cell	 numbers	 sufficient	 to	 perform	 further	 experiments	 were	 reached.	 The	 DNA	 of	
selected	cells	was	extracted,	and	VCNs	were	determined	by	qPCR	and	comparison	with	a	reference	
cell	 clone	 containing	 a	 single	 viral	 integration	 as	 described	 in	 2.2.15.	 MSCs	 transduced	 with	
supernatants	 #193,	 #194	 (the	 two	 constructs	 containing	 an	 IRES	 sequence),	 and	 #160	
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followed	by	cells	modified	with	 supernatants	#159,	#162	 (the	 two	constructs	 in	which	SERPINA1	 is	
driven	by	pPGK),	 and	#163	 (pPGK_pac_pEFS_SEPRINA1)	which	had	mean	VCNs	of	2.3,	2.8,	 and	3.2	
(Figure	11).	Average	VCNs	achieved	with	supernatant	#161	(pEF1a_SERPINA1_pPGK_pac)	were	~10-
fold	 lower	as	compared	to	constructs	#193	and	#194	(P	<	0.05),	and	only	 in	one	experiment	out	of	
four	 performed,	was	 it	 possible	 to	 harvest	 cells	 for	VCN	measurement	 after	 antibiotic	 selection	of	
cells	 transduced	 with	 supernatant	 #164	 (pPGK_pac_pEFa1_SERPINA1);	 in	 the	 three	 other	
experiments	 no	 cells	 survived	 the	 antibiotic	 selection.	 Taken	 together,	 the	 VCN	 results	 generated	
after	 antibiotic	 selection	 and	 long-term	 culture	 of	 selected	 cells	 support	 the	 ones	 achieved	 by	
intracellular	flow	cytometry	before	selection	and	expansion,	confirming	that	constructs	#160,	#163,	
#194	 (all	 constructs	 in	 which	 pEFS	 is	 driving	 SERPINA1	 expression),	 and	 #194	




Figure	10:	Representative	 flow	cytometry	results	 for	 intracellular	AAT	stains	achieved	before	and	
after	antibiotic	selection.	Antibiotic	 selection	of	 transduced	cells	with	puromycin	yields	>95%	pure	
populations	of	MSCs	expressing	AAT.	Primary	human	MSCs	were	transduced	with	viral	vector	#194,	
and	 intracellular	 staining	 for	 AAT	 and	 subsequent	 flow	 cytometric	 measurement	 were	 performed	








Figure	11:	Highest	VCNs	achieved	 in	 cells	modified	with	 supernatants	#193	and	#194.	Analysis	of	
VCNs	 after	 antibiotic	 selection	 and	 long-term	 culture	 of	 the	 cells	 yielded	 highest	 values	 for	MSCs	
transduced	 with	 viral	 supernatants	 #193	 (pPGK_SERPINA1_IRES_pac)	 and	 #194	
(pEFS_SERPINA1_IRES_pac),	 followed	 by	 #160,	 and	 #163	 (constructs	 in	 which	 pEFS	 is	 driving	
SERPINA1	expression,	and	a	second	promoter	is	used	to	drive	pac	expression).	Primary	human	MSCs	
derived	from	two	healthy	donors	were	transduced	with	viral	supernatants	#159–#194,	selected	with	
puromycin,	 expanded,	 and	 harvested	 for	 DNA	 preparation.	 VCNs	 were	 determined	 by	 qPCR	 and	
comparison	to	a	reference	cell	clone	with	a	single	viral	integration.	Bars	represent	average	values	of	
1–6	independent	experiments	±	SD.	Small	numbers	below	the	graph	indicate	the	number	of	separate	
experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	 between	
control	 construct	 #194	 and	 all	 other	 constructs	 was	 calculated	 applying	 the	 Kruskal-Wallis	 test		
(P	=	0.0041),	followed	by	Dunn's	multiple	comparisons	test	(194	vs.	159:	ns,	194	vs.	160:	ns,	194	vs.		
161:	*,	194	vs.	162:	ns,	194	vs.	163:	ns,	194	vs.	164:	ns,	194	vs.	193:	ns).	*	P	<	0.05.	
3.2.3.2. EF1a and EFS promoters lead to higher AAT expression than pPGK after antibiotic 
selection and long-term expansion of MSCs 
In	the	next	step	the	stability	of	AAT	expression	in	transduced	MSCs	was	determined	after	antibiotic	
selection	 and	 cell	 expansion.	 The	AAT	protein	 content	 in	 cell	 culture	 supernatants	of	 selected	 and	
expanded	 MSCs	 was	 measured	 by	 ELISA	 and	 compared	 to	 flow	 cytometry	 expression	 data	
determined	by	MFI	of	 intracellularly	stained	AAT	 in	cells	prior	 to	antibiotic	selection.	MSCs	derived	
from	 two	 donors	 were	 transduced	 with	 the	 eight	 gamma-retroviral	 supernatants,	 subjected	 to	
antibiotic	 selection,	 expanded,	 and	 seeded	 for	harvest	of	 supernatants.	After	 48	hours	 cell	 culture	
supernatants	were	 collected,	 and	 the	 concentration	of	 secreted	AAT	protein	determined	by	ELISA.	
Consistent	with	MFI	data	measured	before	antibiotic	 selection,	AAT	expression	after	 selection	and	
long-term	culture	was	highest	 in	 cell	 culture	 supernatants	derived	 from	cells	 transduced	with	 viral	
vectors	using	either	the	EFS	or	the	full-length	EF1a	promoter	to	drive	SERPINA1	expression,	with	an	
average	 AAT	 yield	 of	 ~500ng/1x105	 cells/viral	 integration	 in	 48	 hours	 (Figure	 12).	 AAT	 content	 in	
supernatants	 after	 transduction	of	MSCs	with	 vectors	 #159	and	#162	 (constructs	 in	which	pPGK	 is	
driving	 SERPINA1	 expression)	 was	 significantly	 lower	 (~95ng/1x105	 cells/VCN/48h;	 P	 <	 0.05);	 viral	
supernatant	#193	(pPGK_SERPINA1_IRES_pac)	yielded	 intermediate	results.	 In	only	one	experiment	
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Figure	 12:	 AAT	 expression	 is	 markedly	 higher	 from	 pEF1a	 and	 pEFS	 as	 compared	 to	 pPGK	 as	
determined	 by	 ELISA.	 Transduction	 of	MSCs	with	 viral	 supernatants	 generated	 from	 constructs	 in	
which	SERPINA1	 is	driven	by	either	pEF1a	or	pEFS	yielded	higher	amounts	of	AAT	secreted	into	the	
cell	 culture	supernatant	as	compared	 to	constructs	 in	which	AAT	 is	driven	by	pPGK	after	antibiotic	
selection	and	long-term	expansion	of	selected	cells.	Primary	human	MSCs	derived	from	two	healthy	
donors	were	transduced	with	viral	supernatants	#159–#194,	selected	with	puromycin,	expanded	and	
seeded	 at	 a	 concentration	 of	 1x104	 cells	 and	 250µL	medium/cm².	 Cell	 culture	 supernatants	 were	
collected	 after	 48	 hours,	 and	 AAT	 protein	 content	was	 assessed	 by	 ELISA.	 Bars	 represent	 average	
values	of	1–6	independent	transduction	experiments	±	SD,	normalized	to	1x105	cells	and	divided	by	
VCN.	 Small	numbers	below	 the	graph	 indicate	 the	number	of	 separate	experiments	performed	 for	
each	 viral	 construct.	 Statistical	 significance	 of	 differences	 between	 control	 construct	 #194	 and	 all	






pEF1a)	 led	 to	 low	 transduction	 efficacies	 and	 markedly	 decreased	 cell	 numbers	 after	 antibiotic	
selection	 (data	 not	 shown),	 these	 four	 constructs	 were	 excluded	 from	 subsequent	 experiments.	
Constructs	#160,	#163,	and	#194	(all	 three	constructs	 in	which	SERPINA1	 is	driven	by	pEFS)	yielded	
comparable	 results	 regarding	 transduction	 efficacy	 and	 expression	 and	 were	 subjected	 to	 further	
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3.2.4. Constructs containing an IRES sequence yield higher MSC numbers after 
antibiotic selection as compared to constructs containing two promoters 
As	 described	 above,	 transduction	 efficacies	 and	 AAT	 expression	 were	 comparable	 among	 the	
remaining	 vectors	 #160,	 #163,	 #193,	 and	 #194	before	 and	 after	 antibiotic	 selection	 and	 long-term	
expansion	 of	 the	 selected	 cells.	 However,	 it	 had	 been	 noted	 that	 cell	 numbers	 after	 antibiotic	
selection	 varied	markedly	 between	 the	 constructs	 even	when	 transduction	 efficacies	were	 similar.	












Taken	 together,	 these	 results	 demonstrated	 that	 the	 retroviral	 expression	 plasmid	 #194	was	 best	
when	compared	to	the	other	seven	constructs	tested	with	regards	to	transduction	efficacy	and	AAT	






construct	 #194	 results	 in	 higher	 cell	 yields	 after	 antibiotic	 selection	 when	 compared	 to	 cells	
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with	 puromycin	 at	 a	 concentration	 of	 [3µg/mL],	 and	 expanded	 until	 confluency,	 when	 cells	 were	
counted.	 Bars	 represent	 average	 values	 of	 4	 independent	 transduction	 experiments	 ±	 SD.	 Due	 to	
different	sizes	of	culture	vessels	used	for	expansion	in	different	experiments,	values	were	normalized	
to	the	highest	cell	number	yielded	in	each	experiment	(=	100%).	Statistical	significance	of	differences	
between	 cell	 numbers	 recorded	 for	 control	 construct	 #194	 and	 the	 three	 other	 constructs	 was	
calculated	applying	the	Kruskal-Wallis	test	(P	<	0.0001),	followed	by	Dunn's	multiple	comparisons	test	
(194	vs.	160:	**,	194	vs.	163:	ns,	194	vs.	193:	ns).	**	P	<	0.01.		




a	 different	 viral	 backbone	 could	 potentially	 further	 increase	 transduction	 efficacy	 and	 AAT	
expression.	 To	 this	 end,	 we	 chose	 a	 lentiviral	 system	 to	 compare	 with	 the	 gamma-retroviruses.	




3.3.1. Titers achieved using the lentiviral backbone are four-fold higher 
Accordingly,	 the	 expression	 cassette	 pEFS_SERPINA1_IRES_pac_oPRE	 was	 transferred	 from	 the	
gamma-retroviral	 backbone	 (pSERS11)	 to	 a	 lentiviral	 pCCL	 backbone	 by	 In-Fusion	 cloning	 as	
described	 in	 2.2.1.2.	 Briefly,	 an	 expression	 cassette	 present	 in	 pCCL	 was	 removed	 by	 restriction	
enzyme	digestion,	homology	arms	were	created	5’	and	3’	of	the	SERPINA1-pac-cassette	by	PCR,	and	
the	 cassette	 was	 transferred	 to	 pCCL	 by	 recombination.	 A	 comparison	 of	 the	 schematic	 of	 both	
plasmids	is	depicted	in	Figure	14.	
	
Figure	 14:	 Schematic	 representation	 of	 gamma-retroviral	 expression	 vector	 #194	 and	 lentiviral	
expression	vector	#215.	
Two	batches	of	viral	 supernatant	#215	were	produced	by	transient	 triple	 transfection	of	293T	cells	
and	 titers	were	determined	on	HT1080	 fibrosarcoma	cells	as	described	 in	detail	 in	2.2.3	and	2.2.4.	
Two	batches	of	viral	supernatant	#194	were	generated	for	subsequent	experiments.	Consistent	with	
published	data	 340,	 the	average	 lentiviral	 titer	was	higher	 than	the	retroviral,	 in	our	case	~four-fold	
(#194:	[2.9x105	TU/mL];	#215:	[1.2x106	TU/mL];	Figure	15).		
	






as	 compared	 to	 the	 gamma-retroviral	 vector.	 Expression	 cassette	 pEFS_SERPINA1_IRES_pac_oPRE	
was	cloned	 into	 the	 lentiviral	pCCL	backbone,	2	batches	of	 supernatants	of	 transfer	plasmids	#194	
and	#215	each	were	generated	using	the	respective	helper	plasmids,	and	titers	were	determined	on	
HT1080	 cells.	 Symbols	 represent	 average	 values	 from	 8–14	 independent	 transductions	 per	 viral	




3.3.2. Transduction behavior differs between gamma-retro- and lentiviral vector 
3.3.2.1. Transduction efficacy 
To	analyze	potential	differences	in	transduction	efficacy	between	the	gamma-retroviral	and	lentiviral	
vector	 and	 to	 assess	 a	 dose	 response,	 primary	 human	 MSCs	 derived	 from	 three	 donors	 were	
transduced	with	both	viral	supernatants	at	four	MOIs,	ranging	from	0.25	to	5.0.	Cells	were	analyzed	
by	intracellular	flow	cytometry	for	AAT	protein	72	hours	after	transduction.	Due	to	high	inter-donor	
variability	 in	 transduction,	 results	 were	 normalized	 to	 the	 highest	 transduction	 achieved	 in	 the	
respective	experiment	(=	100%).	In	all	experiments	performed,	transduction	efficacies	at	lower	MOIs	
(0.25	 and	 0.75)	 were	 higher	 when	 the	 gamma-retroviral	 supernatant	 was	 used.	 At	MOI	 0.25,	 the	
average	 normalized	 transduction	 efficacy	was	 ~50%	of	 the	maximal	 transduction	 achieved	 in	 each	
experiment	 using	 supernatant	 #194	 and	 ~20%	 using	 vector	 #215	 (P	 <	 0.05;	 Figure	 16).	 However,	
when	MSCs	were	gene-modified	at	 the	 ten-fold	higher	MOI	of	 2.5,	 average	 transduction	efficacies	
achieved	with	the	gamma-retroviral	supernatant	increased	only	modestly	(from	~50%	at	MOI	0.25	to	
~53%	 at	 MOI	 2.5),	 whereas	 average	 normalized	 transduction	 was	 improved	 more	 than	 four-fold	
when	cells	were	transduced	with	the	lentiviral	vector	(from	~20%	at	MOI	0.25	to	~90%	at	MOI	2.5).	
Transduction	 of	 human	 MSCs	 at	 MOI	 2.5	 was	 thus	 almost	 twice	 as	 high	 with	 the	 lentiviral	
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analysis	was	 performed	 to	 assess	 if	 the	 two	dose	 response	 curves	 generated	 by	 fitting	 the	means	





transduction	 with	 the	 gamma-retroviral	 supernatant	 was	 more	 than	 twice	 as	 high	 as	 the	 one	
achieved	 using	 the	 lentiviral	 vector	 (P	 <	 0.05);	 however,	 using	 a	 10-fold	 higher	MOI,	 transduction	
efficacy	with	 lentiviral	 supernatant	 #215	was	 increased	more	 than	4-fold,	 resulting	 in	 transduction	
efficacies	 almost	 twice	 as	 high	 as	 the	 ones	 achieved	 with	 the	 gamma-retroviral	 vector	 #194		
(P	 <	 0.01).	 When	 comparing	 the	 2	 dose	 response	 curves,	 there	 was	 a	 statistically	 significant	
difference	in	the	slopes	(P	=	0.0006).	Symbols	represent	the	average	of	5	independent	transduction	
experiments	 for	 MOIs	 0.25,	 0.75,	 and	 2.5,	 and	 3	 for	 MOI	 5.0	 ±	 SD.	 Due	 to	 high	 variance	 in	




3.3.2.2. Vector Copy Number 
To	 assess	 the	 influence	 of	 the	 viral	 vector	 on	 transduced	 MSCs	 having	 undergone	 more	 ex	 vivo	
manipulation	 procedures	 and	 longer	 culture	 periods,	 the	 cells	 generated	 in	 the	 dose	 response	
experiment	 described	 above	were	 subjected	 to	 antibiotic	 selection	 and	 long-term	 expansion;	DNA	
was	extracted,	and	VCNs	were	determined.	A	graphic	representation	of	the	results	is	shown	in	Figure	
17.	 The	 data	 were	 congruent	 with	 the	 flow	 cytometry	 findings:	 Average	 VCNs	 were	 higher	 after	
transduction	with	the	gamma-retroviral	vector	at	 lower	MOIs	 (MOI	0.25:	#194:	2.6,	#215:	1.6;	MOI	
0.75:	 #194:	 2.9,	 #215:	 2.2);	 then,	 a	 trend	 reversal	 was	 observed.	 At	 the	 highest	 MOI	 of	 5.0,	
transduction	using	the	lentiviral	supernatant	yielded	average	VCNs	almost	twice	as	high	as	achieved	
with	 the	 retroviral	 vector	 (MOI	 5.0:	 #194:	 3.2,	 #215:	 6.1;	 P	 <	 0.01)	 while	 VCNs	 measured	 after	
transduction	 with	 the	 gamma-retroviral	 vector	 did	 not	 increase	 at	 all	 with	 increasing	 MOIs		
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the	 means	 were	 different	 confirmed	 that	 there	 was	 a	 significant	 distinction	 in	 the	 slope		












a	 statistically	 significant	 difference	 in	 the	 slopes	 (P	 =	 0.0003).	 Symbols	 represent	 the	 average	 of	 5	
independent	 transduction	 experiments	 for	 MOIs	 0.25,	 0.75,	 and	 2.5,	 and	 3	 for	 MOI	 5.0	 ±	 SD.	
Statistical	significance	of	differences	between	transductions	with	both	supernatants	at	the	same	MOI	
was	 calculated	 using	 Sidak’s	 multiple	 comparisons	 test	 (194	 vs.	 215:	MOI	 0.25:	 ns,	 MOI	 0.75:	 ns,		
MOI	2.5:	ns,	MOI	5.0:	**).	**	P	<	0.01.		
3.3.2.3. Expression of transgenic AAT 
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gamma-retro-	 and	 lentiviral	 vectors	 at	 MOIs	 ranging	 from	 0.25–5.0	 as	 measured	 by	 MFI	 are	
different.	 At	 the	 lower	 MOIs	 analyzed	 (0.25	 and	 0.75),	 MFIs	 achieved	 with	 the	 gamma-retroviral	
supernatant	were	~25%	higher	than	the	ones	measured	after	transduction	with	the	lentiviral	vector	
(P	 <	 0.01	 and	 P	 <	 0.001,	 respectively);	 however,	 MFIs	 were	 highest	 for	 MSCs	 transduced	 with	
lentiviral	vector	#215	at	MOI	5.0	in	all	3	experiments.	When	comparing	the	2	linear	regression	curves,	
there	 was	 a	 statistically	 significant	 difference	 in	 the	 slopes	 (P	 <	 0.0001).	 Symbols	 represent	 the	
average	of	5	independent	transduction	experiments	for	MOIs	0.25,	0.75,	and	2.5,	and	3	for	MOI	5.0	±	
SD.	Due	 to	 different	 flow	 cytometer	 settings	 used	 for	 acquiring	 the	 data	 in	 different	 experiments,	
values	 were	 normalized	 to	 the	 highest	 MFI	 measured	 in	 each	 experiment	 (=	 100%).	 Statistical	
significance	 of	 differences	 between	MFIs	 generated	with	 both	 supernatants	 at	 the	 same	MOI	was	
calculated	 using	 Sidak’s	 multiple	 comparisons	 test	 (194	 vs.	 215:	 MOI	 0.25:	 ***,		
MOI	0.75:	**,	MOI	2.5:	ns,	MOI	5.0:	ns).	**	P	<	0.01;	***	P	<	0.001.		
In	the	next	step,	the	expression	data	generated	by	flow	cytometry	was	confirmed	by	measurement	of	
transgenic	 AAT	 secreted	 from	 pure	 populations	 of	 transduced,	 selected	 MSCs	 after	 long-term	
expansion.	As	detailed	in	2.2.16,	selected	cells	were	seeded	at	defined	numbers,	supernatants	were	
collected	 after	 48	hours,	 and	AAT	 content	was	determined	by	 ELISA.	 Figure	 19	depicts	 a	 graphical	
representation	of	the	results.	AAT	expression	from	selected	MSCs	measured	by	ELISA	correlated	well	
with	 MFI	 data.	 At	 lower	 MOIs,	 AAT	 expression	 from	 cells	 transduced	 with	 the	 gamma-retroviral	




MOI	0.25	 to	~2800ng	AAT/1x105	 cells/48h	at	MOI	5.0).	 In	 contrast,	AAT	yield	 increased	more	 than	
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donor	 variability.	 However,	 when	 comparing	 the	 linear	 regression	 fits	 of	 the	 average	 AAT	 yields,	





with	 gamma-retro-	 and	 lentiviral	 vectors	 at	MOIs	 ranging	 from	0.25–5.0	as	determined	by	ELISA	
are	different.	At	the	lower	MOIs	analyzed	(0.25	and	0.75),	AAT	contents	achieved	with	the	gamma-
retroviral	 supernatant	 were	 higher	 than	 the	 ones	 measured	 after	 transduction	 with	 the	 lentiviral	
vector	(by	the	factor	of	~1.8	at	MOI	0.25	and	~1.5	at	MOI	.075,	respectively);	however,	AAT	yield	was	
highest	 for	MSCs	 transduced	with	 the	 lentiviral	 supernatant	 at	MOI	 5.0	 in	 all	 experiments.	When	
comparing	the	2	linear	regression	curves,	there	was	a	statistically	significant	difference	in	the	slopes	
(P	 =	 0.0494).	 Symbols	 represent	 the	 average	of	 3	 independent	 transduction	 experiments	 for	MOIs	
0.25,	0.75,	and	2.5,	and	2	for	MOI	5.0	±	SD.	Due	to	the	accidental	use	of	medium	containing	human	
plasma	 and	 thus	 AAT	 for	 the	 production	 of	 cell	 culture	 supernatants	 in	 one	 experiment,	 AAT	




A	 further	 set	 of	 experiments	 sought	 to	 determine	 if	 AAT	 expression	 per	 viral	 integration	 differed	
depending	on	which	vector	backbone	was	used.	Figure	20	shows	a	graphical	representation	of	AAT	
expression	data	normalized	 to	VCNs.	Average	AAT	expression	per	vector	copy	 in	 samples	collected	
after	 gamma-retroviral	 transduction	 appeared	 slightly	 higher	 than	 that	measured	 for	 the	 lentiviral	
vector	 (gamma-retroviral	 vector:	 [829ng	 AAT/1x105	 cells/48h/VCN];	 lentiviral	 vector:	 [754ng	
AAT/1x105	 cells/48h/VCN]);	 however,	 the	 results	 did	not	 reach	 statistical	 significance	 (P	 =	 0.4856),	
indicating	 that	once	 the	 transgene	cassette	 is	 integrated	 into	 the	host	genome,	gene	expression	 is	
fairly	independent	of	the	viral	backbone	used.	This	finding	is	consistent	with	published	data	329.		
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Figure	 20:	AAT	 yield	 [ng/1x105	 cells/48h]	 from	 human	MSCs	 transduced	with	 gamma-retro-	 and	




mean.	 Statistical	 significance	was	 calculated	 by	 unpaired	 two-tailed	 t	 test	with	Welch’s	 correction		
(P	 =	 0.4856).	 Gaussian	 distribution	 of	 the	 data	 was	 confirmed	 by	 D'Agostino	 &	 Pearson	 omnibus	
normality	test.		
3.3.2.4. Summary 
These	 results	demonstrate	 that	 transduction	with,	 and	AAT	expression	 from,	 the	gamma-retroviral	
vector	#194	at	varying	MOIs	follows	a	markedly	different	pattern	as	compared	to	the	lentiviral	vector	





efficacies	 and	 VCNs	 were	 already	 considerably	 high	 even	 at	 low	 MOIs,	 reaching	 an	 average	
normalized	value	of	~50%	of	the	maximum	transduction	possible	and	an	average	VCN	of	2.6	at	MOI	
0.25;	however,	these	values	did	not	appreciably	increase	even	when	20-fold	more	viral	particles	were	
used	 for	 genetic	 modification,	 suggesting	 that	 retroviral	 transduction	 was	 close	 to	 the	 maximum	
possible	already	at	low	MOIs.	This	pattern	was	reflected	by	the	AAT	expression	data	generated	from	
gamma-retrovirally	transduced	MSCs	as	determined	by	MFI	and	AAT	protein	determination	by	ELISA.	
When	 analyzing	 AAT	 expression	 normalized	 to	 viral	 integrations,	 though,	 there	 was	 no	 difference	
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3.4. Confirmation of functionality of AAT expressed from MSCs 
3.4.1. Transgenic AAT secreted from MSCs is functional 
To	assess	if	AAT	secreted	from	transduced	MSCs	was	functional	with	regards	to	its	actions	as	a	serine	
protease	 inhibitor,	 a	 neutrophil	 elastase	 inhibitor	 screening	 assay	 was	 performed	 as	 detailed	 in	
2.2.17.	Briefly,	 supernatants	of	gamma-retrovirally	and	 lentivirally	 transduced	MSCs	were	collected	
and	 incubated	with	 neutrophil	 elastase	 before	 the	 addition	 of	 a	 fluorescent	 elastase	 substrate.	 In	
case	 of	 inhibition	 of	 neutrophil	 elastase	 by	 the	 supernatant,	 hydrolyzation	 of	 the	 substrate	 was	
reduced,	 resulting	 in	 a	 decreased	 RFU	 output.	 To	 compare	 transgenic	 AAT	 expressed	 from	
transduced	MSCs	 to	 physiological,	 non-transgenic	AAT,	 natural	 full	 length	AAT	 from	human	 serum	





with	 PBS	 before	 serum-free	 DMEM	 was	 added.	 During	 the	 16-24-hour	 incubation	 in	 serum-free	
DMEM	many	 of	 the	 cells	 died,	 and	 AAT	 expression	was	 ~four-fold	 lower	 as	 compared	 to	 the	 AAT	
protein	content	usually	generated	from	the	same	number	of	plated	cells	in	medium	containing	serum	
(data	 not	 shown).	 Hence,	 the	 supernatants	 were	 concentrated	 to	 a	 concentration	 of	 [³2000ng	
AAT/mL]	as	measured	by	ELISA.		
Supernatants	collected	from	three	different	batches	of	MSCs	transduced	with	viral	vector	#194	and	








Figure	 21:	 Transgenic	 AAT	 secreted	 from	 primary	 human	 MSCs	 is	 functional.	 Concentrated	
supernatants	 collected	 from	 MSCs	 transduced	 with	 vector	 #194	 and	 #215,	 respectively,	 potently	
inhibit	neutrophil	elastase	comparable	to	[2000ng/mL]	natural	human	AAT.	Supernatants	harvested	
from	 transduced	 and	 native	 MSCs	 derived	 from	 two	 donors	 were	 analyzed	 using	 the	 neutrophil	
elastase	 inhibitor	 screening	 kit	 and	 compared	 to	 natural	 human	 full	 length	 AAT	 protein	 in	
concentrations	 from	 [250–2000ng/mL].	 DMEM	 was	 used	 as	 a	 negative	 control	 yielding	 100%	
neutrophil	 elastase	 activity.	 Bars	 represent	 average	 values	 from	 3	 independent	 transductions	 and		
3–7	independent	supernatant	collections	per	viral	vector	±	SD.	Statistical	significance	of	differences	
between	negative	control	DMEM	and	all	other	samples	tested	was	calculated	applying	the	Kruskal-
Wallis	 test	 (P	 =	 0.0002),	 followed	 by	 Dunn's	 multiple	 comparisons	 test	 (DMEM	 vs.		
[2000ng/mL	AAT]:	 **,	 DMEM	 vs.	 [1000ng/mL	AAT]:	 ns,	 DMEM	 vs.	 [500ng/mL	AAT]:	 ns,	 DMEM	 vs.	
[250ng/mL	 AAT]:	 ns,	 DMEM	 vs.	 SN	 MSCs:	 ns,	 DMEM	 vs.	 SN	 MSCs	 #194:	 *,	 DMEM	 vs.		
SN	MSCs	#215:	*).	*	P	<	0.05;	**	P	<	0.01.	





neutrophil	 elastase	 inhibitor	 screening	 assay.	 AAT	 contents	 in	 these	 samples	 as	 well	 as	 in	 natural	
human	AAT	dilution	samples	were	determined	by	ELISA,	and	neutrophil	elastase	activity	was	plotted	





































































AAT	 isolated	 from	human	plasma.	Dilutions	of	 supernatants	collected	 from	MSCs	 transduced	with	
vector	 #194	 and	 #215	 were	 generated,	 and	 inhibition	 of	 neutrophil	 elastase	 was	 assessed.	 AAT	
protein	 content	 in	 diluted	MSC	 supernatant	 samples	 and	 natural	 AAT	 samples	 was	 quantified	 by	
ELISA.	 Only	 samples	 were	 included	 in	 which	 neutrophil	 elastase	 inhibition	 values	 and	 AAT	
concentration	were	measurable	 for	 all	 5	 dilutions	 (MSC-AAT:	 n	 =	 25;	 human	plasma	AAT:	 n	 =	 20).	
Neutrophil	 elastase	 activity	 [%]	was	plotted	against	 log10	 of	AAT	 concentration.	 Curves	were	 fitted	
using	 the	 log(inhibitor)	vs.	 response	model	 (R²	 =	 0.95	 for	AAT	 from	MSCs;	 R²	 =	 0.93	 for	AAT	 from	
human	 plasma).	 There	 was	 no	 statistical	 difference	 between	 both	 groups	 as	 determined	 by	
comparison	of	fits	using	the	Extra	sum-of-squares	F	test	(P	=	0.80).	
3.5. Scale-up, batch generation and characterization 
The	 next	 step	was	 to	 assess	 if	 the	 transduction	 and	 cell	 expansion	 processes	 used	 in	 all	 previous	
experiments	 were	 scalable	 since	 the	 execution	 of	 in	 vivo	 studies	 requires	 large	 quantities	 of	 cells	
from	the	same	batch.	Thus,	we	next	 set	out	 to	produce	 large	batches	of	native	as	well	as	gamma-
retrovirally	 and	 lentivirally	 transduced	 MSCs	 from	 two	 donors	 to	 generate	 a	 supply	 of	 cells	 for	
subsequent	 animal	 studies.	 We	 also	 assessed	 if	 the	 MSCs	 at	 the	 end	 of	 the	 production	 process	
fulfilled	specifications	of	MSC	quality	parameters	(expression	of	typical	surface	markers,	adipogenic	
and	osteogenic	differentiation,	 sterility,	 testing	 for	Mollicutes).	We	also	determined	whether	 there	
was	 a	 difference	 between	 non-modified	 and	 gene-modified	 MSCs,	 and	 if	 the	 cell	 donor	 had	 an	
impact	on	the	outcome	of	the	aforementioned	parameters.		
3.5.1. Surface marker expression 
Flow	 cytometric	 analyses	 of	 surface	 antigen	 expression	 revealed	 that	 values	 were	 comparable	
between	 the	 two	 donors,	 AP00158	 and	 AP00208,	 as	 well	 as	 between	 non-modified	 and	 gene-
modified	MSCs,	and	that	all	four	batches	fulfilled	surface	marker	specifications	(Table	13).	In	all	four	
batches,	 MSC	 content	 was	 well	 above	 90%	 as	 measured	 by	 the	 expression	 of	 CD73,	 CD90,	 and	
CD105,	and	there	were	only	traces	of	contaminating	hematopoietic	cells	such	as	HSCs,	lymphocytes,	
erythrocytes	 or	 thrombocytes	 as	 confirmed	 by	 the	 lack	 of	 cells	 expressing	 CD45,	 CD34,	 CD235a,	
CD41,	CD3,	CD19,	and	CD14.		
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from	 2	 donors.	 Native	 and	 transduced	 MSC	 batches	 from	 two	 donors	 (AP00158	 and	 AP00208)	









Vital	cells	(7AAD-)	[%]	 >80	 95.43	 94.69	 98.61	 91.68	
MSCs	(CD73+/CD90+,	CD34-/CD45-)	[%]	 >90	 92.22	 96.94	 97.66	 92.78	
MSCs	(CD105+,	CD34-/CD45-)	[%]	 >90	 95.77	 95.57	 98.42	 95.71	
HSCs	(CD45+/CD34+)	[%]	 <10	 0.05	 0.07	 0.00	 0.00	
Erythrocytes	(CD235a+)	[%]	 <10	 0.11	 0.07	 0.00	 0.02	
Thrombocytes	(CD41+)	[%]	 <10	 1.63	 2.78	 0.44	 0.89	
T-Lymphocytes	(CD45+/CD3+)	[%]	 <10	 0.00	 0.03	 0.00	 0.00	
B-Lymphocytes	(CD45+/CD19+)	[%]	 <10	 0.00	 0.04	 0.00	 0.00	
Monocytes	(CD45+/CD14+)	[%]	 <10	 0.00	 0.01	 0.00	 0.00	
	
Figure	 23	 depicts	 representative	 flow	 cytometry	 plots	 of	 native	 as	 well	 as	 gamma-retrovirally	
transduced	 MSCs	 from	 one	 donor	 stained	 with	 the	 different	 fluorescently	 labeled	 antibodies	
detecting	MSC	and	hematopoietic	surface	antigens.		




differentiate	 into	 adipocytes	 as	 determined	 by	 Oil	 Red	 O	 staining	 as	 well	 as	 into	 osteoblasts	 as	
assessed	by	Alizarin	Red	staining.	These	results	suggest	that	the	genetic	modifications	performed	did	
not	 alter	 adipogenic	 and	 osteogenic	 differentiation	 capabilities	 of	 the	 engineered	MSCs,	 and	 that	
donors	 AP00158	 and	 AP00208	 are	 comparable	 in	 that	 regard.	 Figure	 24	 shows	 representative	
pictures	 of	 native	 and	 gamma-retrovirally	 transduced	MSCs	 from	 donor	 AP00158	 after	 adipogenic	
and	osteogenic	differentiation.		
3.5.3. Additional parameters 
In	 a	next	 step,	we	characterized	 the	 cell	 yields	 in	 the	 four	batches	produced.	 It	was	possible	 in	all	
cases	to	produce	quantities	>1.5x108	MSCs	(Table	14	and	Table	15),	sufficient	for	the	execution	of	a	
series	 of	 in	 vivo	 studies,	 and	 to	 cryopreserve	 the	 cells	 in	 passage	 five.	 The	 batch	 of	 lentivirally	
transduced	 cells	derived	 from	donor	AP00208	was	expanded	on	 six	5-layer	 cell	 stack	 systems;	 this	
explains	 the	high	cell	yield	of	4.63x108,	about	 twice	 the	amount	of	cells	harvested	 for	 the	gamma-
retrovirally	transduced	batch	(donor	AP00158),	which	was	expanded	on	three	5-layer	cell	stacks.	The	
batches	were	 tested	 for	 sterility	 and	 for	 the	presence	of	Mollicutes	 as	part	of	a	 standard	panel	of	
quality	 control	 assays	 for	 MSCs,	 and	 these	 specifications	 were	 also	 met.	 Batches	 of	 gamma-
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retrovirally	 and	 lentivirally	 modified	 MSCs	 were	 additionally	 characterized	 regarding	 transduction	
efficacy,	outcome	of	the	antibiotic	selection	procedure,	VCN	in	the	bulk	population	of	selected	cells,	





from	 donor	 AP00158	 stained	 for	 MSC	 and	 hematopoietic	 surface	 markers.	 Native	 and	 gamma-
















For	 the	 AAT-expressing	 MSCs	 there	 are	 at	 present	 no	 standard	 specifications	 regarding	 these	
parameters,	thus	specifications	were	chosen	based	on	empirical	“good”	values	generated	in	various	
previous	experiments.	As	these	genetically	modified	cells	were	to	be	used	for	 in	vivo	studies	at	our	
collaborators’	 non-biosafety	 level	 (BSL)	 2	 facilities,	 transduced	MSC	 batches	 were	 assayed	 for	 the	




fulfilled	 standard	 specifications	 regarding	 sterility,	 expression	 of	 surface	 markers,	 differentiation	
potential,	and	testing	for	Mollicutes;	inter-donor	variability	was	negligible	for	the	parameters	tested.		
Native	MSC	batches	 	 	 	
Parameter	 Specification	 AP00158	native	 AP00208	native	
Donor	 	 AP00158	 AP00208	
Number	of	cryopreserved	cells	






Surface	marker	expression	 All	surface	makers	within	specification	(cf.	Table	13)	 Yes	 Yes	
Adipogenic	differentiation	 Several	adipocytes	visible	 Yes	 Yes	
Osteogenic	differentiation	 Osteogenic	mineralization	visible	 Yes	 Yes	
Testing	for	Mollicutes	 Negative	 Negative	 Negative	
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Table	 15:	 Specifications	 of	 genetically	modified	MSC	 batches	 derived	 from	 donors	 AP00158	 and	
AP00208.	 MSCs	 fulfilled	 standard	 specifications	 regarding	 sterility,	 expression	 of	 surface	 markers,	
differentiation	 potential,	 and	 testing	 for	 Mollicutes;	 inter-donor	 variability	 was	 negligible	 for	 the	
parameters	tested.	Transduced	MSCs	also	fulfilled	self-chosen	specifications	for	the	values	of	%AAT-
positive	 cells	 before	 and	 after	 antibiotic	 treatment,	 VCN,	 AAT	 protein	 yield,	 and	 the	 potential	 to	
inhibit	neutrophil	elastase.		
Gene-modified	MSC	batches	 	 	 	
Parameter	 Specification	 AP00158	TD	#194	 AP00208	TD	#215	
Donor	 	 AP00158	 AP00208	
Number	of	cryopreserved	cells	






Surface	marker	expression	 All	surface	makers	within	specification	(cf.	Table	13)	 Yes	 Yes	
Adipogenic	differentiation	 Several	adipocytes	visible	 Yes	 Yes	
Osteogenic	differentiation	 Osteogenic	mineralization	visible	 Yes	 Yes	
Testing	for	Mollicutes	 Negative	 Negative	 Negative	
%	AAT	positive	pre-selection	 >25%	 72,9	 54,0	
%	AAT	positive	post-selection	 >90%	 96,2	 93,9	
VCN	 1.0-5.0	 1,7	 2,4	
AAT	protein	expression		







Testing	for	RCR/RCL	 Negative	 Negative	 Negative	
	
In	 summary,	 all	 batches	 fulfilled	 the	 specifications	 of	 the	 standard	 quality	 parameters.	 Values	 for	
native	 and	 genetically	 modified	MSCs	 were	 comparable,	 and	 also	 inter-donor	 variability	 between	
AP00158	and	AP00208	was	limited	for	the	parameters	tested.		
These	results	suggest	that	the	development	of	a	large	scale	procedure	of	transduction	and	expansion	
of	 AAT-modified	 MSCs	 was	 successful,	 and	 that	 genetic	 modification	 with	 gamma-retroviral	 or	
lentiviral	vectors	for	expression	of	human	AAT	does	not	alter	the	established	quality	parameters	from	
the	 panel	 of	 standard	 assays.	 Moreover,	 both	 gene-modified	 batches	 fulfilled	 all	 self-chosen	
specifications	believed	to	be	a	 reflection	of	“good”	AAT-expressing	MSCs,	and	differences	between	
the	 batches	were	minor.	 Transduction	 efficacies	were	 high	 for	 each	 batch;	 VCNs	were	well	 in	 the	
range	 of	 what	 has	 been	 considered	 safe	 in	 previous	 gene	 therapy	 clinical	 trial	 protocols	 192.	 AAT	
protein	expression	from	both	batches	was	above	the	threshold	chosen	to	characterize	“good”	levels	
of	AAT	expression.	Assaying	of	MSCs	 from	both	batches	 in	 the	neutrophil	 elastase	 assay	 led	 to	 an	
inhibition	of	 the	 elastase	 comparable	 to	 that	 yielded	with	 natural	 AAT	 from	human	plasma	 at	 the	
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same	 concentration.	 Taken	 together,	we	 can	 conclude	 that	 the	 scale-up	 of	 the	 processes	 and	 the	
production	of	comparable	batches	of	native	and	AAT-expressing	MSCs	for	use	in	in	vivo	experiments	
were	successful.		
3.6. In vivo proof of concept study 
3.6.1. Elastase-induced lung emphysema – experimental design 
The	 in	 vivo	 experiments	 described	 in	 this	 work	 were	 conducted	 in	 collaboration	 with	 Ali	 Önder	
Yildirim’s	group	at	the	Comprehensive	Pneumology	Center	at	the	Helmholtz	Zentrum	München.	
To	assess	if	native	and	AAT-MSCs	were	able	to	generate	a	therapeutical	benefit	 in	an	inflammatory	
lung	 disease	 in	 vivo,	 the	 well-established	 model	 of	 elastase-induced	 lung	 emphysema	 331,341	 was	
applied	 in	 order	 to	 represent	 the	 emphysema	 observed	 in	 human	 COPD.	 Female	 C57BL/6N	mice	
were	 divided	 into	 four	 groups	 consisting	 of	 six	 mice	 each	 (Table	 12):	 Mice	 in	 group	 1	 served	 as	
negative	 controls	 and	 received	 PBS,	 while	 mice	 in	 all	 other	 groups	 were	 treated	 with	 a	 single	
intratracheal	 instillation	 of	 porcine	 pancreatic	 elastase	 on	 day	 0.	Mice	 in	 positive	 control	 group	 2	
additionally	 received	an	oropharyngeal	application	of	 saline	on	day	7,	while	mice	 in	group	3	and	4	
were	 oropharyngeally	 instilled	with	 5x105	 native	MSCs,	 and	 5x105	MSCs	modified	 to	 express	 AAT,	
respectively.	On	day	14,	native	and	AAT-MSC	application	in	groups	3	and	4	was	repeated.	Before	the	
mice	 were	 sacrificed	 on	 day	 21	 for	 histological	 and	 BALF	 analysis,	 they	 were	 anesthetized,	
tracheostomized,	and	 lung	 function	measurements	performed	using	 the	Buxco	pulmonary	 function	
testing	system.	One	mouse	in	the	PBS-treated	group	had	to	be	excluded	from	the	analysis	due	to	the	
development	 of	 spontaneous	 emphysema	 (probably	 resulting	 from	 a	 confusion	 of	 this	mouse	 and	
subsequent	inadvertent	elastase	instillation;	A.	Ö.	Yildirim,	personal	communication),	and	one	mouse	
died	in	each	of	the	groups	receiving	elastase	only,	and	elastase	plus	native	MSCs.	The	mouse	in	the	
group	 receiving	 elastase	 only	 died	 shortly	 before	 completion	 of	 the	 pulmonary	 function	 analyses;	
however,	 it	 was	 possible	 to	 perform	 histological	 analyses.	 For	 that	 reason,	 pulmonary	 function	
measurements	generated	from	five	mice	could	be	analyzed	in	the	groups	treated	with	PBS,	elastase,	
and	 elastase	 plus	 native	MSCs,	 and	 from	 six	mice	 in	 the	 group	 receiving	 elastase	 plus	 AAT-MSCs;	
BALF	 and	 histology	 could	 be	 analyzed	 from	 five	 mice	 in	 the	 PBS	 and	 elastase	 plus	 native	 MSCs	
groups,	and	from	six	mice	in	the	elastase	only	and	elastase	plus	AAT-MSCs	groups.		
3.6.2. Amelioration of pulmonary function after treatment with AAT-MSCs 
Instillation	of	 porcine	pancreatic	 elastase	 in	mouse	 lungs	 is	 known	 to	 induce	 a	 breakdown	of	 lung	
tissue	 and	 a	 severe	 destruction	 of	 small	 airways	 that	 is	 comparable	 to	 emphysema	 in	 COPD	
patients	342.	The	model	leads	to	the	formation	of	large	air	pockets	that	replace	lung	tissue	resulting	in	
a	 dramatic	 increase	 of	 lung	 function	 parameters	 343.	 We	 observed	 this	 increase	 in	 pulmonary	
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measures	 in	mice	 receiving	 a	 single	 application	of	 elastase	 compared	 to	PBS-treated	animals	 in	 all	
parameters	analyzed;	however,	all	statistical	analyses	(Figure	25)	were	performed	by	comparing	the	
results	measured	in	groups	3	and	4	(“treatment	groups”	receiving	native	and	AAT-MSCs,	respectively)	
to	 the	 values	 measured	 in	 the	 elastase	 group	 (“disease	 group”)	 in	 order	 to	 assess	 a	 potential	
therapeutic	 effect	 of	 MSC	 treatment	 –	 the	 main	 focus	 of	 the	 current	 work.	 We	 observed	 a	
statistically	 significant	 improvement	 in	 lung	 function	 as	 expressed	 by	 parameters	 measuring	
expiratory	airflow	(forced	expiratory	volume	in	100ms	(FEV100ms):	P	<	0.05,	forced	vital	capacity	(FVC):	







two	 parameters	 the	 diagnosis	 of	 human	 COPD	 is	 based	 on,	 were	 improved	 by	 31.0%	 and	 25.7%,	
respectively.	The	P-value	 for	dynamic	 compliance	 (Cdyn)	was	not	 statistically	 significant	 (P	 =	0.18);	
however,	 the	 same	 trend	 towards	 an	 amelioration	 was	 visible	 as	 for	 the	 other	 parameters	
determined.	 In	 some	of	 the	parameters	analyzed	 (e.g.	 FEV100ms,	 IC)	we	could	observe	an	 indication	
that	treatment	with	native	MSCs	might	as	well	be	beneficial,	however,	comparison	of	these	results	
with	 the	 values	 measured	 in	 the	 elastase-treated	 group	 never	 reached	 statistical	 significance,	
indicating	that	AAT	overexpression	is	required	to	achieve	a	clear	therapeutic	benefit	in	this	model.		
3.6.3. Amelioration of emphysema after treatment with AAT-MSCs 
Next,	 it	 was	 assessed	 whether	 MSC	 treatment	 had	 an	 effect	 on	 the	 emphysema	 present	 in	 this	
model.	To	that	end,	airspace	enlargement	was	quantified	in	H&E	stained	sections	(Figure	26A)	of	lung	
tissue	using	an	emphysema	score	from	0-5	(Figure	26B	and	Table	17).	A	noticeable	amelioration	of	
pulmonary	 tissue	 destruction	 was	 observed	 after	 treatment	 with	 native	 MSCs,	 as	 indicated	 by	 a	
decrease	in	the	average	emphysema	score	from	4.25	±	0.61	in	the	elastase	group	to	3.50	±	0.50	in	
the	mouse	group	receiving	native	MSCs	(equal	to	an	amelioration	of	17.6%	assuming	that	the	score	
of	 elastase-treated	 mice	 corresponds	 to	 100%),	 suggesting	 that	 treatment	 with	 MSCs	 led	 to	
regeneration	 or	 repair	 of	 the	 injured	 lung	 tissue.	 However,	 a	 much	 more	 dramatic	 decrease	 in	
emphysema	was	noticed	when	mice	were	treated	with	AAT-MSCs	(from	4.25	±	0.61	in	the	elastase	
group	to	2.17	±	0.75;	P	<	0.001,	equal	to	an	amelioration	of	49.0%),	indicating	that	the	combination	
of	 AAT	 and	 MSCs	 resulted	 in	 a	 more	 than	 additive	 beneficial	 effect	 that	 led	 to	 an	 enhanced	
amelioration	of	pulmonary	tissue	injury.		





induced	 emphysema	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Lung	 function	 parameters	 were	
measured	using	the	Buxco	forced	pulmonary	maneuver	system.	A:	Expiratory	airflow.	A	statistically	
significant	 beneficial	 effect	 of	 treatment	 with	 AAT-MSCs	 was	 observed	 for	 both	 parameters	
describing	expiratory	airflow	 (FEV100ms:	P	 <	0.05,	 FVC:	P	 <	0.01),	equaling	an	amelioration	of	31.0%	
and	 25.7%,	 respectively.	 B:	 Lung	 compliance.	 While	 application	 of	 AAT-MSCs	 led	 to	 a	 highly	
statistically	 significant	 decrease	 in	 Cchord	 (P	 <	 0.001;	 42.3%	 improvement),	 a	 trend	 towards	
amelioration	 of	 Cdyn	 (P	 =	 0.18)	was	 observed	 after	 treatment	with	 AAT-MSCs.	C:	 Inspiratory	 and	
vital	capacity.	For	IC	as	well	as	VC,	a	statistically	significant	improvement	after	treatment	with	AAT-
MSCs	was	measured	 (IC:	P	 <	 0.01,	VC:	P	 <	 0.05),	 equal	 to	 an	amelioration	of	 these	parameters	by	
30.9%	and	21.7%,	respectively.	MSC-	and	AAT-MSC-treated	groups	were	compared	to	mice	receiving	
elastase	 only	 for	 all	 parameters.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	
means.	Statistical	significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	
native	 MSCs	 and	 AAT-MSCs,	 respectively,	 was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	
followed	 by	 Dunnett's	 multiple	 comparisons	 test.	 Normality	 of	 the	 data	 was	 confirmed	 by	 the	
Kolmogorov-Smirnov	normality	test.	*	P	<	0.05;	**	P	<	0.01;	***	P	<	0.001.	Only	the	clinically	most	
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Table	 16:	 Pulmonary	 function	 measurements	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	
average	 values	 measured	 for	 FEV100ms,	 FVC,	 Cdyn,	 Cchord,	 IC,	 and	 VC	 ±	 SD.	 n	 =	 5	 for	 the	 groups	
receiving	PBS,	elastase,	and	elastase	+	MSCs,	and	n	=	6	for	the	group	receiving	elastase	+	AAT-MSCs.	
	
PBS	 Elastase	 Elastase	+	MSCs	 Elastase	+	AAT-MSCs	
	
Average	 SD	 Average	 SD	 Average	 SD	 Average	 SD	
FEV100ms	 0,6982	 0,0534	 1,1305	 0,0616	 1,0751	 0,0927	 0,9964	 0,0591	
FVC	 0,7075	 0,0538	 1,5133	 0,0797	 1,4853	 0,1044	 1,3062	 0,0672	
Cdyn	 0,0245	 0,0028	 0,0519	 0,0061	 0,0574	 0,0084	 0,0440	 0,0079	
Cchord	 0,0431	 0,0048	 0,0929	 0,0068	 0,0921	 0,0068	 0,0718	 0,0060	
IC	 0,5833	 0,0414	 1,2372	 0,0828	 1,2021	 0,0789	 1,0558	 0,0462	
VC	 0,7702	 0,0756	 1,6131	 0,0758	 1,6139	 0,1380	 1,4299	 0,0795	
	
	
Figure	 26:	 Treatment	 with	 AAT-MSCs	 leads	 to	 significant	 lung	 tissue	 repair/regeneration	
(collaboration	with	A.Ö.	 Yildirim/CPC).	A:	 Representative	 photomicrographs	 of	H&E-stained	 lung	
sections.	 Treatment	 with	 MSCs	 and	 AAT-MSCS	 led	 to	 repair	 and	 regeneration	 of	 lung	 tissue,	 as	
indicated	 by	 a	 decrease	 in	 airspace	 enlargement	 noticeable	 in	 the	 respective	 slides.	 Shown	 are	
representative	slides	from	one	mouse	each	treated	with	PBS,	elastase,	elastase	plus	native	MSCs,	and	
elastase	plus	AAT-MSCs.	B:	Marked	amelioration	of	emphysema	in	AAT-MSC-treated	mice.	Airspace	
enlargement	was	assessed	by	using	an	emphysema	scoring	 system	 ranging	 from	0–5.	Each	 symbol	
represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	 distribution	 of	 the	 data	 was	
analyzed	by	 the	Kolmogorov-Smirnov	normality	 test.	 Statistical	 significance	of	differences	between	
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Table	 17:	 Emphysema	 scoring	 results	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 the	
emphysema	scoring	results	for	mice	in	all	groups.	
Mouse	No.	 PBS	 Elastase	 Elastase		+	MSCs	
Elastase		
+	AAT-MSCs	
1	 0,0	 4,0	 3,0	 2,0	
2	 0,0	 5,0	 4,0	 2,0	
3	 excluded	 4,0	 3,0	 3,0	
4	 0,0	 3,5	 3,5	 3,0	
5	 0,0	 5,0	 4,0	 1,0	
6	 1,0	 4,0	 died	 2,0	
	
3.6.4. Increased inflammation scoring after treatment with MSCs 
When	designing	this	in	vivo	study,	we	were	aware	of	the	possibility	that	the	administration	of	human	
cells	 expressing	 a	 human	 protein	 to	 immunocompetent	 mice	 might	 cause	 an	 immune	 response	
against	the	foreign	antigens.	Moreover,	during	the	histopathologic	examination	of	the	H&E	sections	
in	 the	 context	 of	 the	 assessment	 of	 the	 emphysema	 scoring	 an	 increase	 of	 inflammatory	 cell	
recruitment	to	the	lungs	of	mice	treated	with	MSCs	and	AAT-MSCs	was	observed	(Figure	27A).	Thus,	
in	a	next	step	an	analysis	of	the	 inflammation	score	was	performed	using	a	scoring	system	ranging	
from	 0–3	 (Table	 18).	 As	 graphically	 represented	 in	 Figure	 27B,	 there	 was	 a	 marked	 increase	 in	
inflammation	 score	 from	 0	 ±	 0	 in	 the	 elastase	 group	 to	 1.50	 ±	 1.0	 in	 the	 group	 receiving	 MSCs		
(P	<	0.01)	and	to	1.83	±	0.75	in	the	group	treated	with	AAT-MSCs	(P<	0.001).	 It	 is	possible	that	this	
inflammatory	 response	 results	 from	 the	 application	 of	 human	MSCs	 and	 human	MSCs	 expressing	
human	AAT	in	immunocompetent	mice,	fostering	an	immune	response	against	the	foreign	cells	and	
protein.		






Figure	 28	 and	 a	 summary	 of	 the	 data	 presented	 in	 Table	 19.	 As	 for	 the	 pulmonary	 function	
parameters	described	 in	3.6.2,	we	were	mainly	 interested	 in	 the	possible	effect	of	our	 “treatment	
groups”	in	comparison	to	the	“disease	group”.	Thus,	analyses	of	statistical	significance	were	carried	
out	 by	 comparing	 values	measured	 for	 the	MSC-treated	 groups	vs.	 the	 elastase	 only	 group.	 There	
was	 no	 significant	 difference	 in	 total	 cell	 numbers	 in	 these	 three	 groups;	 however,	 a	 statistically	
significant	 increase	 in	 absolute	 average	 lymphocyte	 and	 eosinophil	 counts	 in	 the	 mouse	 group	




elastase	group	 to	19240	±	 3499	 in	 the	AAT-MSC	group;	P	<	0.001;	 eosinophils:	 from	0	 to	19775	±	
11171;	P	 <	0.01)	was	noted;	 a	marked	 rise	 in	 these	 cell	 numbers	was	 also	observed	 in	 the	 groups	
treated	 with	 native	 MSCs,	 however,	 statistical	 significance	 was	 only	 reached	 for	 lymphocytes		
(P	 <	 0.01).	 Concomitant	 with	 these	 results	 was	 a	 tendency	 towards	 decreased	 numbers	 of	
macrophages	in	both	groups	treated	with	MSCs	(from	100778	±	22579	in	the	elastase	group	to	75453	
±	 39084	 in	 the	 MSC-treated	 group,	 and	 to	 78631	 ±	 23263	 in	 the	 AAT-MSC	 group),	 as	 well	 as	
neutrophils	 in	 the	AAT-MSC	group	(from	730	±	390	 in	 the	elastase	group	to	450	±	722	 in	 the	AAT-




of	 lymphocytes	and	eosinophils	were	markedly	 increased	 in	both	mouse	groups	treated	with	MSCs	
compared	 to	 the	 group	 receiving	 elastase	 only	 (lymphocytes:	 MSCs:		
P	 <	 0.0001,	 AAT-MSCs:	 P	 <	 0.0001;	 eosinophils:	 MSCs:	 P	 <	 0.05,	 AAT-MSCs:	 P	 <	 0.001),	 and	
percentages	of	macrophages	were	significantly	decreased	(MSCs:	P	<	0.0001,	AAT-MSCs:	P	<	0.0001).		
	
Figure	 27:	 Treatment	 with	 AAT-MSCs	 leads	 to	 significant	 increase	 in	 inflammation	 scoring	
(collaboration	with	A.Ö.	 Yildirim/CPC).	 A:	 Representative	 photomicrographs	 of	H&E-stained	 lung	
sections.	 Instillation	 of	MSCs	 and	 AAT-MSCs	 leads	 to	 inflammatory	 cell	 recruitment	 to	 the	mouse	
lungs.	Shown	are	representative	slides	from	one	mouse	each	treated	with	PBS,	elastase,	elastase	plus	
native	MSCs,	 and	 elastase	 plus	AAT-MSCs.	B:	 Significant	 increase	 of	 inflammation	 score	 in	 native	
and	 AAT-MSC-treated	 mice.	 Inflammation	 score	 was	 assessed	 by	 using	 a	 scoring	 system	 ranging	
from	 0–3.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	
distribution	 of	 the	 data	 was	 analyzed	 by	 the	 Kolmogorov-Smirnov	 normality	 test.	 Statistical	
significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	MSCs	and	
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Table	 18:	 Inflammation	 scoring	 results	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 the	
inflammation	scoring	results	for	mice	in	all	groups.		
Mouse	No.	 PBS	 Elastase	 Elastase		+	MSCs	
Elastase		
+	AAT-MSCs	
1	 0,0	 0,0	 0,0	 1,0	
2	 0,0	 0,0	 2,0	 2,0	
3	 excluded	 0,0	 1,0	 2,0	
4	 0,0	 0,0	 2,0	 3,0	
5	 0,0	 0,0	 2,5	 1,0	




MSCs	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	No	 significant	 difference	 in	 total	 cell	 numbers	 was	
noted.	A	statistically	 significant	 increase	 in	 the	absolute	number	of	 lymphocytes	and	eosinophils	 in	
mice	 receiving	 AAT-MSCs	 in	 comparison	 to	 mice	 treated	 with	 elastase	 only	 was	 observed	
(lymphocytes:	P	<	0.001,	eosinophils:	P	<	0.01).	The	same	effect	was	noted	for	native	MSCs;	however,	
statistical	 significance	was	 only	 reached	 for	 lymphocytes	 (P	 <	 0.01).	 Accompanied	 by	 these	 results	
was	 a	 trend	 towards	 lower	macrophage	 counts	 in	 both	 groups	 treated	with	MSCs,	 and	 neutrophil	
counts	in	the	AAT-MSC	groups.	Mouse	lungs	were	lavaged	3	times	with	PBS,	cells	were	pelleted,	and	
the	 pellet	 resuspended	 in	medium	 for	 the	 total	 cell	 count.	 Cytospins	 of	 the	 cell	 suspension	 were	
prepared	 for	 differential	 cell	 counting.	 MSC-treated	 groups	 were	 compared	 to	 mice	 receiving	
elastase	 only	 for	 all	 cell	 types.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	
means.	Gaussian	distribution	of	 the	data	was	analyzed	by	 the	Kolmogorov-Smirnov	normality	 test.	
Statistical	significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	
MSCs	 and	 AAT-MSCs,	 respectively,	was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	 followed	 by	
Dunnett's	multiple	comparisons	test	for	total	cells,	macrophages,	lymphocytes,	and	eosinophils,	and	
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statistically	 significant	 increase	 in	 the	 relative	 proportions	 of	 lymphocytes	 and	 eosinophils	 in	mice	
receiving	 either	 native	MSCs	 or	 AAT-MSCs	 in	 comparison	 to	 mice	 treated	 with	 elastase	 only	 was	
observed	(lymphocytes:	MSCs:	P	<	0.0001,	AAT-MSCs:	P	<	0.0001;	eosinophils:	MSCs:	P	<	0.05,	AAT-
MSCs:	P	<	0.001),	while	macrophage	percentages	were	markedly	decreased	(MSCs:	P	<	0.0001,	AAT-
MSCs:	P	<	0.0001).	Mouse	 lungs	were	 lavaged	3	 times	with	PBS,	cells	were	pelleted	and	 the	pellet	
resuspended	in	medium	for	the	total	cell	count.	Cytospins	of	the	cell	suspension	were	prepared	for	
differential	cell	counting.	MSC-treated	groups	were	compared	to	mice	receiving	elastase	only	for	all	
cell	 types.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	
distribution	 of	 the	 data	 was	 analyzed	 by	 the	 Kolmogorov-Smirnov	 normality	 test.	 Statistical	
significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	MSCs	and	
AAT-MSCs,	 respectively,	 was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	 followed	 by	 Dunnett's	
multiple	 comparisons	 test	 for	 total	 cells,	macrophages,	 lymphocytes,	 and	eosinophils,	 and	Kruskal-
Wallis	test,	followed	by	Dunn’s	multiple	comparisons	test	for	neutrophils.	*	P	<	0.05;	***	P	<	0.001;	
****	P	<	0.0001.	
Table	 19:	Cell	 counts	 in	 the	 BALF	 (collaboration	with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 average	 cell	
numbers	counted	in	the	BALF	of	the	mice	for	total	cells,	macrophages,	neutrophils,	lymphocytes,	and	
eosinophils	±	SD.	n	=	5	 for	 the	groups	receiving	PBS,	and	elastase	+	MSCs,	and	n	=	6	 for	 the	group	
receiving	elastase	and	elastase	+	AAT-MSCs.	
	
PBS	 Elastase	 Elastase	+	MSCs	 Elastase	+	AAT-MSCs	
	
Average	 SD	 Average	 SD	 Average	 SD	 Average	 SD	
Total	cells	 46500	 14748	 105583	 23570	 104500	 58986	 117083	 29087	
Macrophages	 45308	 14421	 100778	 22579	 75453	 39084	 78631	 23263	
Neutrophils	 0	 0	 730	 390	 768	 753	 450	 722	
Lymphocytes	 1193	 331	 4076	 2638	 15628	 9164	 19240	 3499	
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In	summary,	application	of	AAT-MSCs	 led	to	significantly	 improved	respiratory	 function	parameters	
and	 enhanced	 regeneration	 and	 repair	 of	 lung	 tissue	 as	 indicated	 by	 a	 dramatic	 decrease	 in	
emphysema	 scoring	 in	 a	 model	 of	 elastase-induced	 lung	 emphysema.	 However,	 treatment	 with	
native	 and	 AAT-MSCs	 also	 induced	 an	 inflammatory	 response	 in	 the	 mouse	 lungs	 as	 well	 as	
significant	accumulation	of	 lymphocytes	and	eosinophils	 in	 the	BALF,	which	will	need	to	be	 further	
investigated.		








4.1. Targeting construct 
One	 major	 aim	 of	 the	 present	 work	 was	 to	 design	 an	 optimized	 transfer	 vector	 for	 the	 genetic	
modification	 of	 human	MSCs	 to	 express	 the	 serine	 protease	 inhibitor	 AAT.	 Several	 considerations	





variant	 5,	 accession	 number	NM_001127701.1).	 The	 5’	UTR	 of	 transcript	 variant	 1	 has	 a	 relatively	
small	 size	 of	 261	 bases,	 as	 do	 the	majority	 of	 the	 transcript	 variants.	 Therefore,	 it	 could	 easily	 be	
included	 in	 the	 expression	 construct	 without	 having	 to	 fear	 a	 major	 drop	 in	 viral	 titers.	 Our	
hypothesis	was	that	the	5’	UTR	might	contain	sequences	inducing	cap-independent	translation	344,345,	
serve	as	a	natural	site	for	the	potential	binding	of	regulatory	factors	such	as	miRNAs	346,	or	comprise	




During	 the	 ordering	 process	 of	 the	 SERPINA1	 expression	 cassette	 from	GeneArt,	 a	modified	 Kozak	
consensus	sequence	327	was	inserted	5’	of	the	SERPINA1	start	codon	to	ensure	efficient	initiation	of	










from	 including	 it	 in	 our	 list	 of	 promoters	 to	 be	 tested.	 Instead,	 we	 focused	 on	 the	 following	
constitutive	 promoters	 in	 order	 to	 assess	 the	 impact	 of	 different	 promoters	 on	 gene	 expression	
levels:	 The	 PGK	 and	 EF1a	 promoters	 are	 human	 physiological	 promoters	 normally	 driving	 the	
expression	of	ubiquitous	proteins	crucial	for	glycolysis	356,357	and	protein	translation	358,	respectively,	








pPGK	 and	 pEF1a	 is	 detectable	 over	 several	 weeks,	 while	 viral	 promoters	 are	 more	 prone	 to	
silencing		363,364.	Another	reason	to	favor	physiological	promoters	over	strong	viral	promoters	despite	
their	high-level	gene	expression	is	safety:	In	all	documented	cases	of	insertional	transformation	that	




third	 promoter	 analyzed	 was	 pEFS	 (pEF1a	 short),	 the	 intron-less	 form	 of	 pEF1a	 described	 by	
Schambach	and	colleagues	329.	Comprising	only	233	bases,	it	is	almost	six	times	shorter	than	the	full	
length	EF1a	promoter,	which	 is	expected	 to	be	beneficial	with	 regards	 to	 resulting	viral	 titers,	 and	
expression	 from	 pEFS	 has	 been	 described	 to	 be	 approximately	 half	 of	 pEF1a	 in	 HSCs	 329.	 These	
features	make	pEFS	a	 very	 attractive	 candidate	promoter,	 and	 indeed	 is	 it	 presently	being	used	 in	
several	gene	therapy	clinical	trials	worldwide	189,366,367.	The	CAG	promoter	consists	of	the	CMV	early	
enhancer	 in	combination	with	 the	chicken	beta	actin	promoter	and	usually	yields	higher	 transgene	
expression	as	 compared	 to	 the	promoters	described	above	 335.	 Thus,	 it	was	 included	 to	 serve	as	 a	
positive	control	for	high	expression	in	early	experiments.	As	expected,	MFI	values	of	AAT	expressed	
from	 pCAG	 measured	 by	 flow	 cytometry	 for	 intracellular	 AAT	 were	 twice	 as	 high	 as	 e.g.	 MFIs	
measured	 for	 AAT	 driven	 from	 pEF1a.	 Transduction	 efficacies	 of	 primary	 MSCs,	 however,	 were	
unacceptably	 low	 using	 pCAG,	 probably	 due	 to	 very	 low	 viral	 titers,	 with	 the	 large	 size	 of	 the	
promoter	of	~1600	bases	most	likely	being	the	reason	for	these.	Thus,	pCAG	was	not	included	in	any	
further	 experiments,	 and	 the	 three	 promoters	 tested	 for	 SERPINA1	 expression	were	 pPGK,	 pEF1a,	
and	pEFS.		
In	addition	to	SERPINA1,	the	pac	gene	was	needed	to	be	expressed	in	the	targeting	construct	to	allow	
for	 antibiotic	 selection	 of	 transduced	 cells.	 Thus,	 the	 next	 point	 to	 consider	 when	 designing	 our	
expression	vector	was	how	the	pac	gene	should	be	co-expressed.	Common	strategies	used	to	drive	
the	expression	of	more	 than	one	gene	per	 targeting	construct	make	use	of	multiple	promoters	 368,	
IRES	 sequences	 369,	 fusion	 proteins	 370	 or	 insertion	 of	 cleavage	 signals	 such	 as	 2A	 peptides	 371,372.	
Among	 these	 strategies,	 multiple	 promoters	 and	 the	 utilization	 of	 IRES	 sequences	 are	 the	 most	
frequently	employed	337.	Thus,	we	decided	to	assess	both	approaches	and	drive	pac	expression	from	
either	a	 second	promoter	or	use	 the	well	described	EMCV	 IRES	sequence	332,333	 to	 link	both	genes.	
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Due	 to	 pEF1a	 being	 the	 largest	 promoter	 under	 evaluation,	 and	 because	 we	wanted	 to	 keep	 the	
construct	sizes	as	small	as	possible,	the	choice	was	narrowed	down	to	pPGK	and	pEFS	promoters	for	
pac	expression	in	evaluation	of	the	two	promoter	approach.		
Another	point	of	 consideration	 regarding	 the	use	of	 two	promoters	was	 their	 configuration	within	
the	expression	cassettes.	 It	has	been	described	 that	 two	active	 transcription	units	 linked	 in	cis	 can	




The	mechanisms	 leading	 to	 this	 perturbation	 of	 one	 transcription	 unit	 by	 another	 are	 diverse	 and	






arrangement	 in	 the	 retroviral	 vector	would	 lead	 to	 highest	SERPINA1	 expression.	 Thus,	 a	 series	 of	
combinations	 were	 evaluated:	 SERPINA1	 driven	 from	 pPGK,	 pEF1a,	 and	 pEFS,	 and	 the	 expression	
cassette	placed	5’	of	the	pac	cassette	in	some	constructs,	and	3’	in	others,	resulting	in	a	total	of	six	
gamma-retroviral	transfer	plasmids.	As	our	focus	was	optimizing	SERPINA1	expression,	permutations	








one	 long	mRNA	containing	both	genes	 is	produced	during	 transcription	of	 the	expression	cassette.	
This	is	not	necessarily	the	case	when	two	promoters	are	used	as	only	one	of	the	transgenes	may	be	
expressed	while	 the	promoter	of	 the	second	gene	becomes	silenced.	However,	concerns	 regarding	
the	IRES	approach	were	raised	by	the	fact	that	oftentimes	the	gene	downstream	the	IRES	sequence	is	
expressed	 at	markedly	 lower	 levels	 compared	 to	 the	 upstream	 gene	 381.	 Thus,	 as	maximizing	 AAT	
yield	 was	 our	 main	 focus,	 SERPINA1	 was	 only	 tested	 in	 a	 position	 5’	 of	 the	 IRES	 sequence,	 and	
expression	from	pPGK	and	pEFS	were	compared	in	two	constructs.	The	EF1a	promoter	was	not	used	
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in	an	IRES	construct	due	to	its	 large	size	and	the	fact	that	the	IRES	sequence	by	itself	 is	 larger	than	
pPGK	 and	 pEFS	 combined.	 Thus,	 for	 this	 construct	 a	massive	 drop	 in	 viral	 titers	would	 have	 been	




point	 of	 view,	 our	 best	 guess	 regarding	 the	 construct	 becoming	 the	 lead	 candidate	 among	 all	 the	
vectors	 designed	 was	 construct	 #194	 due	 to	 several	 reasons:	 First,	 with	 a	 size	 of	 the	 expression	
cassette	 of	 ~4500	 base	 pairs,	 it	 was	 one	 of	 the	 smallest	 constructs	 suggesting	 that	 resulting	 viral	
titers	would	most	 likely	 be	 higher	 than	 those	 of	 larger	 cassettes	 338.	 Second,	 as	 detailed	 above,	 it	
contains	 an	 IRES	 sequence	 instead	 of	 a	 second	 internal	 promoter,	 thus	 minimizing	 the	 risk	 of	
transcriptional	 interference	 on	 one	 hand,	 and	 guaranteeing	 expression	 of	 both	 transgenes	 after	
antibiotic	 selection	on	 the	other.	And	 third,	 it	 has	been	described	 that	pEF1a	yields	~4-fold	higher	
transgene	expression	than	pPGK	in	primary	MSCs	as	well	as	different	cell	 lines	362,364;	assuming	that	




4.2. Viral titers 
With	 regard	 to	 the	 viral	 titers	 obtained	with	 the	 SERPINA1	 constructs,	 the	 highest	 value	 reached,	
[3x105	 TU/mL],	 appears	 relatively	 low	 at	 first	 glance.	 However,	 the	 procedure	 of	 transduction	
included	the	use	of	adherent	cells	without	the	addition	of	compounds	neutralizing	negative	charges,	
such	 as	 the	 cationic	 PLL.	 These	 chemicals	 are	 oftentimes	 added	 to	 improve	 transduction	 by	
minimizing	repulsion	between	cells	and	viral	particles	382–384.	Such	being	the	case,	the	conditions	we	
chose	were	suboptimal	for	transduction.	However,	we	were	interested	in	comparing	the	titers	of	the	
constructs	 in	 order	 to	 transduce	 our	 cells,	 primary	 human	MSCs,	 with	 the	 same	 amount	 of	 viral	
particles	in	subsequent	experiments.	Thus,	we	chose	the	fastest	and	easiest	way	of	transducing	the	
cells,	 resulting	 in	 the	 lower	absolute	 titers	observed.	A	 second	 issue	 regarding	SERPINA1	 construct	
titers	is	the	negative	impact	of	a	larger	genetic	payload	on	viral	titers.	This	effect	has	been	described	
for	lentiviral	vectors,	with	the	reason	for	decreased	titers	linked	to	inefficient	incapsidation	of	larger	
viral	 RNA	 genomes	 into	 infectious	 particles	 338,339,385.	 In	 these	 publications	 the	 addition	 of	 ~1000	
bases	 to	 the	provirus	 led	 to	 a	 ~10-fold	decrease	of	 lentiviral	 titers.	 For	 the	 retroviral	 vectors	 used	
here	 the	 effect	 was	 much	 more	 pronounced:	 In	 our	 hands,	 the	 addition	 of	 ~1000	 bases	 to	 the	
expression	cassette	in	constructs	in	which	SERPINA1	is	driven	from	pEF1a	results	in	a	massive	drop	in	
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titers	 of	 close	 to	 two	 log	 units.	 This	 discrepancy	 may	 result	 from	 the	 different	 transduction	




4.3. Transduction of primary MSCs and expression of transgenic AAT 
The	 transduction	efficacy	and	 transgenic	AAT	protein	expression	were	assessed	 in	 two	ways:	 First,	
the	percentage	of	cells	intracellularly	staining	positive	for	AAT	as	well	as	the	MFI	of	these	cells	used	
as	an	indicator	of	expression	strength	were	measured	shortly	after	transduction	by	flow	cytometry.	




to	 compare	 the	 expression	 constructs	 at	 a	 time	when	 the	MSCs	were	 in	 early	 passages	 following	
transduction,	and	at	a	point	when	the	cells	were	 in	higher	passages	after	culture	for	several	weeks	
and	subjected	to	ex	vivo	procedures	such	as	cell	expansion	or	antibiotic	selection.	This	 is	important	
for	 the	potential	 application	of	 these	 cells	 in	 a	 gene	 therapy	 setting.	 The	MSCs	at	higher	passages	
having	undergone	these	ex	vivo	manipulation	steps	more	closely	 resemble	the	 final	cell	product	as	
compared	to	the	cells	analyzed	shortly	after	transduction.	The	relative	performance	of	the	constructs	
tested	 stayed	 the	 same	 at	 different	 times,	 i.e.	 the	 same	 constructs	 yielded	 good	 results	 in	 all	
experiments,	 and	 the	 “bad”	 vectors	 were	 inferior	 in	 all	 analyses.	 It	 was	 thus	 possible	 for	 us	 to	
conclude	that	the	results	observed	were	constant	over	time	and	not	influenced	by	MSC	expansion	or	





Culturing	cells	 for	extended	culture	 time	as	described	above	would	most	 likely	have	enabled	us	 to	
observe	any	potential	unwanted	effects	such	as	silencing	of	gene	expression	386	or	cytotoxicity	of	AAT	
overexpression.	We	could	not	detect	 these	phenomena	 in	any	of	 the	experiments	performed,	thus	
we	could	assume	that	genetic	modification	of	primary	human	MSCs	with	our	retroviral	vectors	leads	
to	non-cytotoxic,	 long-term	 transgenic	AAT	expression.	This	 is	of	 great	 importance	 for	a	 cell-based	
gene	therapy	approach,	since	the	therapeutic	benefit	relies	on	stable	expression	of	the	therapeutic	
transgene	over	 a	 prolonged	period	of	 time.	As	 of	 yet,	 it	 is	 not	 clear	 how	 long	MSCs	persist	 in	 the	
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levels	were	constant	even	after	cryopreservation	of	 transduced	and	selected	MSCs,	 thawing	of	 the	
cells	 and	 expansion,	 indicating	 that	 transgene	 silencing	 is	 not	 a	 problem	 in	 our	 approach.	 As	









Another	 important	 point	 is	 that	 when	 transducing	 primary	 MSCs	 with	 our	 eight	 retroviral	
supernatants,	it	was	striking	that	although	the	cells	had	been	treated	with	the	same	amount	of	viral	
particles	 for	 each	 construct,	 transduction	 efficacies	were	not	 similar	 as	might	 have	been	expected	
(Figure	 8):	 MSCs	 transduced	 with	 supernatants	 #161	 and	 #164	 (in	 which	 SERPINA1	 expression	 is	
driven	from	pEF1a)	only	reached	transduction	efficacies	of	about	10–30%	of	the	ones	measured	with	
#160,	 #163,	 #194	 (all	 three	 constructs	 which	 contain	 pEFS	 to	 express	 SERPINA1)	 or	 #193	
(pPGK_SERPINA1_IRES_pac),	while	#159	and	#162	(constructs	in	which	SERPINA1	expression	is	driven	
by	pPGK)	yielded	 intermediate	results.	As	the	constructs	producing	these	 low	results	were	also	the	








proteins	 shed	 from	 packaging	 cells	 or	 non-transducing	 viral	 particles	 390.	 Adding	 pure	 viral	
supernatant	 to	 the	 MSCs	 might	 create	 an	 unhealthy	 environment	 for	 the	 cells,	 and	 the	 waste	
products	 present	 in	 the	 supernatant	 might	 impede	 transduction,	 both	 factors	 together	 possibly	
giving	 an	 explanation	 why	 transduction	 efficacies	 of	 constructs	 #161	 and	 #164	 were	 that	 low.	




efficacies	were	 not;	 there	 appeared	 to	 be	 a	 dependence	 of	 the	 results	 on	 the	 promoter	 used:	 All	
constructs	containing	pEFS	reached	similar	high	values,	while	the	results	achieved	with	pPGK	vectors	
tended	 to	 be	 lower.	 Furthermore,	we	 showed	 that	 AAT	 expression	 from	pPGK-based	 constructs	 is	
also	 lower	 in	MSCs	 than	 that	seen	 from	pEFS-based	vectors	 (Figure	9).	This	might	have	 led	 to	cells	
expressing	low	levels	of	AAT	ending	up	in	the	negative	gate	during	flow	cytometry	analysis.	If	this	was	
the	 case,	 the	 transduction	 efficacies	 of	 pPGK	 constructs	 would	 have	 been	 underestimated,	
potentially	explaining	the	results	observed.	The	AAT	expression	seen	from	vector	#193,	a	construct	
containing	the	PGK	promoter	and	an	IRES	sequence	instead	of	a	second	promoter,	was	higher,	and	
transduction	 efficacies	 obtained	 with	 this	 construct	 were	 more	 similar	 to	 that	 seen	 with	 pEFS	
constructs,	which	would	support	the	abovementioned	hypothesis.	VCN	data	from	bulk	populations	of	
transduced	 and	 selected	 MSCs,	 however,	 contradict	 this	 idea.	 Also	 in	 these	 analyses,	 which	 are	
independent	 of	 the	 strength	 of	 AAT	 expression,	 pPGK-based	 constructs,	 especially	 the	 ones	
containing	a	second	promoter,	fared	poorly	(Figure	11),	thus	confirming	the	flow	cytometry	data	and	
indicating	that	these	constructs	indeed	lead	to	lower	transduction	efficacies.		
Due	 to	 high	 donor-to-donor	 variability,	 in	 order	 to	 compare	 transduction	 efficacies	 as	 described	
above,	it	was	necessary	to	normalize	the	values	determined	in	each	experiment	to	the	highest	result	
measured	 in	 the	 same	 run.	 The	 fact	 that	 MSCs	 derived	 from	 different	 donors	 yield	 very	 diverse	
results	 when	 the	 same	 experiment	 is	 performed,	 is	 a	 common	 problem	 in	MSC	 research	 391,392.	 A	
representative	example	of	the	impact	of	the	cell	donor	on	transduction	efficacies	is	shown	in	Figure	
30.	A	5-fold	difference	was	seen	in	transduction	efficacies	when	using	the	same	viral	supernatant	on	




Figure	 30:	 Impact	 of	 cell	 donor	 on	 transduction	 efficacies	 achieved	 with	 constructs	 #159,	 #160,	
#162,	and	#163.	Normalized	transduction	efficacies	differed	by	the	factor	5	between	2	cell	donors.	
Primary	human	MSCs	derived	from	2	healthy	donors	(AP00109	and	AP00158)	were	transduced	with	
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assessed	 by	 intracellular	 staining	 for	 AAT	 and	 subsequent	 flow	 cytometric	measurement	 72	 hours	
after	transduction.	Bars	represent	average	values	of	2	independent	transduction	experiments	±	SD.		
In	 the	 present	 study	 we	 also	 compared	 the	 various	 constructs	 by	 values	 not	 impaired	 by	 donor	
variability,	 but	 depending	 solely	 on	 the	 expression	 construct:	 As	 all	 flow	 cytometry	 experiments	
performed	 to	 compare	 the	 eight	 gamma-retroviral	 constructs	 were	 measured	 using	 the	 same	
settings,	 absolute	MFI	 values	 of	 AAT-positive	 cells	 could	 be	 compared	 as	 a	measure	 of	 expression	
strength.	The	same	is	true	for	VCN	determination	which	was	performed	after	antibiotic	selection	of	
the	bulk	cell	population;	as	such,	the	selection	and	subsequent	expansion	processes	compensate	for	
the	 different	 transduction	 efficacies.	 Moreover,	 for	 determination	 of	 AAT	 content	 in	 cell	 culture	
supernatants	 by	 ELISA,	 the	 same	 experimental	 scheme	 was	 applied	 in	 all	 experiments:	 The	 same	
numbers	of	cells	per	cm2	were	plated,	the	same	volume	of	medium	was	added	and	incubated	for	the	
same	time	on	the	cells	before	AAT	protein	content	was	determined.	Thus,	the	(absolute	and	relative)	





The	 low	 transduction	 efficacies	 suggest	 that	 a	 high	 percentage	 of	 cells	 harvested	 from	 a	 healthy	
donor	will	not	get	gene-modified	and	thus	be	eliminated	during	antibiotic	selection.	This	 is	bad	not	
only	from	an	economic	point	of	view,	but	also	implies	that	the	remaining	transduced	cells	will	have	
to	undergo	more	population	doublings	 to	 reach	 cell	 numbers	 sufficient	 for	 treating	 a	patient.	 This	
should	be	avoided	as	cells	in	lower	passages	are	thought	to	produce	better	outcomes	in	clinical	trials	







titers	 and	 transduction	 efficacies	 were	 highest	 in	 pEFS	 constructs.	 Thus,	 there	 was	 no	 reason	 to	
further	evaluate	constructs	comprising	pEF1a.	While	performing	these	experiments,	 it	also	became	
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construct	 was	 further	 characterized	 to	 include	 at	 least	 one	 construct	 in	 which	 SERPINA1	 was	 not	
driven	 from	 pEFS.	 The	 remaining	 four	 constructs	 (#160,	 #163,	 #193,	 and	 #194)	 achieved	 similar	






the	 cells	 to	 survive	 antibiotic	 selection	 with	 puromycin	 at	 the	 used	 concentration.	 Another	 fact	
supporting	this	idea	was	that	for	the	IRES	constructs	cell	numbers	also	agreed	well	with	transduction	
efficacies	 determined,	 i.e.	 50%	 transduction	 efficacy	 would	 result	 in	 approximately	 50%	 of	 the	
transduced	 cells	 surviving	 the	 selection	 process	 during	 the	 first	 days	 of	 selection,	 while	 the	
percentage	of	surviving	cells	was	much	lower	for	the	two	promoter	constructs.	These	results	suggest	




expression	 was	 found	 to	 be	 due	 to	 promoter	 interference	 between	 the	 CMV	 and	 the	 EF1a	
promoter	337.	 While	 in	 this	 publication	 the	 effect	 was	 bidirectional,	 i.e.	 the	 upstream	 promoter	
impaired	transgene	expression	from	the	downstream	promoter	and	vice	versa,	in	our	case	the	effect	
was	unidirectional.	SERPINA1	expression	was	the	same	for	all	three	pEFS	constructs,	 indicating	that	
the	 pPGK_pac	 transcription	 unit	 did	 not	 have	 an	 impact	 on	 the	 pEFS_SERPINA1	 unit.	 Thus,	 the	
differences	 in	pac	expression	seen	may	 result	 from	pEFS,	which	 is	very	 strongly	activated	 in	MSCs,	
competing	with	the	weaker	PGK	promoter	for	the	binding	of	transcription	factors,	enhancers	or	other	
DNA-binding	 proteins,	 resulting	 in	 a	 decrease	 in	 pac	 expression	 in	 the	 constructs	 comprising	 two	
promoters.	 The	 fact	 that	 the	 IRES	 constructs	 were	 not	 affected	 by	 this	 phenomenon	 of	
transcriptional	 interference	 in	 our	 setting	would	 support	 this	 hypothesis.	 Although	pac	 expression	
might	 be	 lower	 than	 SERPINA1	 expression	 in	 the	 IRES-based	 constructs	 as	 described	 for	 gene	
expression	downstream	of	an	IRES	sequence	381,	it	was	sufficient	for	the	selection	process.		
Another	aspect	we	analyzed	was	 if	different	configurations	of	the	expression	units	 (5’	vs.	3’)	 in	the	
expression	 cassette	 could	 have	 an	 influence	 on	 AAT	 expression.	 Swapping	 the	 position	 of	 the	
SERPINA1	 unit	 in	 the	expression	 cassette	did	not	 seem	 to	have	an	 impact	on	AAT	expression.	This	
may	 be	 because	 pEFS	 is	 considerably	 strong	 in	MSCs,	 so	 that	 possible	 effects	 on	 AAT	 expression	
caused	by	the	position	of	the	transcription	units	are	too	minor	to	be	noticed.	Cell	numbers	obtained	
after	antibiotic	selection	 (Figure	13),	however,	suggest	a	position	effect.	Transduction	efficacies	 for	





of	 the	 pac	 unit	 in	 relation	 to	 the	 SERPINA1	 unit	 might	 play	 a	 role	 in	 how	 strong	 transcriptional	
interference	impairs	pac	gene	expression.	
Based	 on	 these	 results,	 construct	 #194	 (pEFS_SERPINA1_IRES_pac)	 was	 selected	 as	 our	 lead	
candidate	for	preclinical	evaluation.		
4.4. Comparison of gamma-retroviral with lentiviral vector 
Another	 aim	 of	 this	 study	 was	 to	 further	 optimize	 AAT	 expression	 by	 evaluating	 a	 second	 viral	
backbone.	 In	 addition	 to	 gamma-retroviral	 vectors,	 lentiviral	 vectors	 are	 the	 only	 viral	 vectors	
currently	used	 for	 clinical	 applications	 leading	 to	 stable	 integration	of	 genetic	 information	 into	 the	




and	 are	 also	 single	 stranded,	 positive-sense	 RNA	 viruses.	 Both	 viral	 vectors	 can	 transfer	 genetic	
payloads	of	approximately	7–10kb	398,399.	The	production	of	gamma-retro-	and	lentiviral	supernatants	
is	 similar,	as	are	 the	 transduction	procedures.	All	 these	 factors	enable	a	direct	comparison	of	both	
vector	 systems.	 Our	 lead	 expression	 cassette	 was	 subcloned	 into	 the	 pCCL	 backbone,	 and	 viral	
supernatants	were	generated.	Although	the	genetic	payload	of	the	lentiviral	vector	is	approximately	
1kb	 larger	 due	 to	 more	 regulatory	 viral	 sequences	 being	 included	 between	 the	 LTRs,	 the	 titers	
achieved	 on	 HT1080	 cells	 were	 higher	 than	 those	 seen	 for	 the	 retroviral	 supernatants.	 The	main	
difference	between	these	two	viral	vectors	is	that	while	gamma-retroviruses	need	dissolution	of	the	
nuclear	 membrane	 of	 the	 host	 cell	 for	 successful	 insertion	 of	 their	 genome	 into	 the	 host	 DNA,	
lentiviruses	 transfer	 their	 pre-integration	 complex	 into	 the	 nucleus	 through	 the	 intact	 nuclear	
envelope.	Because	of	 this,	 retroviral	 transduction	 is	 limited	 to	mitotic	 cells,	while	 lentiviral	 vectors	
can	also	transduce	growth-arrested	and	terminally	differentiated	cells	400–402.	This	phenomenon	was	
observed	 in	 the	 transduction	experiments	performed	using	MOIs	 ranging	 from	0.25–5.0:	While	 for	
the	gamma-retroviral	supernatant,	there	was	only	a	very	slight	 increase	 in	normalized	transduction	
efficacy	when	the	MOI	was	increased	10-fold	(from	~50%	of	the	maximum	transduction	achieved	in	
each	 experiment	 at	 MOI	 0.25	 to	 ~53%	 at	 MOI	 2.5),	 lentiviral	 transduction	 went	 from	 ~20%	 of	
maximum	at	MOI	0.25	to	~90%	at	MOI	2.5,	indicating	that	at	MOI	0.25	almost	all	dividing	cells	were	
transduced	with	the	retroviral	supernatant,	so	that	the	maximum	transduction	possible	was	reached.	
With	 the	 lentiviral	 supernatant,	 transduction	 efficacies	 were	 less	 than	 half	 of	 that	 seen	 with	 the	
retroviral	vector	at	the	lowest	MOI,	but	rose	in	a	dose-dependent	manner	when	more	viral	particles	











different	 transduction	 behavior	 from	 the	 lentiviral	 vector.	 No	 increase	 in	 VCNs	 or	 AAT	 expression	




hypothesized	that	 it	was	 linked	to	 the	gamma-retroviral	 supernatant.	 Indeed	 it	has	been	described	
that	molecules	present	 in	retroviral	supernatants	such	as	free	envelope	glycoproteins	or	negatively	
charged	molecules	secreted	from	the	producer	cell	line	such	as	glycosaminoglycans	or	proteoglycans	
can	 interfere	 with	 transduction	 at	 high	 MOIs	 384,390,403–405.	 For	 transductions	 at	 lower	 MOIs,	 the	
volume	 of	 viral	 supernatant	 used	 was	 low,	 suggesting	 that	 potential	 repressive	 effects	 on	
transduction	would	have	been	 lower;	at	high	MOIs,	however,	when	 larger	volumes	of	 supernatant	




AAT	 expression	were	 desired,	 and	 scalable	 transduction	was	 an	 aim,	 the	 lentiviral	 vector	 appears	
preferable	 to	 the	 gamma-retroviral.	However,	 if	 the	 goal	was	 not	 to	 reach	maximum	 transduction	
levels,	but	if	a	well-balanced	ratio	between	AAT	expression	and	number	of	integrations	per	cell	was	
required,	 the	 gamma-retroviral	 system	 appears	 to	 be	 superior,	 since	 much	 less	 viral	 supernatant	
would	be	needed	employing	the	gamma-retroviral	system	to	yield	this	result.		
Importantly,	regulatory	agencies	are	less	likely	to	approve	a	cell	therapy	product	having	high	levels	of	
vector	 integrations	due	 to	safety	concerns:	The	more	viral	 integrations,	 the	higher	 the	chance	 that	
regulatory	elements	such	as	promoters	or	enhancers	included	in	the	provirus	may	interfere	with	the	
surrounding	chromatin	of	 the	host	cell,	which	could	 lead	to	deregulation	of	nearby	oncogenes	and	
insertional	 transformation	 185–187.	 The	 lentiviral	 integration	 pattern	 is	 thought	 to	 be	 safer	 than	 the	
retroviral	406–411.	However,	to	the	author’s	knowledge,	no	case	of	genotoxicity	has	been	described	for	
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needed	 in	 this	 approach	 as	 compared	 to	 aiming	 for	 transduction	 efficacies	 of	 about	 half	 and	
expression	 levels	of	~2/3	of	the	maximum,	which	required	20-fold	 less	volume	of	gamma-retroviral	
supernatant	 in	our	preclinical	experiments.	The	first	approach	would	therefore	be	more	expensive,	
while	 it	 is	unknown	 if	maximum	transduction	and	expression	are	required	to	achieve	a	therapeutic	
benefit.	Also,	in	a	clinical	gene	therapy	setting,	it	is	preferable	to	treat	as	many	patients	as	possible	
with	 the	 same	 batch	 of	 viral	 supernatant	 to	 ensure	 optimal	 comparability	 of	 the	 results.	 Using	
producer	 cell	 lines	 expressing	 the	MLV	 gagpol	 and	 the	 GaLV	 env,	 as	 it	 is	 commonly	 done	 for	 the	
generation	 of	 gamma-retroviral	 supernatants,	 it	 is	 possible	 to	 produce	 batches	 of	 high-titer	
supernatants	in	liter	volumes	for	clinical	trials	412–414.	To	establish	such	scale-up	production	processes	
is	more	 difficult	 for	 lentiviral	 vectors,	 since	 due	 to	 the	 toxicity	 of	 the	 VSV.G	 protein	 there	 are	 no	
GMP-compliant	 packaging	 cell	 lines	 for	 VSV.G-pseudotyped	 lentiviral	 vectors	 available	 to	 date	 415.	
Taken	 together,	 both	 viral	 vectors	 have	 advantages	 and	 disadvantages,	 and	 further	 experiments,	
especially	assessing	the	amount	of	MSCs	and	AAT	needed	to	achieve	a	therapeutic	benefit,	need	to	
be	performed	to	be	able	to	select	the	viral	vector	that	is	better	suited	for	the	present	application.		
4.5. Functionality of transgenic AAT 
The	 next	 aim	 was	 to	 confirm	 the	 functionality	 of	 transgenically	 expressed	 AAT.	 AAT	 is	 normally	
primarily	 expressed	 in	 hepatocytes	 (70–80%),	 but	 neutrophils,	mononuclear	 phagocytes,	 intestinal	
epithelial	and	lung	alveolar	cells	are	also	able	to	synthesize	small	amounts	of	the	protein	217,257.	Bone	
marrow	derived	MSCs,	however,	are	not	thought	to	produce	AAT	naturally	243.	AAT	is	a	glycoprotein	
with	 a	 highly	 ordered	 tertiary	 structure	 that	 is	 co-	 and	 posttranslationally	 modified,	 and	 whose	
function	 depends	 on	 a	 conformational	 transition	 from	 “stressed”	 to	 “relaxed”	 during	 binding	 to	
proteases	231,251,416,417.	Because	it	is	a	secreted	protein,	it	contains	a	targeting	signal	that	is	cleaved	by	
signal	 peptidase,	 allowing	 secretion.	 To	 confirm	 that	AAT	expression	 in	MSCs	 results	 in	 a	 correctly	
cleaved,	N-glycosylated	and	folded	protein,	thereby	preserving	AAT	functionality,	a	functional	assay	
of	 neutrophil	 elastase	 inhibition	 by	 AAT	 was	 used.	 The	 assay	 confirmed	 that	 concentrated	
supernatants	 from	serum	free	cultures	efficiently	 inhibited	neutrophil	elastase,	demonstrating	 that	
AAT	 secreted	 from	 transduced	 MSCs	 is	 functional.	 MSC-derived	 AAT	 was	 also	 found	 to	 inhibit	
neutrophil	 elastase	 with	 approximately	 the	 same	 efficiency	 as	 natural	 AAT	 isolated	 from	 human	
plasma,	currently	used	in	clinical	trials	of	AAT	augmentation	for	AAT	deficiency	321.	
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a	 chronic	 inflammatory	 response	 to	 inhaled	 irritants,	emphysema,	 small	 airway	 fibrosis	and	mucus	
hypersecretion,	 leading	 to	 an	 irreversible,	 progressive	 airflow	 limitation	 and	 loss	 of	 lung	 function	




symptoms	 that	are	comparable	 to	 the	human	disease	such	as	chronic	 lung	 inflammation,	 impaired	
lung	function,	emphysema,	mucus	hypersecretion,	and	small	airway	wall	thickening	and	remodeling	
are	 induced	8.	However,	this	model	requires	several	months	of	exposure	to	cigarette	smoke	before	
emphysematous	changes	and	alterations	 in	 lung	 function	occur,	 thus	making	 it	very	expensive	and	
also	not	suitable.	More	importantly,	it	cannot	fully	reproduce	the	severity	of	the	human	disease,	but	




A	 second	 commonly	 applied	 in	 vivo	 COPD	model	 is	 the	 elastase-induced	 emphysema	model.	 This	
model	was	developed	based	on	two	observations:	First,	 it	was	described	in	the	1960s	that	patients	
suffering	 from	AAT	deficiency	develop	early	emphysema	and	COPD	 200,419.	And	 second,	 around	 the	
same	 time,	 the	 induction	 of	 emphysema	 in	 rats	 by	 installation	 of	 the	 protease	 papain	 was	
reported	201.	 It	 is	 generally	 accepted	 that	 a	 protease-antiprotease	 imbalance	 is	 one	 of	 the	 major	
pathogenetic	 factors	 for	 the	 development	 of	 smoke-induced	 emphysema	 in	 COPD	 patients.	 The	
underlying	hypothesis	is	that	proteases,	which	are	released	from	inflammatory	cells	recruited	to	the	
small	 airways	 by	 cigarette	 smoke,	 destroy	 the	 parenchymal	 matrix	 of	 the	 lung,	 leading	 to	
emphysema	3,418,420.	On	these	grounds,	the	elastase-induced	model	was	thought	to	be	appropriate	as	
a	 proof	 of	 concept	 study	 of	 AAT-MSCs.	Moreover,	 the	 elastase	model	 is	 a	 rapidly	 inducible	 short-
term	model,	 thus	allowing	a	quick	assessment	of	 the	potential	 therapeutic	benefit	of	a	 treatment;	
mice	 can	 be	 analyzed	 after	 21	 days	 in	 this	 model.	 In	 addition,	 the	 elastase	 model	 generates	
emphysema	 from	 a	 single	 application	 of	 elastase,	while	 in	 the	 smoke-induced	model	mice	 usually	
have	 to	 be	 subjected	 to	 cigarette	 smoke	 twice	 daily	 421,422.	 The	 elastase	model	 is	 preferable	when	
therapeutic	agents	 for	alveolar	 repair	and	 regeneration	are	evaluated:	 In	 contrast	 to	 lesions	 in	 the	
smoke-induced	 model,	 emphysema	 in	 the	 elastase	 model	 is	 permanent	 and	 additionally	 more	
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severe,	 and	 has	 been	 described	 to	 even	 continue	 progressing	 for	 more	 than	 five	 months	 after	
instillation	 of	 elastase	 341,342,	 making	 it	 possible	 to	 assess	 a	 potential	 therapeutic	 benefit	 more	
easily	418,420.		
MSCs	have	been	described	to	contribute	to	lung	regeneration	in	various	diseases	142.	Thus,	we	tested	









produce	 more	 sensitive	 and	 specific	 results	 343.	 Through	 collaboration	 with	 the	 Comprehensive	
Pneumology	Center,	we	were	able	to	employ	invasive	lung	measurements	using	the	Buxco	system	to	




and	 thus	was	 excluded	 from	 statistical	 analysis	 since	 comparing	 the	 other	 groups	with	 this	 group	
would	 yield	 statistically	 significant	 results	 without	 contributing	 additional	 information	 regarding	 a	





providing	an	 indication	 that	 these	 results	might	be	highly	 relevant	 for	 the	human	disease.	We	also	
saw	 a	 dramatic	 improvement	 in	 the	 two	 factors	 describing	 lung	 volumes,	 IC	 and	 VC,	 as	 well	 as	
Cchord,	 which	 is	 a	 measure	 for	 compliance,	 representing	 the	 ability	 of	 the	 lung	 to	 stretch	 and	
expand.	Due	to	the	breakdown	of	lung	tissue	and	the	resulting	airspace	enlargement	in	emphysema,	
this	 parameter	 is	 drastically	 increased	 in	 the	model	 we	 employed,	 and	 treatment	 with	 AAT-MSCs	
reversed	this	increase	by	>40%	(mean	Cchord:	PBS:	0.0431;	elastase:	0.09291;	elastase	+	AAT-MSCs:	
0.07182).	 The	 only	 pulmonary	 function	 parameter	 that	 did	 not	 reach	 statistical	 significance	 is	 the	
second	 measure	 for	 compliance,	 Cdyn;	 however,	 the	 same	 trend	 towards	 an	 amelioration	 after	
treatment	with	AAT-MSCs	was	clearly	visible.	Treatment	with	non-modified	MSCs	did	not	result	in	a	






As	 for	 pulmonary	 functions,	 application	 of	 AAT-MSCs	 resulted	 in	 a	 clear	 improvement	 of	 the	
emphysema	 score	of	 ~50%	 that	was	 also	 statistically	 significant	 (P	 <	 0.001).	Again,	 the	effect	 seen	
with	 non-modified	 MSCs	 was	 substantially	 smaller,	 and	 did	 not	 reach	 statistical	 significance.	 This	
indicates	that	AAT	has	not	only	an	additional	beneficial	effect	on	lung	function	when	combined	with	
MSCs,	but	also	on	repair	and	regeneration	of	pulmonary	tissue.	This	finding	could	shed	light	onto	the	
mode	 of	 action	 of	 AAT	 in	 this	 model.	 It	 has	 been	 described	 that	 the	 elastase	 used	 to	 induce	
emphysema	is	cleared	from	the	mouse	lungs	within	24	hours	424,	but	that	the	airspace	enlargement	
continues	even	when	the	elastase	is	long	gone	331,425.	Together,	this	suggests	that	the	beneficial	effect	
of	 AAT	 in	 this	 model	 is	 not	 solely	 due	 to	 protease	 inhibition,	 but	 has	 an	 additional	
immunomodulatory	 component	 as	 well,	 a	 very	 well	 recognized	 phenomenon	 in	 protease	
biology		216,257,426.	
During	analysis	of	the	lung	sections	it	was	seen	that	apart	from	the	amelioration	of	lung	destruction	
in	 mice	 treated	 with	 AAT-MSCs,	 there	 was	 also	 a	 profound	 increase	 in	 inflammatory	 cells	 in	 the	
tissue,	 reflected	 by	 a	 significantly	 higher	 inflammation	 score	 when	 compared	 to	 mice	 receiving	
elastase	 alone.	 This	 was	 true	 for	 both	mouse	 groups	 receiving	MSCs	 (MSCs:	 P	 <	 0.01;	 AAT-MSCs:		
P	<	0.001).	This	finding	was	corroborated	by	analysis	of	total	and	differential	cell	counts	in	the	BALF	
of	 the	mice,	which	 revealed	 a	 drastic	 increase	 in	 absolute	 and	 relative	 lymphocyte	 and	 eosinophil	
counts	in	all	mice	receiving	either	MSCs	or	AAT-MSCs.	The	inflammatory	response	was	more	distinct	
in	the	group	receiving	AAT-MSCs,	suggesting	that	the	murine	immune	cells	may	be	reacting	against	
the	 human	 MSCs,	 and	 potentially	 against	 the	 human	 AAT	 protein	 being	 secreted	 from	 the	 cells.	
Indeed,	it	has	been	described	that	the	repeated	administration	of	human	AAT	and	human	albumin	is	
immunogenic	 in	 immunocompetent	 mice	 427.	 However,	 since	 MSCs	 have	 been	 described	 to	 be	
immune-evasive	in	many	studies	99,428–430,	an	alternative	hypothesis	would	be	that	the	inflammatory	
infiltrate	 is	needed	to	effect	tissue	repair	and	regeneration	431.	Thus,	further	studies	to	analyze	this	




When	 analyzing	 absolute	 differential	 cell	 numbers,	 there	 was	 a	 trend	 towards	 lower	macrophage	
counts	 in	 both	MSC	 groups;	 however,	 these	 differences	 did	 not	 reach	 statistical	 significance.	 Still,	
when	 calculating	 relative	 proportions	 of	 the	 cells	 in	 the	 BALF,	 there	was	 a	 significant	 decrease	 in	
macrophages,	which	are	one	of	the	major	cell	 types	 involved	 in	the	pathogenesis	of	COPD,	 in	both	





elastase	 instillation.	 Remarkably,	 four	 out	 of	 six	 mice	 had	 no	 neutrophils	 in	 their	 BALF	 after	
treatment	 with	 AAT-MSCs.	 These	 observations	 suggest	 that	 human	MSCs,	 and	 even	more	 human	
MSCs	 expressing	 human	 AAT,	 appear	 to	 exert	 immunomodulatory	 effects	 on	 the	major	 cell	 types	
involved	in	the	pathogenesis	of	the	lung	disease.		
Native	MSCs	showed	only	a	mild	improvement	of	emphysema,	and	had	a	very	minor	effect	on	lung	
function	 parameters.	 This	 is	 in	 contrast	 to	 published	 studies	 133,164,432,433,	 which	 describe	 a	 clear	
beneficial	effect	of	MSC	treatment	 in	elastase-induced	emphysema	in	mice.	This	discrepancy	might	
be	due	to	different	experimental	 setups	 133,164,	diverging	MSC	numbers	used	 433,	and	different	MSC	
sources	 analyzed	 164.	 Also,	 pulmonary	 function	 measurements	 were	 not	 always	 performed,	 the	
assessment	of	an	amelioration	of	the	disease	was	based	on	histological	findings,	where	the	effect	of	
MSCs	seems	to	be	more	pronounced	(also	in	our	case).		
The	model	employed	here	 is	very	stringent,	since	 it	 is	a	model	of	treatment	and	not	prevention.	 In	
our	case,	 the	 first	application	of	 the	cells	was	made	seven	days	after	elastase	 instillation	when	the	




A	 question	 raised	 by	 the	 positive	 results	 obtained	with	 AAT-MSCs	 is	 why	 the	 relatively	moderate	






instilled	 into	 the	 mice	 twice,	 one	 time	 on	 day	 7,	 a	 second	 time	 on	 day	 14,	 and	 the	 mice	 were	
sacrificed	on	day	21,	the	total	amount	of	secreted	AAT	would	be	~50µg,	not	considering	half-life	of	
the	 protein	 or	 cell	 death.	 The	 blood	 volume	 of	 mice	 is	 in	 the	 range	 of	 1.5–2.5mL	 435,	 thus	 the	
maximum	 systemic	 human	 AAT	 concentration	without	 calculating	 any	 losses	would	 be	 ~25µg/mL,	




injury.	 It	 has	 been	 suggested	 that	 AAT	 serum	 concentrations	 reaching	 20%	 of	 physiological	 serum	
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levels	 are	 sufficient	 to	 protect	 the	 alveoli	 in	 humans	 436.	Moreover,	 it	 has	 been	 also	 found	 that	 in	
humans,	the	distribution	of	AAT	is	fairly	heterogeneous,	and	that	e.g.	 in	the	epithelial	lining	fluid	of	
the	 lower	 respiratory	 tract,	 AAT	 levels	 are	 only	 10%	 of	 serum	 levels	 under	 physiological	
conditions	217,	 indicating	 that	 the	 addition	 of	 even	 small	 amounts	 of	 extra	 AAT	 might	 have	 even	









mechanisms	by	which	AAT-MSCs	are	able	 to	ameliorate	 lung	 function	and	effect	pulmonary	 tissue	
repair	and	regeneration	better	understood.	The	 inflammatory	response	elicited	 in	the	mouse	 lungs	
after	treatment	with	MSCs	should	be	studied	in	detail,	e.g.	by	conducting	a	study	with	murine	MSCs	
expressing	murine	AAT.		
An	 interesting	 question	 that	 also	 needs	 clarification	 is	 how	 strong	 the	 additive	 effect	 of	 AAT	 and	




AAT-MSCs.	 These	microvesicles	or	 exosomes,	 as	 already	mentioned	briefly	 in	 the	 introduction,	 are	
circular	 membrane	 fragments	 released	 from	 MSCs,	 that	 are	 involved	 in	 the	 transfer	 of	 cellular	
material	 and	 in	 cell-cell	 communication,	 and	 have	 recently	 emerged	 as	 a	 mechanism	 of	 MSC-
mediated	 functions	 437,438.	 Since	 microvesicles	 have	 been	 described	 to	 maintain	 the	 functional	




In	 summary,	 this	 study	provides	 the	 first	 proof	of	 concept	 for	 the	 treatment	of	 inflammatory	 lung	
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Curriculum vitae   
	
120 
6. Supplemental material  
6.1. Sequences 
SERPINA1	 CDS:	 Bases	 262	 to	 1518	 of	 the	 full	 reference	 sequence	 published	 at	
http://www.ncbi.nlm.nih.gov/nuccore/NM_000295.4.	
                             262 atgccgtct tctgtctcgt ggggcatcct cctgctggca 
      301 ggcctgtgct gcctggtccc tgtctccctg gctgaggatc cccagggaga tgctgcccag 
      361 aagacagata catcccacca tgatcaggat cacccaacct tcaacaagat cacccccaac 
      421 ctggctgagt tcgccttcag cctataccgc cagctggcac accagtccaa cagcaccaat 
      481 atcttcttct ccccagtgag catcgctaca gcctttgcaa tgctctccct ggggaccaag 
      541 gctgacactc acgatgaaat cctggagggc ctgaatttca acctcacgga gattccggag 
      601 gctcagatcc atgaaggctt ccaggaactc ctccgtaccc tcaaccagcc agacagccag 
      661 ctccagctga ccaccggcaa tggcctgttc ctcagcgagg gcctgaagct agtggataag 
      721 tttttggagg atgttaaaaa gttgtaccac tcagaagcct tcactgtcaa cttcggggac 
      781 accgaagagg ccaagaaaca gatcaacgat tacgtggaga agggtactca agggaaaatt 
      841 gtggatttgg tcaaggagct tgacagagac acagtttttg ctctggtgaa ttacatcttc 
      901 tttaaaggca aatgggagag accctttgaa gtcaaggaca ccgaggaaga ggacttccac 
      961 gtggaccagg tgaccaccgt gaaggtgcct atgatgaagc gtttaggcat gtttaacatc 
     1021 cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg caatgccacc 
     1081 gccatcttct tcctgcctga tgaggggaaa ctacagcacc tggaaaatga actcacccac 
     1141 gatatcatca ccaagttcct ggaaaatgaa gacagaaggt ctgccagctt acatttaccc 
     1201 aaactgtcca ttactggaac ctatgatctg aagagcgtcc tgggtcaact gggcatcact 
     1261 aaggtcttca gcaatggggc tgacctctcc ggggtcacag aggaggcacc cctgaagctc 
     1321 tccaaggccg tgcataaggc tgtgctgacc atcgacgaga aagggactga agctgctggg 
     1381 gccatgtttt tagaggccat acccatgtct atcccccccg aggtcaagtt caacaaaccc 
     1441 tttgtcttct taatgattga acaaaatacc aagtctcccc tcttcatggg aaaagtggtg 
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6.3. Plasmid maps – helper plasmids 
6.3.1. Gamma-retroviral helper plasmids 
	
Supplemental	figure	6:	Plasmid	map	of	plasmid	#70	pcDNA3-MLV-gagpol	














6.4. Plasmid maps – gamma-retroviral AAT expression constructs 
	
Supplemental	figure	10:	Plasmid	map	of	plasmid	#159	pSERS11_pPGK_SERPINA1_pEFS_pac	
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6.6. Additional pulmonary function parameters 
	
	
Supplemental	 figure	19:	 Invasive	 lung	 function	measurements	using	 the	Buxco	 forced	pulmonary	
maneuver	system.	Lung	function	parameters	were	measured	applying	the	Fast	Flow	Volume	(FV)	and	
the	Quasistatic	Pressure	Volume	(PV)	tests.	 Invasive	pulmonary	function	analyses	of	resistance	(RI),	
peak	expiratory	flow	(PEF),	and	expiratory	reserve	volume	(ERV).		
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